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Abstract    
 
Background: The CRASH-3 trial hypothesized that Tranexamic Acid (TXA) could reduce 
intracranial bleeding and the risk of head injury death in patients with traumatic brain injury 
(TBI). Because “head injury death” includes death from intracranial bleeding, to simplify the trial 
procedures, the investigators did not collect data on the extent of intracranial bleeding in all trial 
patients. Furthermore, TXA may increase the occurrence of stroke, and this outcome was recorded 
in the trial outcome form, but cerebral infarction as seen on imaging was not. Additional 
information on the hypothesized mechanism of action of TXA in TBI could help explain the 
CRASH-3 trial results. 
 
Research questions, aims and hypotheses: The CRASH-3 Intracranial Bleeding Mechanistic 
Study (IBMS) sought to investigate whether the mechanism of action of TXA in TBI could be 
assessed using routinely collected brain imaging. If so, the IBMS aimed to explore the potential 
effects of TXA on intracranial bleeding and infarction. Specifically, it was hypothesised that TXA 
could reduce intracranial bleeding and/or increase cerebral infarction. 
 
Methods: The IBMS was nested within the CRASH-3 trial: a prospective, double-blind, parallel-
arm, randomised trial. Patients eligible for the CRASH-3 trial, with a Glasgow Coma Scale (GCS) 
score of ≤ 12 or intracranial bleeding on pre-randomisation CT were eligible. Outcomes were 
examined on routinely collected brain scans done pre- and/or post-randomisation. The primary 
outcome is the volume of intra-parenchymal bleeding in patients randomised within three hours 
of injury. Secondary outcomes include new and progressive bleeding, post-neurosurgical 
bleeding, infarction, and a composite “poor outcome”. The primary outcome was analysed using 
a linear mixed model, and dichotomous outcomes using relative risks or hazard ratios.  
 
Findings: The IBMS included 14% of the CRASH-3 trial patients (n=1767/12,737): 884 TXA, 
883 placebo. Patients had a median baseline GCS of 7 (IQR 3–10). Only 46% of patients were 
scanned pre- and post-randomisation (n=812/1767) and 35% were scanned post- but not pre-
randomisation (n=614/1767). A total of 21% of patients had evidence of neurosurgical 
haemorrhage evacuation on a post-randomisation scan. There was no evidence for a reduction in 
intra-parenchymal bleeding with TXA (1.09, 95% CI 0.81–1.45) or in intracranial bleeding in 
neurosurgical patients (0.79, 95% CI 0.57–1.11). There was no evidence for a reduction in the 
composite (RR=1.01, 95% CI 0.93–1.10) or increase in the hazard of infarction with TXA 
(HR=1.31, 95% CI 0.95–1.80). In patients scanned pre- and post-randomisation, there was no 
evidence that TXA reduces progressive bleeding (RR=0.92, 95% CI 0.74–1.13) and no clear 
evidence that TXA reduces new bleeding (RR=0.86, 95% CI 0.72–1.02).  
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Conclusions: Routine imaging cannot provide reliable information on the effects of TXA in TBI. 
The associated methodological flaws mean that the treatment effect estimates are not valid and 
precise. 1) The large proportion of missing post-randomisation scans could depend on whether a 
patient received TXA. 2) The inclusion of a large proportion of severely injured patients may 
dilute effect estimates towards the null. 3) The receipt of TXA may affect whether patients 
undergo neurosurgery, and this complicates the assessment of the effects of TXA using scans 
done post-randomisation and post-neurosurgery.  
 
Implications for future research: If a research protocol mandated that scans were done at a set 
time-point post-randomisation, this would reduce the risk of bias from missing outcomes. If less 
severely injured patients were included, this would reduce the occurrence of neurosurgery and 





























Research Questions, Aim and Hypotheses 
 
In this thesis, I sought to answer a number of research questions to inform the background, 
methods, analysis, and interpretation of this thesis. These questions have been detailed below, 
with a summary of the findings from various reviews that were done as part of this thesis to help 
answer these questions. These questions were explored by conducting reviews of the relevant 
literature and seeking expert opinion. I have listed these questions in the order they were 
encountered in the thesis. This is followed by more specific aims and hypotheses about how 
TXA might influence neuro-radiological outcomes after TBI. 
Research question 1. Have there been, or are there any ongoing, double-blind randomised trials 
of anti-fibrinolytic drugs in patients with TBI?  
• In 2016, I worked with Information Specialist (Deirdre Beecher) at the Cochrane 
Injuries Group to update a Systematic Review published in 2015 in this area. 
• We searched several databases to identify all relevant completed, ongoing and pending 
randomised trials in this area (see Section 1.10 for more information).  
• We identified three ongoing or pending randomised trials on the effects of TXA in TBI. 
I assessed the quality of these trials according to an Epidemiological Risk of Bias tool. 
Of the three trials, the CRASH-3 trial was the largest into the effects of TXA in TBI.  
• I led the publication of this review, highlighting the uncertainty regarding the use of 
TXA in TBI (Thesis Research Paper 1).  
Research question 2. What are the available brain imaging modalities and methods to examine 
intracranial bleeding and infarction? 
• I performed a literature review and found that CT scanning is the most commonly used 
neuro-imaging modality done as part of routine in-hospital patient care and can identify 
larger intracranial bleeds in the acute stage of injury. Other imaging methods, such as 
MRI, are more sensitive and specific in identifying small and large bleeds and other 
pathologies (such as infarction) in the acute stage of injury. However, MRI and its 
specific sequences are not routinely used in all TBI patients or in all hospitals.  
• I performed a literature review and found that automated and manual methods are 
available to estimate intracranial bleeding volume.  
o I found that automated methods result in less measurement error of intracranial 
bleeding volume than manual methods. However, automated methods were not 
used in this thesis because scan assessment happened at each participating 
hospital (as per advice from the Medical Research Ethics Committee) where the 
relevant software would need to be installed on clinical computers with access 
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to scans. Due to potential technical and other difficulties in doing this, I 
explored alternative methods of estimating haemorrhage volume.  
o I identified a number of manual methods that have been used to estimate 
intracranial bleeding volume. One simple manual method (ABC/2) has been 
validated for estimating intracranial bleeding volume.  
Research question 3. Is there a difference in bleeding volume estimates with the manual 
ABC/2 method compared to automated methods, and if so, what factors influence this 
discrepancy? 
• I conducted a systematic literature review on the association between ABC/2 and 
automated methods for estimating haemorrhage volume. I found that the ABC/2 method 
has good agreement with automated methods, especially for bleeds that have spherical 
shapes, and so ABC/2 was chosen to estimate the haemorrhage volume for some bleed 
types in this thesis (see Section 2.24). Because SDH typically has a non-spherical shape, 
an alternative method was used to estimate SDH volume (see Section 2.25).   
Research question 4. Why might patients not be routinely scanned before or after 
randomisation? 
• This thesis found that TBI patients are routinely scanned on admission to hospital. This 
admission scan was done before randomisation, unless patients had a GCS of ≤12, in 
which case the CRASH-3 trial procedure allowed randomisation before CT (to reduce 
time to randomisation).   
• This thesis found that a large proportion of patients who are not scanned after 
randomisation are either mildly injured or severely injured at baseline (according to 
clinical signs such as GCS). Patients who died due to head injury are at greater risk of 
not being scanned after randomisation, compared to those who died of a different cause 
or survived.  
Research question 5. What are some of the statistical approaches to estimate the effect of a 
treatment on a continuous outcome and how do they handle missing data? 
• In this thesis, I considered three statistical approaches to examine the effect of TXA on 
intracranial bleeding. 
o First, I considered Analysis of Covariance (ANCOVA). In ANCOVA, the post-
randomisation bleeding volume can be compared between treatment groups, 
and adjusted using the pre-randomisation bleeding volume. If there are baseline 
differences between treatment groups, ANCOVA is more efficient than the 
CHANGE method (comparing the change in volume from pre- to post- between 
treatment groups) and POST method (comparing the post- volumes between 
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groups, without considering pre- volumes). However, ANCOVA can only 
include patients who are scanned both pre- and post-randomisation. 
o Next, I considered Analysis of Variance (ANOVA) where the post-
randomisation bleeding volume is compared between treatment groups, and 
pre-randomisation bleeding volume is not included in the analysis. This 
approach can include all patients with post-randomisation scans, and so in this 
case may be less biased and more powerful than ANCOVA.  
o Finally, I considered a Linear Mixed Model (LMM). In this analysis, the post-
randomisation bleeding volume can be compared between treatment groups. If 
patients are only scanned pre-randomisation, this information is included the 
estimate of the pre-randomisation bleeding volume. If patients are only scanned 
post-randomisation, this information is included in the estimate of the post-
randomisation bleeding volume. This model allows all patients to be included, 
even if they have missing pre- or missing post-randomisation scans, and so is 
less biased and more efficient than the first two options.  
Research question 6. Can the potential effects of TXA on radiological outcomes be assessed 
using routinely collected brain imaging? 
• This thesis found that the potential effects of TXA on intracranial bleeding and 
infarction cannot be reliably assessed using routinely collected imaging. This is mainly 
because a large proportion of patients are not scanned 24-48 hours after randomisation 
as part of their routine care. The reasons patients are not scanned can be affected by the 
missing values themselves and/or the trial treatment. This thesis found that estimates for 
the effects of TXA based on routinely collected data are at high risk of bias.  
 
Research Aims. This study aims to examine the mechanism by which TXA might exerts its 
effects in isolated TBI, specifically its effect (if any) on intracranial haemorrhage and infarction, 
and whether this varies by time from injury to randomisation. 
• This thesis did not provide a reliable assessment of these aims.  
Research Hypotheses. TXA could reduce intracranial bleeding and/or increase cerebral 
infarction in patients with TBI. 






Structure of PhD thesis   
 
I have written a research paper style thesis that includes five chapters. I have included three 
research papers published in peer reviewed journals between 2016 and 2019. Sections of the 
published versions of the research papers are presented in the main text, with duplicate sections 
omitted or amended for clarity. Copies of the full research papers are included in the Appendices. 
The published research papers are presented in Chapters 1, 2 and 3. I have also included one 
manuscript submitted for publication consideration. This is included in Chapter 3.  
Chapter 1 describes the occurrence of traumatic brain injury (TBI) and intracranial bleeding after 
TBI. Then, the processes by which blood clots (coagulation) and blood clots break down 
(fibrinolysis) will be described, with attention to these processes in patients with TBI. The 
potential effect of an anti-fibrinolytic drug called tranexamic acid (TXA) on intracranial bleeding 
expansion, infarction, and death, will be considered. Research Paper 1 (published in 2016) is 
included in Chapter 1 and considers the evidence for the use of TXA in TBI and highlights the 
uncertainty around its use in this context. This will lead to a discussion on the importance of 
examining the mechanism of action of TXA in TBI, which will lead to the rationale for the current 
study. Relevant sections of Research Paper 2 will be included in this chapter (discussion section 
of protocol, published in 2017). 
Chapter 2 describes the methods for the current study (CRASH-3 Intracranial Bleeding 
Mechanistic Study, IMBS). This study is nested within a large randomised trial, which examined 
the effect of TXA on death and disability in patients with TBI (CRASH-3 trial). Research Paper 
2 (protocol, published in 2017) will be included in this chapter. This includes the CRASH-3 IBMS 
trial design and registration, ethical approval, eligibility criteria, consent to participate, 
participating hospitals, randomisation procedure, primary and secondary outcomes and their 
measurement. The pilot study will be summarised and amendments that were made to the methods 
as a result. The data collection procedure, sample size and data management plan will be 
presented. Confidentiality of patient data and potential risks of participation will be considered. 
Research Paper 3 (statistical analysis plan, published in 2018) is included in this chapter. The 
plans for publication and dissemination will be presented.  
Chapter 3 will start by describing the CRASH-3 IBMS population, including reference to a 
Consolidated Standard of Reporting Trials (CONSORT) diagram and baseline tables. I will 
consider the inter-rater reliability of intracranial bleeding occurrence at baseline. I will describe 
the baseline CT scan data, with attention to the occurrence of intracranial bleeding and other 
neuro-radiological features of TBI. Sections of Research Paper 4 are included in this chapter, 
which describes the baseline CT scan data in the context of the results of the CRASH-3 trial. Then 
I will explore the effect of TXA on intracranial bleeding and infarction (and whether this varies 
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by time to treatment) using data from baseline and follow-up scans. I will present the results from 
the primary and secondary analyses as per the pre-specified statistical analysis plan.  
Chapter 4 will examine the occurrence of missing pre-randomisation and post-randomisation 
scans (i.e. baseline and follow-up scans). The potential reasons for missing scans will be explored, 
including any association between injury severity and missing scans. The potential impact of 
missing scans on treatment effect estimates will be considered.  
Chapter 5 provides a critique of the CRASH-3 IBMS in the context of previous trials in this area, 
and considers the implications for research and practice. I consider the methodological challenges 
in using routinely collected brain imaging to provide valid and precise estimates of the effect of 
TXA on intracranial bleeding and infarction in TBI. Limitations include the large proportion of 
missing post-randomisation scans that could depend on whether a patient received TXA, null bias 
from baseline unsurvivability and misclassification of outcomes, and the possibility that TXA 
may enhance the appearance of bleeding on CT. Strengths include improved knowledge about the 
occurrence of intracranial bleeding in patients with TBI. This study also highlights the importance 
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1.1 Traumatic brain injury occurrence 
 
Traumatic brain injury (TBI) is defined as an alteration in brain function, or other evidence of 
intracranial pathology, caused by external mechanical force 1, 2. Worldwide over 60 million 
people suffer from TBI each year 3. This results in over 10 million deaths or hospitalisations 
each year 4. TBI is the leading cause of death and disability in young adults 5, particularly in 
low-income and middle-income countries where rates of road traffic crashes are increasing 6. 
Projections of global mortality and burden of disease suggest that road traffic crashes will be the 
third major cause of death and disability by 2030 6. Falls are the leading cause of TBI in high-
income countries 7. The population aged over 60 is predicted to double by 2050 8, 9 and with 
individuals remaining mobile and semi-independent to older ages, this places them at an 
increased risk of falls from frailty 2 10. Indeed, the burden of TBI continues to rise in those aged 
over 65 11. Other causes of TBI include contact sports 9 and physical assault 12. Males are more 
likely to die from TBI compared to females at all ages 11, which may reflect differences in risk 
taking 13 or differential exposure to hazards in specific workplaces 14. The estimated cost of TBI 
to the world economy is US $400 billion annually 10. Estimated costs are based on a host of 
consequences of TBI (described below), including direct and indirect medical costs.  
 
The worldwide societal and economic burden of TBI may be reduced by preventative measures 
such as adherence to road safety legislation, improved road conditions and vehicle design, 
countermeasures such as seatbelt and helmet use, and improved hazard management in homes 
and workplaces 15-17. Yet the World Health Organization expects TBI to continue to be a major 
cause of death and disability 18. There is an urgent global need for safe and effective TBI 
treatment and rehabilitation to improve both life expectancy and quality of life 19. Patients who 
survive death from TBI are at risk of physical, psychological, cognitive and other neurological 
problems that can persist for months or years after injury 20-27. Severe TBI often results in motor 
impairment that persists for at least 3 years after the injury 22 and cognitive impairments are 
present for at least 6 months after injury 23. Problems with memory following TBI significantly 
affect an individual’s quality of life 24. This enhances the associated financial burden of medical 
care, psychological therapy, lost wages and reduced productivity, which is pronounced in those 
of a lower socio-economic status 28. To reduce the burden of this life threatening and potentially 






1.2 Cerebral blood circulation 
 
Oxygenated blood is supplied to the brain by four major vessels: two carotid and two vertebral 
arteries 29. The carotid arteries principally supply the anterior portion of the cerebrum with 
blood. The vertebral arteries supply the posterior part of the cerebrum, part of the cerebellum, 
and brainstem with blood. Deoxygenated blood is carried from the brain to the heart via two 
groups of valve-less veins which allow for drainage: the superficial cortical veins and the deep 
or central veins 29. Post-traumatic intracranial bleeding results when intracranial vessels (arteries 
or veins) rupture on impact and blood escapes into the surrounding space. Non-contrast-
enhanced CT imaging of the head is quick and easy to perform, and has high sensitivity for 
detecting acute intracranial bleeding that will need neurosurgical intervention 30. Therefore, it is 
usually the first neuroimaging modality used in TBI across hospital emergency departments 
around the world 31. 
 
1.3 Computed tomography (CT) imaging 
  
A head CT scanner uses x-rays to form a representation of the skull and brain (see Figure 1).  
 
Figure 1. Helical scanning technique comprising rotating x-ray tube and fixed array of detectors. a  
 
A patient lies in the CT scanner, a tunnel like machine, whilst the inside of the scanner rotates 
and takes x-rays of the head from different angles 32. These images are used to display cross-
sections (slices) of the brain. Slice thickness typically ranges from 3-5mm in routine scanning, 
but this can vary depending on the level of detail required for interpretation 32. CT images are 
acquired in the axial plane (top to bottom of the brain). The axial data can be used to reconstruct 
images in other planes, including sagittal (separating the left and right of the brain) and coronal 
(separating the front and back of the brain).  
 
                                                     
a Reproduced from Osborne et al (2016) 32 
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The CT appearance of the skull and brain are based on density relative to water 32. The skull is 
the most dense part of the head and so absorbs the most x-rays; the skull has a bright white 
appearance on CT. Brain tissue is less dense than the skull and absorbs less x-rays, and has a 
grey appearance on CT. Cerebrospinal fluid flows through the brain’s ventricles, and so the 
ventricles absorb few x-rays and have a black appearance on CT. Post-traumatic hyper-acute 
intracranial bleeding has not yet clotted and so it has the same density as blood flowing through 
cerebral vessels on non-contrast enhanced CT 31. Hyper-acute bleeding does not have a distinct 
appearance on CT. In the first few hours after injury, the blood has had opportunity to clot and 
so its appearance on CT appears as hyper-dense. In this acute bleeding phase, the clotted blood 
is more dense than brain tissue (and less dense than the skull) and so has a marked white 
appearance on CT 31, 32.  
 
1.4  Intracranial haemorrhage (bleeding) occurrence 
 
TBI is associated with various neuropathological changes 33. One of the most devastating is 
intracranial haemorrhage b expansion, which increases the risk of death and disability 34. Larger 
intracranial bleeds, wherever located, are associated with an increased risk of death and 
disability compared to smaller bleeds 34, 35. According to clinical measures of TBI severity, such 
as the Glasgow Coma Scale (GCS) 36, patients with intracranial bleeding tend have more severe 
TBI than patients without intracranial bleeding 34. The GCS assesses impairments in 
consciousness indicated by eye, verbal and motor responses c. Each patient receives a total GCS 
score ranging from 3 to 15, with a lower score indicating reduced consciousness. GCS scores 
can be categorised as mild (13-15), moderate (9-12) or severe (3-8). The major advantage of the 
GCS is its simplicity and use as a standardized measure to compare outcomes between patients 
with different injury severities 36. One caveat of GCS assessment is that it may overestimate 
injury severity in patients who are sedated, ventilated, paralysed or intoxicated 37 38.  
 
Several studies have used admission and/or repeat CT scans to describe the temporal course of 
intracranial bleeding progression in patients with TBI. Compared to patients with mild GCS, a 
greater proportion of patients with more severe GCS appear to show evidence of progressive 
bleeding (see Table 1).  
 
 
                                                     
b The terms “bleeding” and “haemorrhage” are used interchangeably in this thesis. 
c The eye opening sub-scale score ranges from 1 to 4, with 1 indicating no response, 2 for response to 
pain, 3 for response to speech and 4 indicating spontaneous response. The verbal sub-scale score ranges 
from 1 to 5, with 1 indicating no response, 2 for incomprehensible sounds, 3 for the use of inappropriate 
words, 4 for confusion, and 5 for orientation to time, place and person. The motor sub-scale score ranges 
from 1 to 6, with 1 indicating no response, 2 for abnormal extension, 3 for abnormal flexion, 4 for flexion 
withdrawal from pain, 5 for movement to localised pain and 6 if the patient obeys commands. 
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Table 1. Intracranial haemorrhage (ICH) on admission and/or repeat head computed tomography (CT) scans) across 
a range of Glasgow Coma Scale (GCS) scores.  
Study authors, 
publication date (n) 
Baseline GCS 
range 
Hours from injury to  
first CT, repeat CT 
ICH on first CT ICH on repeat CT 
Albers et al., 2013 
(n=3,088) 39 
14-15 6, N/A 5% (n=149) 
 
N/A 




14.6 ± 0.7) 


















All patients  
(at least 2ml) * 
51% 
57% 
  >3.5, 24  28% 
*by definition of inclusion criteria 
 
One study in 3,088 patients with mild GCS found that 5% of patients showed evidence of 
intracranial haemorrhage on admission CT 39. In patients with evidence of haemorrhage, 51% 
presented with intra-parenchymal haemorrhage (IPH), 26% with subarachnoid haemorrhage 
(SAH), 17% with subdural haemorrhage (SDH) and 6% with epidural haemorrhage (EDH). No 
patients with intracranial haemorrhage died or deteriorated neurologically within 24 hours of 
admission. Another study included 341 patients with a mild GCS and an admission head CT 
scan showing intracranial haemorrhage. Patients with at least two head CT scans done within 48 
hours of injury were included. Only 1% of patients showed evidence of progressive 
haemorrhage 48 hours after admission (see Figure 2). The time that ICH stopped was 
determined by the time of the last head CT showing no progression of ICH and likely 
overestimated duration of ongoing haemorrhage. Therefore, in patients with mild GCS who 
present to hospital with intracranial haemorrhage, although this bleeding can continue for 24 
hours or longer, most bleeds appear to stop progressing within a few hours of hospital 
admission 40.  
 
 
Figure 2. Temporal course of intracranial haemorrhage (ICH) progression from the time of Emergency 
Department presentation in patients with mild GCS.d 
 
                                                     
d Figure reproduced from Homnick et al (2012) 40.  
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Another study recruited 142 TBI patients across injury severities who had abnormalities on the 
admission CT scan 41. Intracranial haemorrhage progression was seen in 42% of patients 
between admission CT done 2 ± 1.6 hours after injury and repeat CT scanning done within 24 
hours of injury. Furthermore, another study recruited 69 TBI patients except for the most and 
least severely injured, with a baseline CT scan done within 6 hours of injury that showed at least 
2ml of intracranial haemorrhage, but no plan for neurosurgical haemorrhage evacuation within 
24 hours of injury 42. A total of 51% of patients had evidence of progressive haemorrhage 
between admission and repeat CT done within 72 hours of injury 42.  
 
Patients who were scanned earlier after injury (≤ 3.5h vs. > 3.5h) were more likely to have 
expanding haematomas on CT performed 24 hours after injury (57% vs. 28%) 42. If the initial 
CT scan was conducted more than 3.5 hours after injury, the percentage of patients with 
measurable changes in haematoma volume 24 hours after injury was reduced. In a subset of 
patients who had an intermediate scan (most of which were between 6 and 9 hours of injury), 
the mean volume change between the baseline and intermediate scan was 5.7ml, whereas the 
difference in mean volume between the intermediate scan and the 24 hour scan was 0.03ml 42. 
Thus, the maximal change in intracranial haemorrhage volume appeared to occur soon after 
injury.  
 
1.5 Types of intracranial haemorrhage (bleeding) 
 
TBI patients often present with multiple intracranial bleeds of different types 34, 43. Intra-axial  
haemorrhage includes IPH (also referred to as intra-cerebral haemorrhage), which occurs in the 
brain tissue, and intra-ventricular haemorrhage (IVH), which occurs in the ventricles of the 
brain. Extra-axial haemorrhage (epidural, subdural, subarachnoid) occurs between the three 
membranes that surround the brain (dura mater, arachnoid mater and pia mater). EDH occurs 
between the skull and outer membrane of the central nervous system (dura mater). SDH occurs 
between the dura mater and middle membrane of the central nervous system (arachnoid mater). 
SAH occurs between the arachnoid mater and innermost membrane surrounding the central 
nervous system (pia mater). Figure 3 shows axial slices of CT scans with evidence of different 




Figure 3. CT axial slices showing, from left: EDH, SDH, SAH, IPH, IVH. e 
 
The Corticosteroid Randomisation after Significant Head Injury (CRASH) trial is the second 
largest randomised trial in TBI, among 10,008 patients across all injury severities 43. In the 
CRASH trial, 56% of patients presented with at least one intracranial bleed 43. Of 14,000 TBI 
patients in the Trauma Audit and Research Network (TARN), 30% of patients had SDH, whilst 
EDH, SAH and IPH each occurred in 22% of patients 34. Of those with any intracranial bleed, 
45% had one type, 16% had two types, 25% had three types and 14% had four types. The 
prevalence of these bleeds may be partly explained by the mechanism of the primary injury.  
 
 Subdural haemorrhage  
 
High-speed road traffic crashes often result in rapid acceleration-deceleration forces that cause 
bridging veins to rupture between the cortical surface and saggital sinus, causing acute SDH 44. 
Because SDHs are typically venous bleeds (compared to EDHs, which are typically arterial), 
they are at lower pressure and so may not progress as quickly as EDH 45. SDHs most commonly 
occur along the brain’s convexity, but may also occur in the interhemispheric space or along the 
tentorium 46, 47. Haemorrhage within the subdural space can travel freely and often covers the 
entire hemisphere 44. But SDH is not bound by dural-calvarial attachments like EDH and 
therefore also has a potential to enlarge quickly. Indeed, SDH is associated with a larger 
increase in the risk of death than EDH 48. In a study with 1,117 patients with TBI, the highest 
mortality was found in those with SDH and GCS 3-5 (74%), whilst patients with EDH and the 
same GCS had a mortality of 36% 49. In an analysis of the effect of large SDH on mortality, the 
odds ratio halved after adjustment for variables including age (OR 3.36, 95% CI: 2.76 to 4.08) 
34. The association between large EDH and mortality remained virtually unchanged after the 
same adjustment (OR 1.85, 95% CI: 1.36 to 2.51) 34.  
 
SDH may be common in older patients because the brain may atrophy with age 50, and this may 
result in the veins between the cortical surface and saggital sinus becoming stretched, and as 
                                                     
e The spherical white region on each scan shows the skull bone, the grey within shows the brain tissue and 
the off-white lesions of different shapes show the different intracranial haemorrhages Figure produced 
from images provided by https://radiopaedia.org 
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such, susceptible to rupture following head trauma 44. Compared to younger patients, older 
patients with cerebral atrophy may accommodate more intracranial bleeding before their 
consciousness reduces 51. An analysis in 25,082 patients with isolated TBI in the TARN 
database suggested that for an equivalent severity of intracranial injury, older patients present 
with a higher GCS than younger patients (<65 years vs ≥ 65 years of age) 51. Injury severity 
may be obscured in older patients, which may partly explain why older patients with TBI have a 
worse prognosis than younger patients. The pre-injury use of anti-coagulants 52, pre-admission 
functional ability 53, presence of co-morbidities such as hepatic disease, renal disease, cancer, 
and chronic steroid use 54 also worsen prognosis after TBI in older adults 55.  
 
 Epidural haemorrhage  
 
Both traumatic and non-traumatic mechanisms can cause EDH 56. The majority of traumatic 
EDHs are a result of motor vehicle collisions, physical assault or accidental falls 56. The 
incidence is higher amongst adolescents and young adults 34. EDHs can result from arterial or 
venous injury, but most result from arterial rupture of the middle meningeal artery 45. Arterial 
EDHs can develop rapidly and are detected quickly as arterial blood flows at higher pressure 
than venous blood 56. Patients with coagulopathy are at risk of EDH progression that requires 
surgery 57.  
A skull fracture is often present in patients with EDH 56. Motorcycle crashes can cause skull 
fractures that injure the arteries or veins just under the skull (especially the meningeal vessel) 
and increase the risk of EDH 17 58. After helmet laws were revised in Italy in 2000 such that 
helmets became compulsory for all motorcycle-moped-scooter drivers and their passengers, 
helmet use increased from less than 20% to over 96% 17. In a year, the number of patients who 
presented with EDH to a neurosurgical unit substantially reduced (42 vs 4), whilst the number 
of patients with SDH or diffuse injuries decreased to a lesser extent (18 vs 13) 17.  
A study of 160 TBI patients with EDH found that EDHs enlarged by a mean diameter of 7mm 
in 23% of patients, between admission and 8 hours of injury 59. In another study with 118 
patients with EDH, 12% developed a delayed EDH after an initially negative CT scan, whilst 
64% required immediate neurosurgical evacuation after admission 60. Large EDHs often 
substantially increase intracranial pressure and require urgent neurosurgical decompressive 
evacuation. All acute EDHs (and SDHs) 10mm thick or more are considered for evacuation 48. 
The neurosurgical prognosis following traumatic EDH is good for patients who receive rapid 
treatment. A study in 60 patients with EDH reported overall mortality of 25%, and 58% made a 
full recovery or had minimal neurological deficit 61. Faster neurosurgical intervention after coma 
onset (less than 2h vs more than 2h) was associated with less death (17% vs 65%) and better 
recovery (67% vs 13%). Similarly, a study in 82 patients who required neurosurgical evacuation 
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of SDH found that the risk of death reduced if evacuation occurred within 4 hours compared to 
beyond 4 hours of injury (30% vs 90%) 62. 
 
 Subarachnoid haemorrhage  
 
SAH often occurs after arterial or venous injury, and typically distributes in the cerebral sulci 
overlying the brain. In the CRASH trial with 10,008 patients with head injury, 78% of patients 
had an admission head CT scan, and around a third of these patients presented with SAH 43. In a 
study with 169 patients with TBI, of whom 69% had a GCS score of less than 9, the estimated 
prevalence of traumatic SAH was as high as 61% 63. Lower estimates were reported in a study 
with 698 TBI patients where 15% of patients presented with isolated SAH on admission CT 64. 
Compared to patients with other types of intracranial haemorrhage, patients with isolated SAH 
had lower injury severity scores (25.2 ± 11.5 vs. 18.2 ± 10.2: p<0.0001), higher emergency 
department GCS scores (10.5 ± 4.8 vs. 12.6 ± 3.9: p<0.0001), higher discharge GCS scores  
(14.3 ± 1.7 vs. 14.8 ± 0.9: p=0.005), shorter Intensive Care Unit stays (4.9 ± 6.4 vs. 3.1 ± 5.0 
days: p=0.007), lower mortality (14% vs. 4%: p=0.003), and fewer head CT scans (3 ± 2 vs. 2 ± 
1: p<0.0001) 64. Patients with isolated SAH and GCS scores between 13 to 15 demonstrated low 
rates of clinical progression, and when progression did occur, it resolved without further 
intervention. Repeat CT scanning for patients with isolated traumatic SAH is therefore rarely 
indicated because these patients tend to have milder injuries than patients with other types of 
intracranial haemorrhage 64, 65. Although SAH may occasionally clog the arachnoid villi with 
blood degradation products, reduce cerebrospinal fluid absorption and increase the risk of 
hydrocephalus, this is often transient 44.  
 
 Intra-parenchymal haemorrhage 
 
IPHs (cerebral contusions) also tend to occur with head motion from road-traffic crashes and are 
often localised to frontal and temporal lobes at the site of or opposite to the site of impact 
(“coup” and “contre-coup” pattern) 26. IPHs in the frontal and temporal lobes are likely to grow 
in size 41 in a short period of time 66. Whilst small IPHs that progress tend to be clinically silent 
and not require surgical decompression 67, large IPHs in patients with low GCS are more likely 
to progress and often require surgical decompression 68. 
 
A number of studies have described the amount of intracranial haemorrhage expansion that 
occurs soon after injury. In one such study with 262 TBI patients with IPH, 43 IPHs (16%) 
expanded by more than 13ml within 24 hours of injury 69. Compared to patients with mild GCS 
(13-15) or moderate GCS (9-12), patients with severe GCS (<9) were more likely to have IPHs 
that expanded by more than 13ml (0%, 11% and 26%, respectively). There were more 
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expanding IPHs in patients with IPH and associated haemorrhage compared to isolated IPH 
(17% vs 5%). Prognosis is worsened when IPH co-occurs with extra-axial bleeding 70. 
 
 Intra-ventricular haemorrhage  
 
IVH occurs in the brain’s lateral, third or fourth ventricles where the cerebrospinal fluid f is 
produced, and typically occurs several hours after injury 44. One study in 8,374 TBI patients 
with an admission CT scan, found that 118 patients (1%) showed evidence of IVH 71. Of those 
with IVH, 76% either had neurosurgical intervention or a Glasgow Outcome Scale score of 1 to 
3 (i.e. severe disability, persistent vegetative state, or died). Although the estimated volume of 
IVH tends not to be as large as other types of haemorrhage, its occurrence is a poor prognostic 
sign, with expected mortality between 50% and 80% 72. The occurrence of IVH can indicate that 
the flow of cerebrospinal fluid through the ventricles is blocked (obstructive hydrocephalus), 
especially if the fourth ventricle collapses 73. IPH and SAH commonly co-occur with IVH 74. 
Approximately 70% of IVHs are secondary; they occur as an extension of an IPH or SAH into 
the ventricular system 72. 
 
1.6 Intracranial haemorrhage expansion 
 
Studies suggest that the risk of death and disability due to TBI may be reduced by preventing 
intracranial haemorrhage expansion 42, 75, 76. But these studies are observational, and so the 
quality of this evidence is not robust. Furthermore, there is limited evidence on bleeding 
expansion, particularly according to bleed type, and whether expansion of different bleeds 
differentially affects the risk of death and disability.  
One study of 142 TBI patients with a median GCS of 8 suggested that intracranial haemorrhage 
expansion varies according to haemorrhage type 41. Repeat CT scans done within 24 hours of 
injury suggested that IPH appeared to expand in 51% of patients, EDH in 22%, SAH in 17% 
and SDH in 11% of patients. But this study considered any expansion between first and second 
CT scans as evidence for expansion and did not measure the amount of expansion. The different 
eligibility criteria and definitions for expansion between studies make accurate estimation of 
expansion rates difficult. The decision for neurosurgical haemorrhage evacuation between first 
and second scans also complicates assessment of expansion rates. Furthermore, intracranial 
haemorrhage in its hyper-acute phase (before clotting) may not manifest on CT as its 
appearance is based on blood clot density 31. Therefore, intracranial haemorrhage may have 
occurred by the point of the first CT scan, but not be visible. Studies that suggest that the 
prevalence of new bleeding on a second CT scan is greater when the first CT scan is done 
                                                     
f Cerebrospinal fluid cushions the brain and spinal cord.  
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sooner after injury 42 may not necessarily indicate that bleeding happens early, but that bleeding 
in its hyper-acute phase is not visible on a CT scan done very soon after injury 31. The absence 
of data on time from injury to scanning in many studies and the different times to scanning in 
studies that report these data limits understanding of the period over which expansion occurs or 
manifests on imaging. This makes it difficult to examine the effects of treatments aimed at 
reducing haemorrhage expansion; the effects of which may be modified or confounded by the 
time from injury to treatment.  
 
1.7  Coagulation and fibrinolysis 
 
Traumatic injury triggers two key processes: coagulation (the process by which blood clots) and 
fibrinolysis (the process by which blood clots break down). Coagulation involves aggregation 
and deposition of platelets at the point of injury 77. After thrombin is activated, fibrin is 
produced and this interacts with the platelet plug to produce a clot that acts as a haemostatic seal 
at the point of damage 78. Fibrinolysis involves breakdown of the fibrin mesh. Endothelial cells 
secrete tissue plasminogen activator (TPA), which converts plasminogen trapped within the clot 
into plasmin 79. Plasmin attaches to fibrin and initiates clot breakdown.  
 
The unique biochemical and cellular characteristics of the brain may make it prone to abnormal 
coagulation (coagulopathy) 80. But there is no clear consensus on the definition of coagulopathy 
80. This has resulted in a wide range of estimates for the prevalence of coagulopathy in TBI 
patients, with some studies reporting prevalence of 10% and others of 97% 81. These estimates 
vary according to the type of laboratory test used to define coagulopathy, the timings of these 
tests, and the heterogeneity in injury severity 82. Decreased platelet counts, prolonged 
prothrombin time and partial thromboplastin time, and high levels of fibrinogen and fibrin 
degradation products (D Dimer) are observed in patients within the first 3 hours of TBI 83. The 
highest D-dimer concentrations were found in the most severely injured patients 84. One study in 
61 head injury patients with a mean baseline GCS of 10 ± 4 reported that the 11 patients who 
died (6 of whom died due to head injury) had evidence of coagulopathy 85. 
 
A meta-analysis of 34 studies that reported the frequency of coagulopathy after TBI found that 
one third of patients with TBI have laboratory evidence of abnormal coagulation based on 
parameters such as fibrinogen, fibrin degradation products and anti-thrombin levels . The odds 
of mortality in patients with coagulopathy after TBI are nine times higher than in TBI patients 
without coagulopathy (OR 9.0, 95% CI 7.3–11.6); the odds ratios varied from 4 to 161 between 
studies. The odds of unfavourable outcome as measured by the Glasgow Outcome Scale (score 
of 1–3) are more than 30 times higher in TBI patients with coagulopathy (OR 36.3, 95% CI 
18.7–70.5); the odds ratios varied from 16 to 58 between studies 81. Estimates for the prevalence 
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of coagulopathy in this analysis are imprecise, which may reflect differences in study size and 
varying definitions for coagulopathy. This would explain heterogeneity in clinical outcomes 
between studies.  
 
Several studies suggest that TBI patients who have coagulopathy also have progressive 
intracranial haemorrhage. Specifically, coagulopathy is associated with an increased risk of 
progressive EDH (OR 0.36, 95% CI 0.15–0.85) 86. But the association between coagulopathy 
and risk of haemorrhage may not be causative as some TBI patients with coagulopathy do not 
































Research Paper 1 
 
The rest of this chapter includes Research Paper 1. The permission to reproduce this paper in 
this thesis is included in Appendix 1 and the full published version is included in Appendix 2. I 
have amended the published version of Research Paper 1 for clarity and presented this in the 
next section.  
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1.8 Tranexamic acid (TXA) 
 
Tranexamic acid (TXA) reduces bleeding by inhibiting the enzymatic breakdown of fibrin 
blood clots. Plasmin binds to fibrin via lysine-binding sites and then splits fibrin into fibrin 
degradation products. TXA is a molecular analogue of lysine that inhibits fibrinolysis by 














Figure 4. A: Normal fibrinolysis. B: Fibrinolysis inhibited by tranexamic acid.  g 
 
1.9  Effectiveness of TXA in reducing haemorrhage 
 
TXA is used routinely in some cases of trauma and in surgery. For example, it reduces the need 
for blood transfusion in surgical patients 88, 89. A systematic review of 104 randomised trials of 
TXA in surgical patients found that it reduces the number of patients receiving a blood 
transfusion by one-third and halved the need for further surgery to control bleeding 88. 
A systematic review of randomised trials of TXA following acute traumatic injury found that 
TXA reduces the risk of death due to bleeding by 15% (RR 0.85, 95% CI 0.76 to 0.96; p = 
0.0077) 90. There is no apparent increase in the risk of vascular occlusive events with TXA 
following acute trauma (RR 0.69, 95% CI 0.44 to 1.07; p=0.096). Although three randomised 
trials were included in the review, the CRASH-2 trial provided 99% of the data into the effect of 
TXA in acute trauma. The CRASH-2 trial is a large, randomised, double-blind, placebo 
                                                     
g The persmission to reproduce Research Paper 1 in this thesis includes persmission to reproduce this figure (see 
Appendix 1). Figure from Research Paper 1 (see Appendix 2). 
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controlled trial that explored the effects of TXA on death among adult trauma patients with, or 
at risk of, significant haemorrhage 91. The trial recruited 20,211 trauma patients with extra-
cranial bleeding from 274 hospitals in 40 countries. Patients were randomly allocated to receive 
1 gram (g) of TXA infused over 10 minutes, followed by an intravenous infusion of 1g over 
eight hours, or matching placebo (sodium chloride, 0.9%).  
 
TXA treatment within an hour of injury reduced the risk of death caused by bleeding by about 
one third (RR 0.68; 95% CI 0.57 to 0.82; p < 0.0001). TXA treatment between one and three 
hours of injury reduced the risk of death caused by bleeding by about one fifth (RR 0.79; 95% 
CI 0.64 to 0.97; p = 0.03). There was no apparent benefit after three hours of injury, and TXA 
might even be harmful after this period (RR 1.44; 95% CI 1.12 to 1.84; p = 0.004).  
  
1.10 TXA as a potential treatment in TBI 
 
If TXA is effective after TBI, it should be most effective when given soon after injury, when 
intracranial bleeding is ongoing 40. If early increased fibrinolysis exacerbates bleeding and 
increases the risk of death 84, we would expect TXA to be most effective during this period. 
Furthermore, the potential anti-inflammatory effects of TXA may be important in reducing the 
extent of inflammation (oedema) around cerebral contusions 92, 93. Neuro-inflammation is an 
important secondary injury mechanism after TBI that contributes to ongoing neurodegeneration 
and neurological impairment 92 94. Any anti-inflammatory effect of TXA would be particularly 
important for patients with severe isolated TBI who may have a shutdown in fibrinolysis 95-97.  
 
However, there is also the potential for harm. In particular, TXA may increase the risk of 
cerebral thrombosis and ischaemia 98. Cerebral ischaemia is an important secondary injury 
mechanism after TBI that worsens neurologic outcome and increases mortality 99, 100. It can be 
precipitated by raised intracranial pressure, which can lead to cerebral hypo-perfusion 101-104. In 
addition, thrombotic disseminated intravascular coagulation may increase the risk of cerebral 
microthrombi, which are often seen in the brains of TBI patients who die within 24 hours of 
injury 105. By inhibiting fibrinolysis, TXA might increase the risk of cerebral ischaemia and 
thrombosis in TBI patients. 
 
A 2015 systematic review of randomised trials of anti-fibrinolytic agents identified two relevant 
completed trials of TXA in TBI (see Table 2) 106, 107 h.  
 
                                                     
h The following databases were searched: the Cochrane Injuries Group's Specialised Register, The Cochrane Library, 
Ovid MEDLINE(R), Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations, Ovid MEDLINE(R) Daily and 




Table 2. Patients with intracranial haemorrhage, cerebral ischaemia, and mortality outcomes in 
two randomised trials of TXA in patients with traumatic brain injury. Values are numbers 
(percentages) unless stated otherwise. 
 
CRASH-2 Intracranial Bleeding Sub-study 
(2012) 106 
Yutthakasemsunt et al  
(2013) 107 
Outcome TXA Placebo Relative risk (95% CI) TXA Placebo Relative risk (95% CI) 
Intracranial haemorrhage 44 (36) 56 (44) 0.80 (0.59 to 1.09) 21 (18) 32 (27) 0.65 (0.40 to 1.05) 
Focal ischaemic lesion / stroke 6 (5) 12 (9) 0.51 (0.20 to 1.32) 0 3 (3) - 
Deaths 14 (11) 24 (18) 0.60 (0.33 to 1.11) 12 (10) 17 (14) 0.69 (0.35 to 1.39) 
 
Both trials were judged to be at low risk of bias across several domains (sequence generation, 
allocation concealment, blinding, incomplete outcome data and selective reporting) i. However, 
neither was large enough to answer the question definitively – the confidence intervals were 
wide and the P values statistically non-significant. The first trial (n=249) examined the effect of 
TXA in patients with extracranial bleeding but who also had TBI 106. The second trial (n=229) 
examined the effect of TXA in patients with poly-trauma and TBI, or isolated TBI 108. Both 
trials used information from pre- and post-randomisation CT scans to estimate the extent of 
bleeding and ischaemia. Both trials recruited patients who were within eight hours of injury but 
the numbers were not large enough to determine the balance of risks and benefits from TXA and 
whether this varies by time to treatment.  
 
When the two randomised trials are combined in a meta-analysis, there appears to be a 
statistically significant reduction in intracranial haemorrhage (RR 0.75, 95% CI 0.58 to 0.98, 
p=0.03) and mortality (RR 0.63, 95% CI 0.40 to 0.99, p=0.05) with TXA. In one trial, focal 
ischaemic lesions occurred in 5% of TXA-treated patients and 9% of placebo-treated patients 
(RR 0.51, 95% CI 0.20 to 1.32; p=0.17) 106. In the second trial, there were three strokes in the 
placebo group compared with none in the TXA group 107. However, because the confidence 
intervals for intracranial haemorrhage, death and ischaemic lesion outcomes are so wide, the 
quality of this evidence is low. Furthermore, the patients in one of the trials had extracranial 
bleeding in addition to intracranial bleeding 106. Because TXA reduces mortality in extracranial 
bleeding (CRASH-2), the mortality reduction seen in this trial could be from the extracranial 
injury rather than any effect on the brain injury itself. These trials do not reliably address the 
uncertainty regarding the effect of TXA on disability and thrombotic adverse effects including 
stroke. 
                                                     
i The quality of the evidence was rated as ‘high’, ‘moderate’, ‘low’ or ‘very low’ according to the Grading 
of Recommendations, Assessment, Development and Evaluations (GRADE) approach. The GRADE 
approach considers: impact of the risk of bias of individual trials; precision of the pooled estimate; 
inconsistency or heterogeneity; indirectness of evidence; impact of selective reporting and publication 
bias on effect estimate. Risk of bias was assessed using The Cochrane Collaboration’s ‘Risk of bias’ tool.  
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In 2016, a review of trial registries identified three ongoing randomised trials of TXA versus 
placebo in patients with isolated TBI (see Table 3). These trials evaluated the effect of TXA on 
death, disability, vascular occlusive events, and other adverse events in TBI. These trials will 






Table 3. Randomised trials of TXA use in TBI. 
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In two of the trials (n=1402) patients were randomised within two hours of injury in the 
prehospital setting (NCT02645552, NCT01990768). To date, the CRASH-3 trial, with a sample 
size of approximately 13,000 patients, is the largest randomised trial into the effect of TXA in 
TBI 109. In the CRASH-3 trial, patients were randomised in hospital and within eight hours of 
injury (NCT01402882) 109.  
 
Given the prevalence of TBI in older adults, a proportion of TBI patients enrolled in the 
CRASH-3 trial may receive anti-thrombotic treatments pre-admission, including anti-coagulant 
and anti-platelet medication 110. Anticoagulant therapy may increase the risk of intracerebral 
haemorrhage 111 and so TXA could reduce haemorrhage expansion in these patients. This 
reduction may be greater in patients receiving specific anti-thrombotic treatments 112. However, 
TBI patients who use anti-coagulant medication because of an underlying pro-thrombotic risk 
113 may not benefit with TXA, especially since TBI patients may be at risk of developing 
intravascular micro-thombosis 114. Therefore, the efficacy of TXA in TBI patients who used 
anti-thrombotic drugs pre-admission may be of clinical importance as these patients may be at 
greater risk of fatal bleeding or thrombosis. 
 
The size of the CRASH-3 trial should ensure that TXA and placebo groups are balanced with 
regards to known and unknown confounders, such as the use of oral anticoagulant and 
antiplatelet medication, the concomitant degree of coagulopathy, and the use and timing of anti-
thrombotic prophylaxis (e.g. low molecular weight heparin) 115. Therefore, it is unnecessary to 
standardise TXA and placebo groups for clinical management factors that may influence the 
extent of bleeding. Unless patients are randomised according to subgroup categories, any 
differences in the treatment effect may not be due to the factor defining the subgroup but some 
other factor associated with the subgroup 116. The CRASH-3 trial entry form does not measure 
all factors known to affect the extent of bleeding or thrombosis at baseline, and randomise 
patients on the basis of the primary intervention and these secondary factors. This would be 
logistically challenging and would result in a smaller trial. Instead, the entry form includes a 
small number of key patient characteristics to ensure a large and high-quality trial can be done 
where known (measured and unmeasured) and unknown confounders are balanced at baseline. 
 
The results from the three more recent trials should provide clinicians with information about 
whether TXA is effective in reducing death and disability without increasing thrombotic events. 
These trials will also provide information about whether the effect of TXA varies by injury 
severity and time to treatment. Information on the effect of TXA administered within one hour, 
between one and three hours, and after three hours of injury may be more useful than the 





1.11 Mechanism of action of TXA in TBI 
 
Although the CRASH-3 trial provides information on the effect of TXA on head injury death, it 
does not provide information on the mechanism by which TXA might exert its effects in TBI. 
An understanding of the mechanism of action of TXA and insight into factors that might affect 
this mechanism, is critical in the appropriate generalisation of trial results 117. If TXA reduces 
mortality by reducing intracranial haemorrhage as hypothesised, we may expect there to be less 
haemorrhage on head CT scans of TXA-treated patients. This information, along with the 
results of the main CRASH-3 trial, could inform the administration of TXA in TBI. If TBI 
patients who receive TXA soon after injury have less haemorrhage expansion compared to those 
who receive TXA later, then time between injury and treatment is a factor relevant to the 
mechanism of action which, with the results of the main CRASH-3 trial, should be considered 
when making treatment decisions. Furthermore, if TXA increases the risk of cerebral infarction, 
we may expect to see more infarcts in TXA-treated patients, particularly in those treated after a 
more prolonged period following injury 118. This information could be used to prevent adverse 
outcomes and ensure those receiving TXA are those most likely to benefit from it.  
 
The CRASH-3 Intracranial Bleeding Mechanistic Sub-Study (IBMS) will include a sample of 
CRASH-3 trial patients. The effect of TXA on intracranial haemorrhage and infarction will be 
examined using routinely collected brain scans done pre-randomisation and post-randomisation. 
The knowledge gained from the CRASH-3 IBMS will add to the evidence base and could 
benefit the clinical management of patients with head injuries. 
 
1.12  Aims 
 
This study aims to examine the mechanism by which TXA might exerts its effects in isolated 
TBI, specifically its effect (if any) on intracranial haemorrhage and infarction, and whether this 













This chapter includes sections of Research Paper 2 (study protocol) and Research Paper 3 
(statistical analysis plan). The permission to reproduce Research Paper 2 in this thesis is 
confirmed in Appendix 3 and a copy of the full published version is included in Appendix 4. The 
permission to reproduce Research Paper 3 in this thesis is included in Appendix 5 and a copy of 
the full published version is included in Appendix 6. I amended and re-organised some sections 
of the published papers for clarity and have presented these in this chapter. 
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Please note that the terms cerebral ischaemia and cerebral infarction in the paper titles refer to 
the same outcome. This was amended from ischaemia to infarction in order to avoid confusion 




































2.1 Trial registration 
The CRASH-3 trial was prospectively registered at the International Standard Randomised 
Controlled Trials registry (ISRCTN15088122) on 19 July 2011, and ClinicalTrials.gov on 25 
July 2011 (NCT01402882). The registries were updated with details for the CRASH-3 IBMS on 
20 December 2016. 
 
2.2 Trial design  
The CRASH-3 IBMS is a mechanistic, prospective, randomised, placebo-controlled, parallel 
group, international, multi-centre, double-blind trial nested within the CRASH-3 trial 
(NCT01402882).  
 
2.3 Eligibility criteria 
Patients who fulfil the eligibility criteria for the CRASH-3 trial, with a GCS of 12 or less or 
intracranial bleeding on a CT scan done before randomisation, are eligible for inclusion in the 





Figure 5. Flowchart: inclusion criteria for the CRASH-3 trial (blue boxes show additional 







                                                     




















































 adult  
 with traumatic brain injury  
 within 8 hours of injury 
 any intracranial bleeding on CT scan OR a GCS of 12 or less 
 Where the responsible clinician is substantially uncertain as to 




































Appropriate consent process (e.g. waiver, representative) 
RANDOMISE (TXA)  
Entry Form Completed 
Give loading dose over 10 minutes  
Give maintenance dose over 8 hours 
 
STUDY OVERVIEW  
RANDOMISE (Placebo)  
Entry Form Completed 


























2.4 Trial status 
The first patient was enrolled in the CRASH-3 trial on 20 July 2012. Data collection for the 
CRASH-3 IBMS started in February 2016. The CRASH-3 trial completed recruitment on 31 
January 2019. Routinely collected brain imaging data from patients included in the CRASH-3 
IBMS was examined for the purpose of the IBMS and recorded in a web database before this 
date. A total of 1,767 CRASH-3 trial patients’ scans were examined as part of the IBMS; these 
patients either had a pre-randomisation scan, a post-randomisation scan, or both pre-
randomisation and post-randomisation scans. 
 
2.5 Participating hospitals 
The hospitals participating in the IBMS were selected based on the number of patients enrolled 
in the CRASH-3 trial, whether it was possible for the scan assessor (Abda Mahmood) to 
perform on-site examination of electronic brain imaging done as part of routine care at that site, 
and the willingness of the trial principal investigator at site to take part. These hospitals were 
selected between February 2016 and January 2019, as the CRASH-3 trial was ongoing. We 
invited ten of the highest recruiting CRASH-3 trial hospitals in the United Kingdom (UK) to 
take part (Queen Elizabeth Hospital, Birmingham; Royal London Hospital, London; University 
Hospital Coventry, Coventry; Salford Royal Hospital, Salford; St George’s Hospital, London; 
King’s College Hospital, London; St Mary’s Hospital, London; Addenbrooke’s Hospital, 
Cambridge; John Radcliffe Hospital, Oxford, Southmead Hospital, North Bristol). We also 
invited four hospitals in Malaysia to take part: Hospital Sungai Buloh, Penang General Hospital, 
Hospital Sultanah Nur Zahirah and Hospital Sultanah Bahiyah. We will report the names of all 
participating sites in the final results publication, including the number of patients included in 
the IBMS at each site. All regulatory and ethical approvals were in place before data for the 
IBMS were collected at each site.  
 
2.6 Ethical approval 
The UK Medical Research and Ethics Committee and Health Research Authority reviewed the 
protocol and supporting documents for the IBMS and provided a favourable ethical opinion on 
8 June 2016 (Research Ethics Committee Reference 12/EE/0274). All participating UK 
hospitals provided Research and Development approvals and letters of access for the IBMS to 
be conducted at their respective sites. The Malaysian Medical Research and Ethics Committee 
reviewed the protocol and supporting documents for the IBMS and provided favourable ethical 
opinion on 16 May 2017 (Reference (25) KKM/NIHSEC/P12-476). All relevant local ethical 




Favourable ethical opinion was received from the Observational/Interventions Research Ethics 
Committee at LSHTM on 24 May 2016 (Reference11535). The relevant Medical Research and 
Ethics Committees will review important protocol modifications for approval before 
implementation, and registries updated as appropriate. 
 
The CRASH-3 trial protocol section “CT scan study” clarified that a separate protocol for this 
study would be presented (Section 2, Trial Design, 2.1 Overview, Page 10) 119. The UK 
Medicines and Healthcare Products Agency (MHRA) confirmed that the CRASH-3 IBMS 
protocol did not alter the main CRASH-3 trial protocol, and so did not require submission to 
MHRA for approval.  
 
2.7 Consent to participate 
TBI patients are physically and mentally incapable of providing informed consent to participate 
in a clinical trial. As acknowledged in the Declaration of Helsinki, patients who are incapable of 
giving consent are an exception to the general rule of informed consent in clinical trials 120. 
Section 24 of the declaration states that “For a research subject who is legally incompetent, 
physically or mentally incapable of giving consent or is a legally incompetent minor, the 
investigator must obtain informed consent from the legally authorized representative in 
accordance with applicable law. These groups should not be included in research unless the 
research is necessary to promote the health of the population represented and this research 
cannot instead be performed on legally competent persons” 120.  
In the CRASH-3 trial, patients are unable to provide consent and so consent is sought from the 
patient’s relative or a legal representative 121. If the patient’s relative or a legal representative are 
not available, consent is sought from two clinicians, and the patient is randomised into the trial 
if these two clinicians agreed for the patient to be randomised 121. If the patient regains capacity, 
they are informed about the trial and written consent sought to continue their participation in the 
trial. If a patient or patient representative declines consent, they are withdrawn from the trial and 
their participation in the trial discontinued. For patients who were included in the trial but did 
not regain capacity, written informed consent is sought from a relative or legal representative. 
The requirements of relevant local and national ethics committees are adhered to at all times. 
The CRASH-3 trial included consent to extract data from patient medical records. Collecting 
CT scan data for the CRASH-3 IBMS is consistent with the consent procedure used in the 
CRASH-3 trial. It would be impractical to re-consent patients or relatives/legal representatives 
to access CT scans, particularly for patients who have deceased or are disabled as a result of 
their injuries, where re-consent would be distressing and unwelcome. The London School of 




approvals to extract CT data from the CRASH-3 trial without further patient consent. Patients 
who withdrew from the main CRASH-3 trial were not included in the CRASH-3 IBMS. 
 
2.8 Randomisation into the CRASH-3 trial 
TBI patients eligible for inclusion into the CRASH-3 trial are randomly allocated to receive 
TXA or matching placebo (0.9% sodium chloride) and the trial treatment is started as soon as 
possible. Patients are randomised by selecting the lowest available numbered pack from a block 
of eight treatment packs. An independent statistician from Sealed Envelope (London, UK) 
prepared the randomisation codes using a computerised random number generator. These codes 
are shared with a certified clinical trial supply company so the treatment packs can be prepared 
in accord with the randomisation list. 
There is no need to withhold any clinically indicated treatment in the CRASH-3 trial. TXA or 
placebo are provided as an additional treatment to the usual management of TBI. The 1g loading 
dose of the trial treatment is administered by intravenous injection immediately after 
randomisation in hospital. The 1g maintenance dose (by intravenous infusion) should start as 
soon as the loading dose is completed.  
 
2.9 Adverse events in the CRASH-3 trial 
Any untoward medical occurrence affecting a trial patient up to 28 days after randomisation will 
be reported in line with the CRASH-3 trial protocol. If the patient develops an adverse event 
during the treatment phase, the trial drug should be stopped. In this situation, the patient should 
be treated in line with local procedures and then followed up.  
 
2.10 Unblinding in the CRASH-3 trial (before recruitment is complete) 
The treatment allocation is double-blinded such that trial team members, outcome assessors and 
patients are unaware of whether a trial patient will receive TXA or placebo. In the CRASH-3 
trial, if there are contraindications to TXA following randomisation, the trial treatment should 
be stopped and all standard clinical care provided. Unblinding is only necessary if the clinician 
believes that clinical management depends importantly upon knowledge of whether the patient 
received TXA or placebo. In this case, a 24 hour telephone service is available to confirm 
whether the patient received TXA or placebo.  
It will not be necessary to unblind treatment allocation on the basis of data from the CRASH-3 
IBMS, as these data are collected as part of routine patient care, and any clinical decisions made 





The independent Data Monitoring Committee monitor the unblinded results as the CRASH-3 
trial is ongoing, and may recommend for the early termination of the trial if there is clear 
evidence for benefit or harm with TXA. The final decision for early termination lies with the 
Trial Steering Committee.  
All data for the CRASH-3 trial will be subject to statistical monitoring and approximately 10% 
of data will be subject to on-site monitoring. Consent Forms will be monitored centrally by the 
Trial Coordinating Centre (where permission is given to do so). Investigators/institutions are 
required to provide direct access to source data/documents for trial-related monitoring, audits, 
ethics committee review and regulatory inspection. All trial-related and source documents must 
be kept for at least five years after the end of the trial. As all the CRASH-3 IBMS data will be 
collected directly from source data by the study lead (Abda Mahmood), additional monitoring 
will not be done for this data. 
 
2.12 Potential risks 
The effective radiation dose from a CT scan is about 2 millisievert (mSv) which is 
approximately the amount received from background radiation in eight months. Because 
CRASH-3 IBMS will use data from CT scans done as part of routine patient care, patients will 
not be exposed to extra radiation.  There is no additional burden or risk to the patient as a result 
of their participation in the CRASH-3 IBMS. It is standard care for all patients with TBI and 
associated clinical signs to have a CT scan. Follow-up CT scans are often conducted for 
diagnostic purposes around 24 to 72 hours after the initial scan. Steps taken to minimise the 
risks associated with handling personal data will be detailed in the Confidentiality section.  
 
2.13 Confidentiality 
Only staff with authorised access to the scans, either as clinicians or research contract holders, 
will be able to retrieve and review them. Completed scan data forms will be uploaded onto a 
secure web database. Access to the database is only possible for authorised individuals, who 
have login accounts and passwords. The entry and outcome scan data forms will contain no 
patient identifiable data. Scans include the date and time of the scan and this information could 
potentially be used by anyone with access to the hospital radiology system to identify the 
patient. For this reason, scan data forms will only include the randomisation number, the time 
interval between the injury and the scan (pre-randomisation scan form) and the time interval 
between randomisation and the scan (post-randomisation scan form). As no personal data will 




2.14 Sample size 
We originally planned for the CRASH-3 IBMS to be conducted in 1,000 CRASH-3 trial 
patients. This sample size was based on the reduction in intracranial bleeding volume seen with 
TXA in the CRASH-2 Intracranial Bleeding Sub-study 106. We expected a 15% reduction in 
intracranial bleeding with TXA (24ml TXA, 28ml placebo), a correlation of 0.6 between pre- 
and post-randomisation bleeding volumes, and a standard deviation of 28ml. This gave an 
unadjusted sample size estimate of 1542 patients to achieve 80% power to detect the expected 
treatment effect, which was reduced to 987 patients with adjustment (1542*(1-(0.62)) 122. The 
sample size estimates were reviewed and approved by Medical Statisticians at LSHTM.  
The blinded data from 1,000 patients showed that because sites could randomise patients before 
a CT scan was done if the patient had a GCS score of 12 or less, pre-randomisation CT scans 
were often not done (26%), or done only minutes after randomisation (10% of patients were 
scanned between 1 and 30 minutes after randomisation). TXA may not have had sufficient 
opportunity to act and its effect on intracranial bleeding or infarction manifest on a scan done 
this quickly after randomisation. The inclusion of these scans would dilute any effect of TXA 
on intracranial bleeding and infarction towards the null. Increasing the sample size could reduce 
some of this null bias. Furthermore, given the less frequent occurrence of post-randomisation 
cerebral infarction compared to intracranial bleeding (7% vs 97%), increasing the sample size 
would allow for a more reliable examination of the effect of TXA on cerebral infarction.  
The sample size was increased to include a maximum of 2,000 patients. This was the 
approximate maximum number of patients I could feasibly collect data from before the 
CRASH-3 trial completed recruitment. I did not expect to collect data from 2,000 patients (due 
to many international sites not using electronic imaging, and the limited time and resources for 
this study). This upper bound was chosen to prevent delays in data collection as a result of 
protocol amendments that would be needed should the sample size be increased again.    
Assuming that 47% of patients will be dropped (26% pre-randomisation, 21% post-
randomisation) from a study with 2000 patients because they are not scanned pre- or post-
randomisation, this leaves a study with 1060 patients who are scanned both pre- and post-
randomisation. Using the same standard deviation (adjusted for baseline), correlation and 
baseline adjustment values as the original sample size calculation, there is 83% power to detect 
the expected treatment effect. Realistically, I expected around 1,700 patients could be included 
in the CRASH-3 IBMS. If we assume that around 47% of patients will be dropped from the 
analyses, this leaves a study with 901 patients scanned pre- and post-randomisation. Using the 
same standard deviation (adjusted for baseline), correlation and baseline adjustment values as 
the original sample size calculation, a study with 901 patients would have 76% power to detect 




2.15 Interim analyses 
There are no interim analyses planned for the CRASH-3 IBMS because this is an exploratory 
study to help explain the CRASH-3 trial results; these analyses from a small sample of trial 
patients are unlikely to provide overwhelming evidence of benefit or harm with TXA. The 
findings from the CRASH-3 IBMS may inform the interpretation of the CRASH-3 trial results, 
but are unlikely to be used in isolation to support clinical decisions, especially before all data in 
the IBMS have been examined and before the CRASH-3 trial completes recruitment. The final 
analysis of the unblinded results will take place after CRASH-3 trial recruitment is complete, 
the data have been cleaned and the CRASH-3 trial database and CRASH-3 IBMS database have 
been locked as per the procedures detailed in the Data Management Plan (DMP) (version 1.0) 
(see Appendix 9).  
 
2.16 Publication and dissemination plans 
The results from this trial will be published in peer reviewed journals. Dissemination of results 
to patients will take place via the media, trial website (www.crash3@lshtm.ac.uk) and relevant 
patient organisations. All participating sites will be credited in key publications.  
 
2.17 Funding 
The CRASH-3 IBMS is fully funded by LSHTM (Grant reference EPAA6020). The design, 
management and interpretation of the CRASH-3 trial and IBMS are entirely independent of the 
manufacturers of TXA or the funders.  
 
2.18 Indemnity 
LSHTM accepts responsibility attached to its sponsorship of the CRASH-3 trial and IBMS and, 
as such, would be responsible for claims for any non-negligent harm suffered by anyone as a 
result of participating in the CRASH-3 trial and IBMS. The indemnity is renewed on an annual 
basis and LSHTM assures that it will continue renewal of the indemnity for the duration of this 
trial. 
 
2.19 Sponsorship and trial management 
The CRASH-3 trial and IBMS are sponsored by LSHTM and its responsibilities coordinated by 
the Clinical Trials Unit. The responsibilities of the Clinical Trials Unit are overseen by the Trial 




Group, Protocol Committee, Independent Data Monitoring Committee, Trial Steering 




2.20 Primary outcome  
The mean volume of IPH will be compared between trial arms in patients randomised within 
three hours of injury, adjusting for prognostic covariates. 
In the original IMBS protocol 123, we said the total volume of intracranial bleeding would be 
compared between treatment groups. Since publishing the protocol, we collected blinded data 
from 1700 trial patients, which suggest that any effect of TXA on intracranial bleeding 
expansion may only be reliably detected in IPH. These bleeds are less likely to be surgically 
evacuated compared to SDH and EDH, which are often larger and therefore substantially 
increase intracranial pressure and require urgent neurosurgical evacuation. Large SDHs and 
EDHs are easier to evacuate because they occur outside of the brain tissue, whereas IPHs often 
occur deep within the brain tissue so it is difficult to evacuate them without causing further 
harm. Therefore, we may not be able to reliably examine the effect of TXA on SDH and EDH 
expansion given that large bleeds are often evacuated before we can examine any effect of TXA 
on them. Including bleeds that may not be affected by TXA in the primary outcome would 
dilute any effect of TXA on intracranial bleeding expansion to the null.  
Furthermore, when excluding patients who have undergone neurosurgery by the first rated post-
randomisation scan, the proportional expansion of IPHs from pre- to post-randomisation is 
greater than for all other types of intracranial bleeding. Indeed, a recent randomised trial found a 
statistically significant reduction in spontaneous intracerebral bleeding expansion with TXA 124 
k. Finally, IPHs are often spherical in shape, so there is less measurement error with the ABC/2 
method of volume estimation compared to SDH and EDH, which have concave and convex 
shapes, respectively. For these reasons, the primary outcome will examine the effect of TXA on 
the total volume of IPH. 
In the original IBMS protocol 123 , the primary outcome included all patients randomised within 
8 hours of injury. Since the protocol was published, an individual patient data meta-analysis was 
published which included 40,138 patients with acute severe bleeding enrolled in randomised 
trials of TXA 125. This meta-analysis showed that immediate treatment improved the odds of 
survival by more than 70% (OR 1·72, 95% CI 1·42–2·10; p<0·0001). Thereafter, the survival 
                                                     
k Please note that the TICH-2 trial examined the effect of TXA on spontaneous intracerebral bleeding 




benefit decreased by about 10% for every 15 minutes of treatment delay until 3 hours, after 
which there was no benefit. To quantify any reduction in bleeding volume with TXA compared 
to placebo in the IBMS, we must examine the primary outcome during the interval where 
bleeding is at greatest risk of expansion. If there is a minimal change in bleeding volume after 
three hours of injury, including patients treated after three hours of injury in the primary 
analysis will dilute any effect of TXA towards the null. Therefore, we will restrict the analysis 
of the primary outcome to three hours of injury. 
2.21 Secondary outcomes  
(a) Frequency of progressive bleeding in patients randomised within 3 hours of injury: number 
of patients with a post-randomisation scan with a total bleeding volume of more than 25% of the 
volume on the pre-randomisation scan; 
(b) Frequency of new bleeding in patients randomised within 3 hours of injury: number of 
patients with haemorrhage on the post-randomisation scan that was not seen on the pre-
randomisation scan; 
(c) Number of patients with cerebral infarcts seen on a post-randomisation scan and not known 
to be present pre-randomisation; l 
(d) Mean volume of intracranial bleeding seen after randomisation in patients who undergo 
neurosurgical haemorrhage evacuation. 
(e) Composite poor outcome: progressive bleeding (“a” above), new bleeding (“b” above), 
cerebral infarction (“c” above), head injury death, or the need for neurosurgery within 28 days 
of injury. 




                                                     
l A 25% increase in haemorrhage volume between pre- and post-randomisation scans was used to define 
progressive haemorrhage in the two previous double-blind randomised trials of TXA on haemorrhage 
expansion in TBI 106, 107. The same definition was chosen in the CRASH-3 IBMS to ensure synthesis of 







2.22 Estimating haemorrhage volume on head CT 
 
Patients often undergo one brain CT scan as part of routine medical care prior to randomisation 
into the CRASH-3 trial. After randomisation into the CRASH-3 trial, many patients are scanned 
again as part of routine medical care. In the IBMS, we will measure the volume of intracranial 
haemorrhage on pre-randomisation and post-randomisation CT scans. I conducted a systematic 
literature review of the methods and scales that have been used to estimate haemorrhage 
occurrence and volume on head CT. I have provided an overview of the methods, findings and 
conclusions of this review below.  
Objectives. To identify a simple validated method to estimate intracranial haemorrhage volume 
on head CT scans.  
Search methods. In March 2016, I searched PubMed, Embase and Medline online databases 
for publications written in English or translated into English.  
Selection criteria. I searched for studies that used CT grading scales, classifications or 
categorisations of intracranial haemorrhage.  
Search terms. To identify relevant studies, I used Medical Subject Headings (MESH) and 
searched the Titles and Abstracts of studies included in these databases using specific search 
terms. For intracranial haemorrhage, search terms included: Intracranial hemorrhage, traumatic 
[MeSH Terms], intracranial haemorrhage, intracranial hemorrhage, intracranial bleed*, 
intracranial clot*. For CT scans, search terms included: Tomography, X-Ray Computed [MeSH 
Terms], Computed tomogram*, CT scan*, CT head, head CT. For CT rating scales, search 
terms included: CT class*, CT grad*, CT scale*, CT categor*, grading scal*, classification 
scal*, classification grad*, classification system, scale*, grade*, classification*. I searched for 
studies that included at least one term from each of the three lists of terms i.e. studies that 
reported CT rating scales including intracranial haemorrhage.  
Data collection. I performed the electronic searches in each database and reviewed the Titles 
and Abstracts of the articles to explore whether they provided relevant information on the 
review objectives (one rater, Abda Mahmood, Candidate).  
Main results. I identified 12 relevant studies and have summarised these in Tables 4 and 5. Table 
4 describes six established CT rating scales that include a categorisation of intra-cranial 
haemorrhage. Table 5 describes six further rating scales used for the characterisation of intra-




Table 4. Established CT rating scales that include examination of intra-cranial haemorrhage.  
CT rating scale Year 
published 
Rating scale categories 
Fisher scale 126 
  
1980 Groups 1-4:  
1, no SAH/IVH;  
2, diffuse thin (<1mm) SAH with no clots;  
3, localised clots and/or layers of blood (>1mm in thickness) +\- 
ICH/IVH;  
4, no or thin SAH + ICH/IVH 
World Federation of 
Neurological 
Surgeons (WFNS) 
SAH grading 127 
1988 Grade 1-5: 
1, GCS score of 15 without focal deficit 
2, GCS score of 13/14 without focal deficit 
3, GCS score of 13/14 with focal deficit  
4, GCS score of 7-12 
5, GCS score of 3-6 
Marshall scale 128 
 
 
1991 Diffuse injury I-IV:  
I, (no visible IC pathology);  
II, cisterns present with midline shift (0-5mm) and/or lesion densities – no 
high or mixed-density lesion >25cm3 may inc. bone fragments/foreign 
bodies;  
III, (swelling), cisterns compressed/absent with midline shift (0-
5mm)/mixed density >25cm3;  
IV, (shift), midline shift >5mm – no high/mixed density lesion>25cm3;  
Evacuated mass lesion, any lesion surgically evacuated;  
Non-evacuated mass lesion – high/mixed density lesion >25cm3, not 
surgically evacuated 
ABC/2 129 1996 A: greatest haemorrhage diameter by CT 
B: diameter 90 degrees to A 
C: approximate number of CT slices with haemorrhage multiplied by slice 
thickness 





2005 Basal cisterns (0, normal; 1, compressed; 2, absent); 
Midline shift (0, no shift / <=5mm; 1, shift > 5mm); 
Epidural mass lesion (0, present; 1, absent); 
Interventricular blood or tSAH (0, absent; 1, present) 
*final score is sum of scoring items + 1 
Modified Fisher 
scale 131 
2006 Grade 0-4:  
0, no SAH/IVH;  
1, focal/diffuse, thin SAH, no IVH;  
2, focal/diffuse, thin SAH, with IVH;  
3, focal/diffuse, thick SAH, no IVH;  
4, focal/diffuse, thick SAH, with IVH 











Table 5. Other CT measurement techniques including categorisation of intra-cranial haemorrhage.  
Author(s) Year 
published 
n with [injury] Measurement technique and/or findings 
Peterson & 
Esperson 132 
1984 54 w/ EDH 
(artificial) 
Volume estimate (0.5 x height x length x depth) 
moderately reliable.  
 
Midline shift and “vessel-free space” poor indicators of 
size.  
Hijdra et al 133 1990 182 w/  
aneurysmal SAH 
Blood in 10 basal cisterns and fissures in 4 ventricles 
graded:  
0, none;  
1, sedimentation in posterior;  
2, partly filled;  
3, completely filled.  
Sum score of IV blood was the total of the four scores 
and ranged from 0-12.  
Greene et al 134  1995 252 w/  
traumatic SAH 
In descending order of contribution to GOS at discharge:  
basal cistern effacement,  
tSAH thickness,  
cortical sulcal effacement,  
mass lesion(s),  
tSAH location.  
 
Midline shift non-sig.  
 
Grade 1-4:  
1, (thin SAH, ≤ 5 mm);  
2, (thick, 5mm);  
3, (thick tSAH with mass lesion(s));  
4, (thick tSAH with mass lesions).  
 
Lower grades, higher GCS and discharge GOS.  
Claassen et al 135 2001 301 w/  
aneurysmal SAH 
Amount and location of SAH, IVH, and ICH quantified.  
Thick clot completely filling any cistern/fissure – best 
predictor of DCI.  
Blood in both lateral ventricles – best predictor of IVH.  
Additive and independent predictors. 
 
Grade 1-4:  
1, no SAH/IVH;  
2, minimal/thin SAH, no IVH in both lateral ventricles;  
3, thick SAH, no IVH in both lateral ventricles;  
4, thick SAH, IVH in both lateral ventricles.  
Wardlaw et al 136 2002 425 w/ TBI 7-point grading scale (normal, mild, moderate, or severe 
focal injury, mild, moderate, or severe diffuse injury) 
Bhattathriri et al 137 2003 
 
43 w/ spontaneous 
ICH 
Site and sides of involvement, scale present on scan itself, 
and length, breadth, height and depth of ICH, and midline 
shift.  









Conclusions. This review identified one method that focuses exclusively on estimating 
haemorrhage volume (i.e. ABC/2). This is a simple validated scale for measuring intracranial 
haemorrhage volume (ABC/2) and shows good agreement with the gold standard of computer-
assisted volumetric analysis, which requires demarcation of the borders of haemorrhage 138-149.  
2.23 Systematic literature review on association between ABC/2 and automated methods 
for estimating haemorrhage volume 
 
The ABC/2 method is a quick and easy technique used to estimate the volume of intracranial 
haemorrhage 129. This method assumes haematoma volume is approximately equal to an 
ellipsoid shape (i.e. three dimensional oval shape). For ease of assessment, the formula for 
calculating the volume of an ellipsoid [4/3 x π x (A/2) x (B/2) x (C/2)] can be simplified to 
ABC/2 if we assume π is equal to 3. This method selects a representative slice near the centre of 
the haematoma on which the bleed is most visible. On this slice, two measurements are taken: 
(A) the maximal diameter; (B) width perpendicular to A. For the measurement of depth, the 
maximal number of slices on which the haematoma is visible is multiplied by slice thickness 
(C). These three measurements are multiplied and the sum divided by two (ABC/2) to provide 
the volume measurement in cm3 (ml). One cubic centimetre is equivalent to one millilitre.  
I conducted a systematic literature review on the association between ABC/2 and computer 
assisted methods of estimating intracranial haemorrhage volume. I have provided an overview 
of the rationale, methods, findings and conclusions from this review below.  
Background. Automated methods provide a more accurate estimate of haemorrhage volume 
compared to manual methods because they can precisely trace the size and shape of a lesion. 
However, manual methods may be the only practical option in some settings, and so the degree 
of agreement between manual and automated methods is relevant for researchers and clinicians 
who may only have resources to use the manual method. If the manual method provides 
sufficiently similar estimates to the gold standard automated method, the decision to use one over 
the other could be based on logistic practicalities and preference.   
 
Objectives. To explore the association and accuracy of the ABC/2 method of estimating 
haemorrhage volume compared to computer-assisted automated volumetric analyses.  
 
Search methods. In March 2016, I searched PubMed, Embase and Medline online databases for 
publications written in English or translated into English.  
 
Selection criteria. I searched for studies that compared the ABC/2 method of estimating 
haemorrhage volume against automated methods of estimating haemorrhage volume. Although 
this review was primarily concerned with the agreement between these two methods, it did not 





Search terms. To identify relevant studies, I used MESH and searched the Titles and Abstracts 
of studies included in these databases using specific search terms. For the ABC/2 method, search 
terms included: ABC/2, ABC/2 method, ABC/2 technique, ABC/2 formula, ABC/2 equation, 
Tada formula. For computer assisted automated methods, search terms included: Image 
processing, computer assisted (MESH), Automated, semi-automated, semi automated, 
planimetr*, computer assisted, computer-assisted, volumetric analys*, software. I searched for 
studies that included one term from each of the two lists of terms i.e. studies that used both manual 
and automated methods.  
 
Data collection. I performed the electronic searches in each database and reviewed the Titles and 
Abstracts of the articles to explore whether they provided relevant information on the review 
objectives (one rater, Abda Mahmood, Candidate). If the Abstracts did not provide the relevant 
information on the correlation and/or agreement between ABC/2 and automated methods, or did 
not provide information on how ABC/2 was used or what specific automated method was used, 
the Methods sections of the articles were reviewed for this information.    
 
Main results. A total of 41 relevant studies were identified. Full texts were not available for 8 of 
these studies. A total of 16 studies provided haemorrhage volumes estimates (or other relevant 
statistics) using manual and automated methods. These findings are summarised in Table 6. 
 
Conclusions. Of the 16 studies that provided relevant information on the review objective, most 
examined the association between manual and automated methods in traumatic or spontaneous 
intra-cerebral haemorrhage (i.e. IPH) (n=11) – one of these studies also estimated the volume of 
SDH using these methods. A smaller proportion of studies were in patients with EDH (n=2), 
infarction (n=2) or gliomas (n=1). Although the majority of studies provided average volume 
measurements for each method (n=11), they did not provide relevant statistics for agreement 
between the manual and automated methods. A total of 14 studies provided correlation 
coefficients, which are not reflective of agreement between methods, as two measures may 










Table 6. Studies on the association between the ABC/2 method and automated methods for 
estimating volumes of intra-cranial bleeding, infarction or tumours.   
 



























91.0 cm3  82.4 cm3 R=0.842 
Wang et al 139 2009 40 Intracerebral Volumetric analysis 46.6 ml 33.8 ml R=0.96 




et al 140 
2011 23 Intracerebral 
Manual slice by slice 
segmentation 
20 cm3 27 cm3 R2=0.96 
Maeda et al 
141 
2013 20 Intracerebral Planimetry 12.8 cm3 15.0 cm3 R=0.98, p<0.001 





Planimetry 46 cm3 32 cm3 R2=0.84 













Regular shape 0.97; 
Irregular shape: 
0.98 
Yan et al 143 2013 344 
Intracerebral 
parenchyma 
Planimetry - - R > 0.9   
Xu et al 144 2014 294 Intracerebral Software 3D Slicer 58.4 cm3 50.4 cm3 t=10.01, p<0.01 
Wang et al 145 2014 106 Intracerebral 




27.8 ±  
35.6 ml  
R2 = 0.97 (p<0.001) 











R2=0.87 (local site) 








21.76 ml R=0.79 
Hu et al 147 2016 35 Epidural Planimetry   R=0.99, p<0.05 












ROI based manual image 






40.42 cm3 R2=0.83 
Khan et al 149 2016 135 
Spontaneous 
intracerebral 










Compared to the manual ABC/2 method, computer-assisted automated volumetric analyses 
precisely trace the size and shape of a lesion, and so provide more accurate estimates of 
haemorrhage volume in irregularly shaped or multi-lobular lesions 129, 143, 145-149, 152, 155-159. It is 
unclear whether the ABC/2 method overestimates 139, 144, 145, 147, 152, 155-158 or underestimates 141, 159 
haemorrhage volume compared to computer-assisted methods, and whether adjusting for the 
depth of the lesion underestimates or overestimates haemorrhage volume 160 148. Furthermore, 
the data collection process is less labour intensive and time consuming when using automated 
methods in a large number of patients as haemorrhage volume can be automatically computed 
rather than manually estimated. Recent studies have confirmed good agreement between ABC/2 
and computer assisted automated methods in intra-cerebral haemorrhage 146. 
Although the ABC/2 method is a less specific measure of haemorrhage volume than computer 
assisted volumetric methods, and overestimation due to false positives would dilute the effect of 
the treatment towards the null, its low sensitivity and underestimation due to false negatives would 
not impact the effect of the treatment on haemorrhage. Furthermore, the more accurate method of 
estimating haemorrhage would require for the software (e.g. OsiriX MD) for conducting 
automated or semi-automated volume estimation to be installed on a clinical computer at each 
hospital site, and this may prove logistically challenging. It would cost approximately £7,660 in 
total for OsiriX MD to be installed at 15 hospital sites 161. Because it is unknown how long it will 
take for this software to be approved for installation for research purposes and installed on clinical 
computers at each hospital site, we judge that this method may only be possible in a smaller 
number of patients given the time constraints and limited budget of a clinical trial. Alternatively, 
the ABC/2 method can be done using clinical imaging software PACs that will already be in place 
at each site. Although a more accurate method in a small trial would result in less measurement 
error, a less accurate method in a larger trial would result in less random error. We believe that 
the ABC/2 method is sufficiently accurate and so we chose to use this method in a larger trial. 
Furthermore, the assessor rating the scans will be blind to treatment allocation and so any bias 
from measurement error should be balanced between treatment groups.  
 
2.24 Estimating IPH, IVH and EDH volume using ABC/2 
 
Volume estimation of intracranial haemorrhage is aided by the characterisation of haematomas. 
The final shape of a haematoma is influenced by its location. IPH and EDH tend to have regular 
shapes that are clearly definable in every dimension (i.e. their length, width and depth can be 
measured on a CT scan). The ABC/2 method assumes the haemorrhage has an ellipsoid shape, 
and has been validated in IPH 138 and EDH 147, 148. We will estimate the volume of IPH and EDH 




In the original protocol, I said that the ABC/2 method had been validated in IVH. Since, I learnt 
that I made an error when interpreting the results of one research study. In this study, patients 
had both IPH and IVH, and the ABC/2 method was validated in IPH but not IVH 146. Despite this, 
the volume of IVH has been estimated using the ABC/2 method in the CRASH-3 IBMS. I will 
consider the implications of this error when interpreting the results.   
 
2.25 Estimating SDH volume using maximum width 
 
SDH are crescent shaped as they follow the pattern of the brain’s convexity. The exact limits of 
SDH are not clearly definable in any dimension. This type of haemorrhage can theoretically 
occupy the entire subdural space. Given that the ABC/2 method assumes the haemorrhage has an 
ellipsoid shape, it would not provide an accurate volume estimation of SDH. Indeed, there have 
been reports of underestimation in SDH volume when using an adapted version of the ABC/2 
method compared with computer assisted volumetric analysis 141, 159.  
Some researchers and clinicians propose that the volume of SDH would be more accurately 
estimated using a formula which takes the difference between two spheres (divided by 8) to 
represent the subdural space that a SDH occupies (see Appendix 10). This method has been tested 
at the Neurosurgical Trauma Unit at the Queen Elizabeth Hospital in Birmingham (UK) and could 
provide more clinically relevant estimates of SDH volume than the ABC/2 method 162. Although 
this method overestimates SDH volume, the investigators expect that this would be less than the 
error from the ABC/2 method. The key measurement in determining the clinical significance of 
a SDH is its width (i.e. the B measurement when using the ABC/2 method) 48. In the CRASH-3 
IBMS, we will measure the maximum width of a subdural bleed, and compute its volume using 
the aforementioned formula (see Appendix 10).   
 
2.26 Total haemorrhage volume  
 
The total haemorrhage volume on each scan will be calculated by totalling the volumes of IPH, 
IVH, EDH and SDH.  
 
2.27 Measurement of SAH 
 
SAHs occur in the area between the arachnoid membrane and the innermost membrane 
surrounding the brain (pia mater). The shape of the subarachnoid space resembles a spider’s web 
and so haemorrhage in the subarachnoid space cannot be clearly measured in any dimension. 




they are criticised for being subjective and not comprehensive enough to serve as a primary 
grading scale for this type of haemorrhage 163. For example, the Fisher scale and its modified 
version do not consider SAH in isolation but in combination with IVH 131.  
In the CRASH-3 IBMS, the size of SAH will be characterized as small, medium or large. Each 
bleed will then be described as focal (localised to a specific location), multiple (not localised but 
not widespread) or diffuse (widespread). This method is also subjective and may have low 
sensitivity and specificity, therefore misclassification would bias the treatment effect towards the 
null value. But we hope that by using this method in a large trial, the bias from measurement error 
would be offset by a reduction in random error.  
 
2.28 Petechial haemorrhage 
Petechial haemorrhage manifests as a very small hyper-intensity on a CT scan. CT scans and 
accompanying radiology reports will be examined to indicate whether petechial haemorrhage is 
present.  
 
2.29 Cerebral infarction 
Cerebral infarction (or ischaemic stroke) is due to the compromise of blood and oxygen flow 
through either large or small arteries supplying the brain parenchyma. Thrombotic occlusion of 
intracranial vessels produce wedge-shaped cortical infarctions. 
Cerebral infarction would reliably manifest on a CT scan done at least 48 hours after 
randomisation 164. However, given that clinical scans are done for diagnostic purposes, it is not 
possible to carry out scans at set time-points post-randomisation. Brain imaging techniques 
including Magnetic Resonance Imaging (MRI) diffusion weighted imaging have higher 
sensitivity and specificity compared to CT in the early diagnosis of infarction, and are often 
clinically warranted when there is a suspected stroke. Therefore, the assessor will examine all 
available brain scans done within 28 days of randomisation and accompanying radiology reports 
for evidence of infarction, and record the time from randomisation to detection.  
Furthermore, given that CT imaging is the first and most common neuroimaging examination 
performed for emergency assessment of suspected acute haemorrhage and stroke around the 
world 165, 166, the majority of scans included in the CRASH-3 IBMS will be CT scans. Therefore, 
it is important to clarify how we will capture this endpoint when only CT scans are available. 
Cerebral infarction manifests as wedge-shaped low attenuation on a CT scan. Given that oedema 
also manifests as low attenuation on CT, the radiology reports that accompany CT scans should 
indicate whether the low attenuation is representative of oedema or infarction. Brain imaging 




artery, middle cerebral artery, posterior cerebral artery, lacunar, cerebellar, brainstem). The 
assessor will examine all available brain imaging to assess whether oedema or infarction can be 
excluded given the appearance of earlier scans. For example, some patients have oedematous 
haemorrhagic lesions which on CT manifests as high density haemorrhage surrounded by low 
density oedema. In later scans, the haemorrhage may resolve but the oedema may remain. If only 
considered alone, the later CT scan may have the appearance of infarction but could be 
representative of residual oedema. We will attempt to minimise such errors by comparing the 
appearance of cerebral infarction/oedema between consecutive scans, and consider the 
accompanying scan reports for radiological opinion. If the available scans and accompanying 
reports are unable to confirm the presence of an infarct, we would seek further radiological and 
clinical opinion. 
2.30 Mass effect and other CT endpoints 
Space-occupying intracranial lesions can displace brain tissue. The shift of midline structures past 
the centre line of the brain will be measured in millimetres (mm). We will also record whether 
mass effect has caused ventricular effacement and sulcal effacement.  
All scans will be rated according to the Marshall classification; the most extensively used CT 
classification scale in TBI 128. Three main characteristics define the Marshall classification: 
presence of mass lesion, degree of compression of perimesencephalic cisterns and degree of 
midline shift. See Appendix 11 for a flowchart developed for the purpose of this study to aid 















DATA COLLECTION, MANAGEMENT AND INTEGRITY 
 
2.31 Data collection procedure 
 
The CRASH-3 trial database will be used to prepare a list of all patients with either a GCS score 
of 12 or less or a pre-randomisation CT scan at participating sub-study hospitals. The list will 
include unique randomisation (box and pack) numbers, date and time of randomisation, and time 
between injury and randomisation into the CRASH-3 trial. The randomisation numbers will be 
used at the participating site to identify the patient using their hospital number. The outcome 
assessor (with training in brain imaging assessment) will hold a letter of access at the participating 
hospital and use the patient hospital number to retrieve and assess pre- and post-randomisation 
scans from the hospital electronic imaging system (usually PACs). The outcome assessor will 
complete the entry and outcome forms at each site using the relevant scans and accompanying 
radiology reports. All data are collected by the same outcome assessor who is blind to treatment 
allocation. m 
If the patient does not have a pre-randomisation scan, only the post-randomisation scan form is 
completed. If the patient does not have a post-randomisation scan, only the pre-randomisation 
scan form is completed. We record whether pre- and/or post-randomisation scans are available so 
we can examine missing data by trial arm.   
In most cases, the post-randomisation scan is the first scan done after randomisation, which is 
normally within 72 hours of randomisation. But ongoing clinical management and the decision to 
randomise without the baseline CT scan means that some patients are scanned within minutes 
after randomisation. TXA would not have had sufficient opportunity to effect haemorrhage or 
infarction in such a way that would manifest on a scan this soon after randomisation. Therefore, 
for patients scanned within minutes of randomisation, we measure all the outcomes of interest on 
the next available post-randomisation scan, which is normally closer to 72 hours of randomisation. 
All available brain imaging (not only CT) is examined for evidence of cerebral infarction. 
The time stamped on the scans will be used to calculate the following time intervals: 1) the time 
between injury and the pre-randomisation CT scan; 2) the time between randomisation into the 
trial and the post-randomisation scan. If a patient has undergone neurosurgery following their 
injury and this is evident on any of the rated scans, information on the date and time of 
neurosurgery will be collected using prospective reports including patient anaesthetic charts. The 
outcome data is collected for all patients included in the CRASH-3 IBMS (unless consent was 
withdrawn) irrespective of whether the trial treatment was received (i.e. on an intention to treat 
                                                     
m As confirmed in the My Contributions section of this thesis (page 5), all scans rated as part of the 




basis). The outcome data are directly uploaded into an electronic database developed for the 
purpose of this trial and accessed at each site. See Appendix 9 for the complete data collection 
working procedure.  
 
2.32 Data management and integrity 
 
All trial data are managed in accord with the IBMS DMP (see Appendix 9) which is stored in 
the Trial Master File. The DMP working procedures are produced in conjunction with LSHTM 
policies and procedures, the Clinical Trials Unit and trial specific working procedures, and 
regulatory requirements. The web database was built to comply with International Conference 
on Harmonisation Good Clinical Practice guidelines (ICH-GCP) Guidelines, United Kingdom 
Clinical Trials Regulations, and the Data Protection Act 167. The database uses MySQL for data 
storage and Hypertext Preprocessor (PHP) to develop the dynamic web pages for the user 
interface. 
Data are collected at each participating site and directly uploaded into the web database. A 
number of computerised validation checks have been built into the database to ensure all 
required fields are complete and irregular entries are flagged. In rare cases of poor internet 
connection or inadequate facilities, paper versions of the Case Report Forms (CRFs) are 
completed and transcribed into the web database as soon as possible. Any revisions to a 
submitted form are saved automatically in a database log with details of who edited the data and 
when edits were made. Any changes made from the initial form submission are highlighted in 
each amended version of a form. All data checks and cleaning are performed by the IBMS lead. 
This includes using a download report facility within the database to review the data for 
inconsistencies and resolve queries as per the procedures detailed in the DMP. The final 
database lock will take place at the end of the trial within three months of the end of data 
collection. Data will be exported for statistical analysis in Stata Version 15 [StataCorp LP, 













SCAN ASSESSOR TRAINING & PILOT TEST OF DATA COLLECTION FORMS  
 
Scan assessor training 
 
I studied the anatomy and function of the human brain whilst completing a BSc (Honours) in 
Applied Psychology (accredited by the British Psychological Society) and MSc in 
Psychological Research (2008-2012). As part of a Research Assistant post at the Department of 
Psychiatry (Warneford Hospital, University of Oxford) and Centre for Functional MRI (now 
Wellcome Centre for Integrative Neuroimaging, John Radcliffe Hospital, University of Oxford), 
I completed a short course in theory and practice of functional and structural brain imaging 
(2015).    
 
For the purpose of data collection for my PhD project, I received one-to-one training in CT scan 
assessment of key intracranial pathologies seen after TBI (2016). During this training, I pilot 
tested the data collection forms in 90 patients at the first site (Queen Elizabeth Hospital, 
Birmingham), as per the above method and under the supervision of a Clinical Research Fellow 
and Neurosurgical Registrar at this site (Dr David Davies). I assessed scans from these patients 
using the data collection forms from the CRASH-2 Intracranial Bleeding Study 106. I accessed 
and examined all scans electronically on PACs at the hospital site. I examined all scans in the 
axial format, in conjunction with their accompanying radiology reports. 
 
Pilot test of data collection forms 
 
I was trained to identify different types of haemorrhage (IPH, IVH, SDH, EDH, SAH) using 
their distinctive shapes and typical locations. I estimated their volumes using the ABC/2 method 
(IPH, IVH, EDH), where possible. I identified different types of mass effect (sulcal effacement, 
ventricular effacement, midline shift) by first comparing the symmetry of the cerebral 
hemispheres. If patients showed evidence of midline shift, I estimated the degree of shift in mm, 
by using the PACs ruler to mark where the midline should be and measure how far it had 
deviated from this location. I also practised identifying peri-haemorrhagic oedema, which often 
manifests as low attenuation surrounding high attenuation on CT, and used consecutive scans to 
confirm if low attenuation was indicative of residual oedema when haemorrhage resolved but 
oedema remained. I was trained to identify signs of cerebral infarction, which if seen on CT, 
often manifests as wedge-shaped low attenuation. I was also trained to identify the occurrence 
of neurosurgical haemorrhage evacuation, and if relevant, the type of neurosurgery evident on 
the scan (e.g. craniotomy, craniectomy). All scans were interpreted in conjunction with their 
accompanying radiology reports. These reports were used to confirm whether patients presented 




detail, and in some cases, comments were brief – confirming there was no interval change 
compared to a previous scan. In these cases, I would use the report from the previous referenced 
scan to examine whether the outcomes of interest were seen on the next scan. Discrepancies 
between the reports and what appeared visible on the scan were discussed with Dr Davies and 
confirmed during the training placement.   
 
As a result of this training placement, the CRASH-2 Intracranial Bleeding Study forms were 
amended for the purpose of the CRASH-3 IBMS. This included using the Marshall 
Classification (a validated TBI rating scale with prognostic value) 128, and excluding a separate 
field for the compression of basal cisterns as basal cistern effacement is included in Diffuse 
Injury III (swelling) of the Marshall Classification.  
 
SAH assessment  
 
The specified categories for SAH (small, medium, large; focal, multiple, diffuse) were included 
in the CRASH-3 IBMS for the reasons detailed in the Outcome Measurement: Measurement of 
SAH section 2.27 above.  
 
The Common Data Elements for Radiological Imaging of Patients with SAH were proposed in 
2019 to facilitate standardization and aggregation of imaging data in patients with SAH 168. 
Because these guidelines were developed after I started data collection for the IBMS in 2016, I 
was not able to consult these in advance of protocol development. These guidelines note that the 
imaging modality (e.g. CT) and type (e.g. non-contrast CT) are core elements that must be 
reported in imaging studies of SAH. These guidelines also propose supplemental elements 
which are highly recommended for specific diseases and therapeutic areas, supplemental 
elements that are commonly collected but whose relevance depends on study design or type of 
research, and exploratory elements which are reasonable to use but require further validation. 
Many of the recommended supplemental elements (i.e. presence of SAH, IVH, SDH, midline 
shift) were recorded in the IBMS. However, the measurement of the size and spread of SAH in 
the IBMS does not readily compare with the SAH definitions in the Common Data Elements 
(i.e. Fisher grade, Hijdra scale). Furthermore, the IBMS did not record whether SAH was 
secondary to ruptured intracranial aneurysms (although I suspect these would be included in the 
Large size classification in the IBMS). Therefore, the size and spread measures of SAH in the 
IBMS could be considered exploratory Common Data Elements 168. Figure 6 shows example 
images of the size (small, medium, large) and spread (focal, multiple, diffuse) ratings of SAH in 
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Figure 6. Examples of the size and spread of SAH on non-contrast CT as measured in the CRASH-3 IBMS.  







                                                     
n Image from Edjlali et al (2015). 169 
o Image from Lang (2016) 170 




EDH, IPH and IVH assessment using ABC/2 method 
 
Scan examination included using the ABC/2 method to estimate the volume of EDH, IPH and 
IVH (as detailed in Section 2.23). This method selects a representative slice of the haemorrhage 
on which the haemorrhage is most visible. On this slice, two measurements are taken to estimate 
the size of the surface area of the bleed: A (maximum length); B (width perpendicular to 
maximum length). These measurements were done using the ruler tool on PACs. For an 
estimate of the depth of the bleed, a third measurement C is taken (number of slices on which 
the bleed is clearly visible multiplied by thickness of each slice). When these three 
measurements are multiplied and the sum divided by 2 (ABC/2), this provides the approximate 
volume of that bleed in cm3 (i.e. ml), assuming the bleed is an approximately spherical shape. 
This method has been validated in IPH and EDH and shows good agreement with automated 
volumetric analysis. The ABC/2 method has not been validated in IVH, but was used to 
estimate IVH volume in the IBMS (as confirmed in Section 2.23). Figure 7 shows an example 
of the A, B and C measurements of an IPH rated on axial slices. For example, if an IPH had a 
maximal length of 33 mm (A) with a perpendicular width of 20 mm (B), and this bleed was 
visible on 5 slices of 5mm thickness each - providing a C estimate of 25mm, the approximate 





Figure 7. ABC/2 method for estimation of Intra-parenchymal haemorrhage (IPH): maximum length (A), 
perpendicular width (B), number of slices (in this case 14 slices) multiplied by thickness of each slice (C).q 
 
                                                     




Not all haemorrhages have a neat spherical shape and so the ABC/2 method is subject to 
measurement error. Figure 8 shows example A and B measurements for IPH and EDH in 
patients included in the CRASH-3 IBMS. Please note that these pictures were taken with 
permission of the PIs at the relevant sites and do not contain any patient identifiable 
information. The different images on which these bleeds were visible (for the measurements of 
C) were not available for the purpose of this illustration, but were used to estimate the volume 
of these haemorrhages. Images showing how IVH volume was estimated were not available for 
the purpose of this illustration. For IVH, the same measurements were taken: longest length (A), 
width perpendicular to the length (B); the number of slices multiplied by slice thickness (C).   
 
Figure 8. Left: Example IPH volume estimation using ABC/2 method: A (99.44mm) and B (35.65mm). Right: 
Example EDH volume estimation using ABC/2 method: A (82.40mm) and B (43.90mm).  
 
SDH assessment 
The more precise method for the estimation of SDH volume was preferred over the ABC/2 
method, for the reasons detailed above (Outcome Measurement: Estimating SDH volume using 
maximum width). The volume of SDH was estimated using the maximum diameter of the 
subdural bleed (as detailed in Section 2.24). The axial slice on which the SDH diameter was 
largest was chosen as the representative slice. For this slice, the maximal diameter of the SDH 
was recorded. Figure 9 shows examples of the SDH slices chosen to estimate the SDH diameter 




















Figure 9. Examples of the slices chosen to estimate SDH diameter in four CRASH-3 IBMS patients with SDH. Top 
left: 32.91mm; Top right: 9.33mm; Bottom left: 26.08mm; Bottom right: 15.6mm.  
 
The SDH maximal diameter value was substituted into the below formula to calculate the 
approximate volume of the SDH. This formula takes the difference between two spheres and 
divides this by 8 to represent the subdural space the SDH occupies ((4/3 π r3 – 4/3 π r3) / 8). The 
division by 8 is because the measurement is for unilateral SDH (divide by 2), SDH is typically 
thicker at the centre and thinner at the sides (divide by 2) and is bound by superior-inferior and 
anterior-posterior cerebral axes (divide by 4). The standard longitudinal diameter (temporal – 
temporal) is used to estimate the radius (i.e. 137mm diameter / 6.85mm radius) 172. For example, 
for a SDH with a diameter of 9.33mm (i.e. 0.933cm), the approximate volume is 60ml:  
[4/3 π (6.85)3 – 4/3 π (6.85-r)3] / 8 
4/3π(6.85)3 - 4/3π(6.85 – 0.933)3 
1346.36 - 867.75 = 478.61 





In order to ensure that no patient identifiable information was recorded on the data collection 
forms, we decided not to record the time of the CT scan. On the pre-randomisation form, we 
recorded the number of hours and minutes between injury and CT scan. On the post-
randomisation form, we record the number of hours and minutes between randomisation and CT 
scan. If needed in future, this information could be used to calculate the timing of the CT scan 
using the CRASH-3 trial data on the date and time of randomisation, the number of hours from 
injury to randomisation, and the CRASH-3 IBMS data on the time from injury to the pre-
randomisation scan.  
























Data were collected from the first site as per the finalised pre-randomisation and post-
randomisation scan forms. Blinded data were reviewed following data collection at this site. A 
summary of the findings follow.  
 
2.33 Summary   
 
From the CRASH-3 trial database, a total of 212 patients were identified as eligible for the 
CRASH-3 IBMS at the first site. These patients were randomised into the CRASH-3 trial 
between February 2013 and July 2016. All patients were scanned before randomisation but the 
scans for one patient were unavailable for reading for technical reasons. Patients were scanned 
within a mean of two hours of injury (SD=0.9). A total of 161 patients (76%) had a post-
randomisation scan and 49 (23%) did not have one done. A total of 19 patients (9%) died before 
the post-randomisation scan. Patients were rescanned within a mean of 58 hours (SD=52.5) after 
randomisation (excluding eight patients who were rescanned more than 10 days after 
randomisation). All patients had CT evidence of intracranial haemorrhage. On the pre-
randomisation scan, 74% of patients had at least one SDH, 71% had SAH, 55% had IPH, 11% 
had IVH, 7% had petechial haemorrhage and 5% had EDH. A total of 14 patients (7%) had 
evidence of a focal ischaemic lesion (acute or historic) on the pre-randomisation scan. A total of 




















2.34 Amendment to eligibility criteria to reduce missing post-randomisation scans r 
 
Of the 49 patients without a post-randomisation scan, 27% had a GCS score of 3 and 41% had a 
GCS score of 14 or 15 (see Figure 10). 
 
Figure 10. Occurrence of missing post-randomisation scans by GCS score.  
 
Examination of the occurrence of missing post-randomisation scans according to GCS score 
suggested that the majority of missing scans were from patients with less severe injuries. The 
pathologies of interest, intracranial haemorrhage expansion and cerebral infarction, 
predominantly occur in the more severely injured 69. So we revised the eligibility criteria from 
the first site onwards to only include patients with a GCS score of 12 or less.  
Although the revision in eligibility criteria (GCS ≤ 12) reduced the amount of missing data from 
patients with mild injuries, a substantial proportion of missing data is from patients with severe 
injuries. Furthermore, the occurrence of missing data could relate to the trial treatment (e.g. 
TXA could reduce intracranial bleeding and so a second scan is not clinically indicated, TXA 
could increase infarction and so a second scan is clinically indicated). Therefore, in the analysis 
plan, there is particular attention to exploring the potential reasons for missing data, as missing 
data can result in biased treatment effect estimates. 
Examination of GCS scores from three subsequent UK sites in which the CRASH-3 IBMS was 
to be conducted indicated that a total of 403 patients had a GCS score of 12 or less (Site 2: 
n=220; Site 3: n=112; Site 4: n=71). We initially planned to conduct the CRASH-3 IBMS in the 
                                                     
r The decision to amend the eligibility criteria to include patients with a GCS of ≤12 was made after the 
first round of data collection at the first site. The original protocol, in which part of the eligibility was 
determined by whether patients has a GCS of  ≤12 or CT with intracranial bleeding, did not change in 
response to this decision. This is because patients with a GCS ≤12 are included in the population of 




UK only, due to ease of access to electronic imaging and the number of patients recruited into 
the CRASH-3 trial. However, because a large proportion of patients have milder injuries, this 
amendment to the procedure meant that international sites were approached to meet the planned 
sample size.   
 
2.35 Simple exploratory analyses 
 
Simple exploratory analyses were performed on the data from Site 1 to examine whether the 
data captured expected associations. SDH is the most common type of intracranial haemorrhage, 
and three simple analyses were performed using SDH size.  
 
SDH was dichotomized as small or large according to whether the maximal width of SDH 
(cumulative if a patient had more than one SDH) was <6mm or ≥6mm, respectively. According 
to the formula for estimating SDH haemorrhage volume (see Appendix 10), a SDH of 6mm 
maximal diameter would have a volume of approximately 25ml. A non-evacuated bleed of 25ml 
or more has the worst grading in the Marshall Classification, and so for the purpose of this 
analysis, a SDH with a diameter of 6mm or more was considered large. s 
 
Pre-randomisation haemorrhage size and head injury death  
 
I would expect patients who died due to head injury to have more intracranial bleeding on their 
pre-randomisation scan compared to patients who died from a different cause or survived. This 
can be examined using the size of SDH seen pre-randomisation and information about the cause 
of death from the CRASH-3 trial outcome form. Patients with larger SDHs (≥ 6mm vs <6mm) 
were at greater risk of head injury death (see Table 7). Specifically, patients with a larger SDH 
were at more than three times the risk of head injury death (RR=3.32, CI 1.79–6.12, p=0.0001).   
 
Table 7. Number (%) of patients with SDH on the pre-randomisation scan by death. 
SDH width  Head injury death Non head injury death / 
alive 
Total 
≥ 6mm  23 (31.5%)   50 (68.5%) 73  
<6mm  13 (9.5%)  124 (90.5%) 137  
Total 36 174 210 
 
 
                                                     
s After conducting these analyses, I noted that there had been an error in my calculation. A SDH of 
3.5mm diameter would have an estimated volume of 25ml and a SDH of 6mm diameter would have an 
estimated volume of 40ml. Therefore, some of the patients in the <6mm group may have bleeds greater 
than 25ml. I did not amend this section to dichotomize bleeds according to whether they were more or 
less than 3.5mm in maximal diameter because the 6mm distinction was what I believed distinguished 




Pre-randomisation haemorrhage size and neurosurgery 
 
Given that larger bleeds are associated with a greater risk of death and disability, I would expect 
patients with large bleeds are at greater risk of neurosurgical haemorrhage evacuation. Indeed, 
the risk of undergoing neurosurgery after randomisation is more than four times greater in 
patients with a larger SDH on the pre-randomisation scan (RR=4.64, CI 2.06–10.48, p=0.0002) 
(see Table 8).  
 
Table 8. Number (%) of patients with SDH on the pre-randomisation scan by the propensity to 
have neurosurgery before the post-randomisation scan.  
SDH width  Neurosurgery  No neurosurgery  Total 
≥ 6mm 20 (25%)  60 (75%) 80  
0-6mm 7 (5.4%)  123 (94.6%) 130  
Total 27 183 210 
 
 
Pre-randomisation haemorrhage size and pre-randomisation midline shift 
 
I would expect larger bleeds to cause more shift of the midline structures. As expected, as the 




















































STATISTICAL ANALYSIS PLAN 
 
2.36 Trial profile 
 
We will show the flow of trial patients in the Consolidated Standards of Reporting Trials 
(CONSORT) diagram. This will include the total number of patients randomised into the IBMS 
divided by treatment arm. Each treatment arm will detail the number of patients who received 
the loading and maintenance doses, the number of patients for whom clinical baseline and 
outcome data was collected, and the number of patients who were scanned before randomisation 
and/or after randomisation. We will report the number of patients included in the primary and 
secondary analyses, the reasons for any post-randomisation exclusions and the number lost to 
follow-up. If after a patient is randomised into the trial, it is found that they did not meet the 
eligibility criteria or did not receive their allocated treatment, they are considered to have 
deviated from the trial protocol. Data from patients who have deviated from the protocol will be 
included in the intention to treat analysis. If a patient or their representative withdraws consent 
for data collection, they will not be included in the CRASH-3 IBMS. 
 
2.37 Baseline characteristics 
 
We will report baseline characteristics, including, age, sex, GCS, pupil reaction, systolic blood 
pressure, mean (and SD) number of hours from injury to pre-randomisation scan, mean (and 
SD) haemorrhage volume (or median and interquartile range), different types of haemorrhage 
(intra-parenchymal, intra-ventricular, subdural, epidural, subarachnoid and petechial), cerebral 
infarction, oedematous lesions, mass effect findings, and the Marshall classification. To check 
that randomisation produced similar groups, we will describe the baseline characteristics of each 
treatment group with frequencies and percentages. 
 
2.38 Inter-rater reliability  
 
The inter-rater reliability of pre-randomisation haemorrhage occurrence, as estimated in the 
CRASH-3 IBMS, will be assessed using relevant Entry Form data from the CRASH-3 trial. This 
will examine consistency among ratings between the CRASH-3 IBMS data collector and clinical 









2.39 Primary analysis: initial plan 
 
In the original protocol, we planned to use analysis of covariance (ANCOVA) to compare the 
mean volume of intracranial bleeding seen after randomisation between treatment groups, 
adjusting for prognostic variables measured pre-randomisation: bleeding volume, time from 
injury to CT scan, GCS, age and systolic blood pressure. We expect covariates to affect bleeding 
volumes in different ways (e.g. older people are likely to have larger bleeds at baseline, more 
severely unconscious people (low GCS) are likely to have larger bleeds at baseline). A linear 
regression analysis using the blinded imaging data from 1,000 patients indicated that the selected 
covariates are predictive of post-randomisation bleeding volume (p<0.05).  
We planned to adjust the primary analysis using these covariates and the stratification factor 
(treatment site) 173. Baseline adjustment eliminates conditional bias arising from a chance 
difference in covariates between treatment groups, and increases precision in the treatment 
effect estimate by factoring out the covariance between baseline factors and post-randomisation 
bleeding volumes 174. We planned to present ratios and 95% confidence intervals to examine the 
relative effect of TXA (versus placebo) on mean bleeding volume. 
However, blinded imaging data from 1,000 patients suggested that only 50% of patients were 
scanned both before and after randomisation, and only these would be retained in complete-case 
ANCOVA analyses. A 50% reduction in power as a result of missing scans would outweigh the 
30% increase in power from baseline adjustment (adjusted analysis requires 1000 patients, 
unadjusted analysis requires approximately 1500 patients; see sample size section) 175. 
Furthermore, because the pre-randomisation mean bleeding volume of the observed data may be 
different from the true pre-randomisation mean bleeding volume, the estimates from the 
ANCOVA model may be biased. 
To retain a larger sample size, we could choose not to adjust the primary analysis using the pre-
randomisation bleeding volume, but at the expense of losing any power gained from adjusting 
for pre-randomisation bleeding. An alternative approach is to use a linear mixed model, which 
without missing data, provides identical treatment effect estimates (and near identical standard 
errors) as the more standard ANCOVA analysis (see Appendix 13). Compared to ANCOVA, 
the advantage of the linear mixed model approach is that patients with missing pre- or post-
randomisation scans can be included in the analysis, potentially reducing bias and increasing 









2.40 Primary analysis: revised plan t 
 
Linear mixed model 176 will be used to compare the mean change in IPH volume from pre- to 
post-randomisation between treatment groups. This model includes pre- and post-randomisation 
volumes as correlated outcomes, with mean post-randomisation volumes allowed to differ by 
treatment group but mean pre-randomisation volumes constrained to be the same, and with 
variances of pre- and post-randomisation volumes allowed to differ.  
The same covariates (time from injury to CT scan, GCS, age, systolic blood pressure, site) will 
be included in the analysis. The main effect of site (which is treated as fixed) is accounted for in 
the model. Because we have relatively few centres (n=14) compared to the number of patients 
(n= ≈1750), we expect any loss in efficiency from this method (compared to the random centre 
effects method) to be minimal. The linear mixed model described above will include an 
interaction between each covariate and whether bleeding volume was measured before and/or 
after randomisation. 
The blinded data indicates that pre-randomisation and post-randomisation bleeding volumes are 
positively skewed. Because bleeding volumes are skewed, this data will be log transformed 
before entered into the linear mixed model. The anti-log of the treatment effect estimate and its 
corresponding 95% CIs will be presented to aid interpretation. The treatment effect estimates 
will provide an estimate of the relative increase or decrease in haemorrhage volume with TXA. 
Sensitivity analysis: Exclude patients who underwent neurosurgical haemorrhage evacuation 
after randomisation 
The blinded data shows that after randomisation 14% of patients had neurosurgery before 
undergoing the first rated post-randomisation scan. In these cases, it is difficult to use the post-
randomisation and post-neurosurgery scan to estimate the treatment effect because any change 
seen in intracranial haemorrhage expansion or infarction could be due to the effect of TXA or 
neurosurgery. The inclusion of these patients in the primary analysis may dilute any treatment 
effect towards the null. Therefore, we will conduct a sensitivity analysis excluding patients who 
underwent neurosurgery before a post-randomisation scan was done.  
 
                                                     
t This revision followed peer review of the Statistical Analysis Plan 177. The first version was submitted to 
Wellcome Open Research for publication consideration on 13 August 2018. One peer reviewer submitted 
a referee report on 17 September 2018 (approved) and another reviewed submitted a report on 18 October 
2018 (approved with reservations). In response to the second reviewer’s reservations (see Appendix 6), a 
revised analysis plan was submitted on 8 January 2019. A third reviewer submitted a referee report on 21 
May 2019 (approved). The Statistical Analysis Plan was approved for publication on 6 June 2019. All 




2.41 Secondary analyses 
 
Composite poor outcome, progressive haemorrhage, new haemorrhage, haemorrhagic 
oedematous lesions and mass effect: We will express the effect of TXA on the occurrence of 
dichotomous endpoints between trial arms, including the frequency of the composite “poor” 
outcome, progressive haemorrhage, new haemorrhage, haemorrhagic oedematous lesions, and 
mass effect outcomes (sulcal effacement, ventricular effacement, midline shift), using relative 
risks and 95% confidence intervals estimated using generalised linear models. We will express 
the effect of TXA on the degree of midline shift (measured in millimetres) using a basic linear 
mixed model, with pre-randomisation midline shift included as an outcome. We will extend this 
model to include covariates: time from injury to scan, GCS, age and systolic blood pressure. 
Cerebral infarction: We will express the effect of TXA on cerebral infarcts measured at up to 
28 days post-randomisation and not known to be present pre-randomisation using hazard ratios 
and 95% confidence intervals. We will conduct a survival analysis using the interval between 
the time of randomisation and the time of the scan on which the infarct was detected. We will 
plot the survival curves in the two treatment groups using a Kaplan-Meier plot. The time to the 
scan on which the infarct was detected will be compared between treatment groups using a log-
rank test. We will conduct a Cox regression analysis to quantify any difference between 
treatment groups in the hazard of detecting an infarct up to 28 days post-randomisation. We will 
conduct a sensitivity analysis excluding the patients who underwent neurosurgery. 
Neurosurgical haemorrhage evacuation after randomisation: If TXA received soon after injury 
reduces intracranial haemorrhage, a patient who received TXA may be less likely to undergo 
neurosurgery to evacuate haemorrhage compared with a patient who received placebo. 
However, in an emergency trauma setting, the decision for neurosurgery occurs at the same time 
or very soon after the time of randomisation. Therefore, TXA received soon after injury may not 
affect the propensity for neurosurgery. But it could affect intracranial bleeding during 
neurosurgery. 
We hypothesise that patients who receive TXA may have less blood on a post-randomisation 
and post-neurosurgery scan compared to patients who receive placebo. We will express the 
effect of TXA on the total volume of intracranial haemorrhage measured on a post-
randomisation and post-neurosurgery scan using a linear mixed model as above. If the patient 
has been scanned pre-randomisation (and pre-neurosurgery), we will include the pre-
randomisation bleeding volume as a variable in the linear mixed model as above. To improve 
the precision of the effect estimate, we will extend this model to include each covariate and its 
interaction with bleeding volume: time from injury to scans, time from neurosurgery to scan, 




We will conduct a survival analysis using the time from randomisation to neurosurgery. The 
time to neurosurgery will be compared between treatment arms using a log-rank test. Because 
the log-rank test will only indicate whether there is a significant difference between treatment 
arms in the time to neurosurgery, we will also conduct a Cox regression analysis to quantify any 
difference in the hazard of neurosurgery between arms. 
Subarachnoid haemorrhage: We will express the effect of TXA on the size (small-medium, 
large) and spread (focal-multiple, diffuse) of subarachnoid haemorrhage between trial arms, 
using relative risks and 95% confidence intervals estimated using generalised linear models. 
2.42 Subgroup analyses 
Time from injury to randomisation: Most intracranial bleeding occurs within hours of injury 40, 
41, 125, 178. Subgroup analyses will examine whether the effect of TXA on intracranial 
haemorrhage is modified by the time from injury to randomisation (≤1 hour, >1 to 3 hours, >3 
to 8 hours). If there is minimal haemorrhage expansion after 3 hours 125, we expect TXA will 
have a lesser effect in reducing haemorrhage expansion in this group compared to the groups 
treated within 3 hours. We will conduct a linear regression analysis with an interaction between 
treatment (TXA, placebo) and time to randomisation (≤1 hour, 1–3 hours, >3–8 hours) to 
examine whether the effect of TXA on intracranial haemorrhage volume varies according to the 
time from injury to randomisation. 
There may be an increase in the frequency of cerebral infarction with TXA in those treated after 
3 hours of injury compared to those treated within 3 hours of injury 98. We will use relative risks 
and 95% confidence intervals estimated using generalised linear models to examine whether the 
effect of TXA on cerebral infarction varies within subgroups of time from injury to 
randomisation (≤3 hours, >3 hours). However, given the lower prevalence of cerebral infarction 
compared to intracranial bleeding, it will be difficult to reliably examine the effect of TXA on 
cerebral infarction within time strata. In a separate report, we will examine whether TXA 
increases the risk of adverse events in an individual patient data meta-analysis of 15,000 
patients with TBI or spontaneous intracerebral haemorrhage (published separately) 179. 
Types of haemorrhage: We will conduct the linear mixed model analysis specified in the 
primary analysis section separately for subdural, epidural and intra-ventricular bleeds. 
2.43 Missing data from scans not done before or after randomisation 
Not all trial patients will be scanned before and after randomisation. We will report the number 
of patients without scans  and baseline data for patients included in the analysis to help identify 




scans are missing equally between treatment arms and appear to be missing completely at 
random (MCAR). In this case, although missing data reduces the precision of the analysis, it 
does not bias the treatment effect 181. 
However, if haemorrhage expansion is associated with the reason the data are missing (patients 
with haemorrhage expansion may die before the second scan, patients without haemorrhage 
may not need to be re-scanned), imbalance in missing data by treatment arm can cause bias. We 
will examine whether the occurrence of missing scans is influenced by fully observed baseline 
variables (e.g. GCS), using relative risks and 95% confidence intervals estimated using 
generalised linear models. If they are, and within defined groups data are missing completely at 
random, the data could be missing at random (MAR) 181. For example, if missingness depends 
on GCS, but within mild, moderate and severe GCS groups missingness is unrelated to 
haemorrhage or infarction, the data are MAR. In this case, a regression analysis which takes 
GCS group into account should give unbiased estimates of the treatment effect 182. 
However, we suspect that within GCS groups, missingness could be related to haemorrhage 
volume (i.e. low GCS patients are expected to have a greater haemorrhage volume than high 
GCS patients). In this case, the data would be missing not at random (MNAR) (i.e. even when 
accounting for the fully observed data, the reason for missing observations still depends on the 
unseen values) 181. 
Because injury severity can partly explain missingness and there are unknown reasons for some 
missingness, it is difficult to confirm whether our missing data will be MAR or MNAR. For the 
purpose of the primary analysis, we will assume missing data are MAR. To examine how robust 
the primary analysis is to the chosen method of handling missing data, we will conduct 
sensitivity analyses assuming missing data are MNAR. Under the MNAR assumption, we will 
compare haemorrhage volumes between treatment groups and explore the possibility that 
missingness of the outcome data is related to prognostic characteristics as well as to the trial 
treatment. If TXA reduces intracranial haemorrhage expansion and the risk of death, patients 
who receive TXA may be more likely to be scanned post-randomisation compared to those who 
receive placebo. On the other hand, if TXA reduces or prevents intracranial haemorrhage 
expansion, post-randomisation scanning may not be clinically indicated in these patients. We 
will conduct sensitivity analyses excluding patients with a low pre-randomisation GCS who 
may have large haemorrhage expansion and therefore not survive to have a post-randomisation 
scan. We will conduct sensitivity analyses excluding patients with a high pre-randomisation 






Best-worst and worst-best sensitivity analyses  
 
A simple approach to explore the impact of missing outcomes on treatment effect estimates are 
“best-worst” and “worst-best” scenarios 183.  
 
For dichotomous outcomes, the best-worst scenario assumes that everyone with missing data in 
the treatment group had a good outcome (e.g. infarction absent) and everyone with missing data 
in the placebo group had a bad outcome (e.g. infarction present). The worst-best scenario 
assumes that everyone with missing data in the treatment group had the bad outcome and 
everyone with missing data in the placebo group had the good outcome. If these methods do not 
give different results, then the impact of missing data on the effect estimate for this outcome 
may be negligible. But if there is a difference, it can provide a range of uncertainty due to 
missing data, and any conclusions regarding the effect of TXA on a given dichotomous outcome 
can be interpreted in the context of this uncertainty 183.  
 
For continuous outcomes, a ‘beneficial outcome’ might be the group mean plus 2 standard 
deviations of the group mean, and a ‘harmful outcome’ might be the group mean minus 2 
standard deviations  of the group mean 183. This represents a possible range of uncertainty given 
95% of the observed data (if normally distributed).  
 
2.44 Between-centre effects 
 
There is no clear evidence for the hypothesis that between-centre differences in unfavourable 
outcome affect the chance of demonstrating a treatment effect in randomised trials of TBI 184. 
This study estimated the between-centre differences beyond the random variation that may 
result from some centres that only treat a small number of patients. Given this evidence and that 
we have no biologically plausible reason to expect any variation in a treatment effect between 
centres, we do not anticipate to find centre effects in the CRASH-3 IBMS. Furthermore, the 
majority of hospitals included in the CRASH-3 IBMS are in the UK. The homogeneity in 
patient characteristics and care facilities is further reason not to expect a between-centre 










3.1 Description of study population 
 
A total of 1767 CRASH-3 trial patients were identified as eligible for the CRASH-3 IBMS. The 
CONSORT diagram describes the flow of patients by treatment group (see Figure 12). A total 
of 884 patients (50%) were randomly allocated to the TXA group and 883 patients (50%) to the 
placebo group. CRASH-3 trial entry and outcome data were collected for all patients in the 
IBMS, who were recruited across 14 hospitals in the UK and Malaysia, between February 2013 
and January 2019. Patients were recruited across 10 hospitals in the UK (n=1146; 65%) and 4 
hospitals in Malaysia (n=621; 35%). Routinely collected imaging data were examined for the 
purpose of the IBMS between February 2016 and January 2019.  
 
A total of 80% of patients in the IBMS were male (n=1413) and 20% were female (n=354). 
Patients had a median age of 45 years (IQR 29 to 63), median systolic blood pressure of 136 
millimetres of Mercury (mmHg) (IQR 120 to 155), and median GCS score of 7 (IQR 3 to 10). 
The CRASH-3 trial entry data indicated that 65% (n=1143) of patients in the IBMS presented 
with a severe GCS (3-8), 30% (n=532) with a moderate GCS (9-12) and 5% (n=92) with a mild 
GCS (13-15). A total of 13% (n=232) of patients presented with bilateral un-reactive pupils, 
11% (n=202) with unilateral reactive pupils and 73% (n=1289) with bilateral reactive pupils. 
Pupil reaction could not be assessed in 2% (n=43) of patients and was unknown in one patient. 
Most patients in the IBMS were randomised into the CRASH-3 trial within 3 hours of injury 
(76%, n=1350); the rest were randomised between 3 and 8 hours of injury (23%; n=415), minus 
two patients who were randomised between 9 and 10 hours of injury (0.1%). All patients were 
included in the analyses even if they did not adhere to the CRASH-3 trial protocol and receive 
their allocated treatment, as per the intention-to-treat principle. This approach preserves the 
prognostic balance afforded by randomization, thereby minimizing any risk of bias from 
comparing groups that differ in prognostic variables 185. See Table 9 for the pre-randomisation 
demographic and clinical characteristics of all patients in the IBMS. 
 
A total of 65% of patients (n=1147) had a pre-randomisation (baseline) CT scan done within a 
median of 2 hours after injury (IQR 1h to 2h). The pre-randomisation scans for 13 patients were 
unavailable for reading for technical reasons (5 TXA group, 8 placebo group). Of those with a 
pre-randomisation scan, 72% (n=829) presented with SAH, 64% (n=732) with SDH, 62% 
(n=709) with IPH, 19% (n=215) with EDH, 16% (n=184) with IVH, and 6% (n=71) with 
petechial haemorrhage. A total of 15% of patients (n=177) presented with haemorrhagic 
oedematous lesions, 1% (n=13) with acute cerebral infarction, 44% (n=503) with midline shift, 




common Marshall Classification rating was Diffuse Injury II (46%, n=533), followed by non-
evacuated mass lesions (43%, n=487). Diffuse Injuries I, III and IV were each rated for 5% or 
fewer patients u. See Table 10 for a summary of pre-randomisation CT scan characteristics 
stratified by treatment group. TXA and placebo groups appear to be approximately balanced for 
all observed demographic and clinical characteristics.  
 
Discrepancies between the CRASH-3 trial time since injury data and timestamp of the first CT 
scan meant that it was not possible to confirm whether five patients in the IBMS were scanned 
pre-randomisation (0.3%). A total of 46% of patients were scanned pre-randomisation and post-
randomisation (n=812/1767). A total of 35% of patients were scanned post-randomisation but 
not pre-randomisation (n=614/1767). A total of 81% of patients were scanned post-
randomisation (n=1431/1767). The post-randomisation scans were done within a median of 23 
hours after injury (IQR 8h to 48h) and 21 hours (IQR 5h to 46h) after randomisation. 
 
 
                                                     
u Marshall Classification: Diffuse Injury I (no intracranial pathology); Diffuse Injury II (midline shift 0-
5mm, basal cistern present, no high/mixed density lesion >25cm3); Diffuse Injury III (midline shift 0-
5mm, basal cisterns compressed/effaced, no high/mixed density lesion >25cm3); Diffuse Injury IV 
(midline shift >5mm, no high/mixed density lesion >25cm3); Evacuated mass lesion (any lesion 
































TXA group  
(n=884) 
Placebo group  
(n=883) 
Sex  
   Male 1413 (80%) 701 (79%) 712 (81%) 
   Female 354 (20%) 183 (21%) 171 (19%) 
Age  
  Median (IQR) age in years 45 (29 - 63) 45 (29 - 64) 45 (29 - 63) 
Glasgow coma score (GCS)  
   Mild (13-15) 92 (5%) 47 (5%) 45 (5%) 
   Moderate (9-12) 532 (30%) 264 (30%) 268 (30%) 
   Severe (3-8) 1143 (65%) 573 (65%) 570 (65%) 
Median (IQR) GCS 7 (3 - 10) 7 (3 - 10) 7 (3 - 10) 
Pupil reaction  
Both react 1289 (73%) 637 (72%) 652 (74%) 
One reacts 202 (11%) 97 (11%) 105 (12%) 
None react 232 (13%) 124 (14%) 108 (12%) 
Unable to assess 43 (2%) 25 (3%) 18 (2%) 
Unknown 1 (<1%) 1 (<1%) 0 (0%) 
Systolic blood pressure   
    < 90 27 (2%) 14 (2%) 13 (1%) 
    90 – 119 370 (21%) 194 (22%) 176 (20%) 
    ≥ 120 1362 (77%) 672 (76%) 690 (78%) 
    Unknown 8 (<1%) 4 (<1%) 4 (<1%) 
Median (IQR) systolic blood pressure 136 (120 - 155) 136 (120 - 156) 136 (121 - 154) 
Hours since injury  
   ≤1  166 (9%) 77 (9%) 89 (10%) 
   >1 to ≤3 1184 (67%) 596 (67%) 588 (67%) 
   >3 417 (24%) 211 (24%) 206 (23%) 
Pre-randomisation CT Scan  
   Yes 1147 (65%) 568 (64%) 579 (66%) 
   No  615 (35%) 313 (35%) 302 (34%) 
   Unknown 5 (<1%) 3 (<1%) 2 (<1%) 
Median (IQR) hours from injury to scan 1.8 (1.4 – 2.4) 1.8 (1.5 – 2.4) 1.8 (1.4 – 2.3) 




















Table 10. Baseline computed tomography characteristics. 






Intracranial bleeding    
Intra-parenchymal 



































Any measurable intracranial bleeding  
   Mean (median) vol, ml 






Subarachnoid 829 (72%) 414 (73%) 415 (72%) 
Petechial 71 (6%) 30 (5%) 41 (7%) 
Oedema    
Oedematous lesions 177 (15%) 95 (17%) 82 (14%) 
Infarction    
Acute cerebral infarction 13 (1%) 3 (1%) 10 (2%) 
Mass effect    
Midline shift 







Sulcal effacement 609 (53%) 318 (56%) 291 (50%) 
Ventricular effacement 456 (40%) 224 (39%) 232 (40%) 
Marshall classification    
Diffuse injury I  25 (2%) 12 (2%) 13 (2%) 
Diffuse injury II 533 (46%) 245 (43%) 288 (50%) 
Diffuse injury III 60 (5%) 37 (7%) 23 (4%) 
Diffuse injury 1V 30 (3%) 16 (3%) 14 (2%) 
Non-evacuated mass lesion 487 (43%) 253 (45%) 234 (40%) 
Unknown 12 (1%) 5 (1%) 7 (1%) 

















3.2 Inter-rater reliability of pre-randomisation haemorrhage occurrence 
 
All data in the CRASH-3 IBMS were collected by one assessor. The CRASH-3 trial entry forms 
were completed by clinical staff in participating hospitals, and included a question on the types 
of intracranial bleeding seen on pre-randomisation CT scans. This information can be used to 
examine the extent to which the CRASH-3 IBMS assessor and the CRASH-3 trial entry form 
assessors recorded the same type of bleed at baseline for the same patient (i.e. inter-rater 
reliability). 
 
The Kappa-statistic indicates the magnitude of inter-rater agreement for dichotomous (yes/no) 
ratings. This calculation is based on the difference between the observed agreement and 
agreement expected by chance alone. Kappa is standardized to lie on a scale of -1 to 1 where 1 
is perfect agreement, 0 is agreement expected by chance, and negative values indicate 
agreement less than chance. Agreement is considered perfect when the Kappa value is between 
0.81 and 0.99, substantial between 0.61 and 0.80, moderate between 0.41 and 0.6, fair between 
0.21 and 0.40, and slight between 0.01 and 0.20 186.  
 
The ratings for EDH occurrence agreed between raters in 89% of patients (kappa = 0.57, 
moderate), IVH in 88% of patients (kappa = 0.50, moderate), SAH in 77% of patients (kappa = 
0.50, moderate), SDH in 74% of patients (kappa = 0.43, moderate), and for IPH in 65% of 
patients (kappa = 0.33, fair). The kappa-statistic had a probability of less than 0.0001 for all 
bleed types, which suggests that the hypothesis that bleed occurrence ratings were randomly 
assigned can be rejected.  
 
Other than the prevalence of SDH where the CRASH-3 trial entry form rating is greater than the 
IBMS rating (67% vs 64%), the prevalence of each bleed is greater according to the IBMS 
rating: SAH (59% vs 72%); IPH (42% vs 62%); EDH (13% vs 19%); IVH (9% vs 16%). A 
discrepancy between ratings may be expected given that the IBMS assessor collected the data 
by assessing scans in conjunction with their accompanying radiology reports that are often 
written post-randomisation, whilst randomisation into the CRASH-3 trial should have been 
based on information known pre-randomisation. The CRASH-3 trial entry forms were often 
completed using verbal report from radiologists or other clinical staff whilst patients were 
having their pre-randomisation CT scan done, and so the most visible or most clinically relevant 
bleed(s) may have been recorded on the entry form. This would plausibly explain discrepancies 
in pre-randomisation bleed occurrence ratings between the IBMS assessor and clinical staff who 






3.3 Intra-rater reliability  
 
During a training placement in March to April 2016 at the Queen Elizabeth Hospital in 
Birmingham, I examined the scans for 90 patients to explore whether the CRASH-3 IBMS was 
feasible. At the time of this assessment, the scans for 7 patients could not be read for technical 
reasons. I did not examine the scans for all the outcomes included in the final data collection 
forms as these had not yet been developed. The priority of the training placement was to explore 
whether scans were routinely done before and after randomisation and the extent to which post-
randomisation scans may be missing. This was also an opportunity to practise using the ABC/2 
method of measuring haemorrhage volume, and so if a patient presented with multiple 
haemorrhages, I estimated the volume of what appeared to be the largest haemorrhage(s). I 
estimated the volume of large IPHs using the ABC/2 method (as discussed in Section 2.24) and 
SDH using the maximum diameter (as discussed in Section 2.25). I also rated scans according to 
the Marshall Classification (see Appendix 11). The training placement (Reading 1) and the final 
data collection for these patients (Reading 2) occurred on separate occasions. The scan 
assessment during Reading 2 was done blind from the assessment during Reading 1.  
In this section, I will assess the degree of agreement between Readings 1 and 2 of the same 
patient’s scan by the same assessor (i.e. the intra-rater reliability). The intra-rater reliability of 
dichotomous and ordinal outcomes will be assessed using the Kappa statistic, and continuous 
outcomes (bleed volume) using Intra-Class Correlations (ICCs).  
Intracranial haemorrhage (pre-randomisation scan) 
A discrepancy between haemorrhage occurrence and volume ratings between Readings 1 and 2 
should be expected. Reading 1 involved estimating the volume of the largest bleeds seen on the 
scan and information about the occurrence of other bleeds was extracted from available 
radiology reports. Reading 2 involved recording the occurrence and volume of all bleeds 
(irrespective of size), where possible, using scans and their accompanying radiology reports.  
During Reading 1 compared to Reading 2, fewer patients were recorded as having IPH (30% vs 
53%), SDH (28% vs 66%), IVH (4% vs 7%) and SAH (14% vs 66%). During Reading 1, EDH 
was referred to as extra-axial haemorrhage (as it is in some radiology reports) and because 
extra-axial haemorrhage could be EDH, SDH or SAH, I was unable to retrospectively confirm 
which patients had EDH for the purpose of this analysis. During Reading 2, a total of 3 patients 
(4%) were recorded as having EDH.   
My ratings for IPH occurrence agreed in 65% of patients (kappa = 0.32, fair) and the hypothesis 
that they were randomly assigned can be rejected (p=0.0006). My ratings for SDH occurrence 
agreed in 61% of patients (kappa = 0.33, fair) and the hypothesis that they were randomly 




(kappa = 0.42, moderate) and the hypothesis that they were randomly assigned can be rejected 
(p<0.0001). My ratings for SAH occurrence agreed in 48% of patients (kappa = 0.16, slight) and 
the hypothesis that they were randomly assigned can be rejected (p=0.0038). Please note that 
because the volume of SAH was not estimated, SAH occurrence was not recorded in a 
standardized way during Reading 1. For the purpose of this analysis, I examined the comments 
of the available sections of radiology reports (recorded as notes during the training placement) 
for 21/82 patients for confirmation of the presence of SAH. This would explain the larger 
discrepancy between Readings 1 and 2 for SAH compared to other types of haemorrhage.   
ICCs were used to examine the reliability of bleeding volume estimates between Readings 1 and 
2 187. The ICC usually has a value between 0 and 1, with higher values indicating stronger 
reliability 188. ICC values less than 0.5 are considered poor, between 0.5 and 0.75 moderate, 
between >0.75 and 0.9 good, and greater than 9 excellent 189. However, whether a given ICC 
value indicates sufficient reliability should depend on the intended use of the method 188. 
The mean of the total bleeding volume (sum of all bleeds) was lower for Reading 1 compared to 
Reading 2 (18.0ml (SD=31.8ml) vs 31.1ml (35.4ml)). The estimated ICC between individual 
readings for each patient is 0.70 (95% CI 0.58 – 0.80), indicating moderate reliability. The ICC 
between mean readings for each patient is 0.83 (95% CI 0.73 – 0.89), indicating good 
reliability. There is evidence to reject the null hypothesis that neither ICC is zero: F(81, 82) = 
5.74, p<0.0001.  
The mean of the total IPH volume was higher for Reading 1 compared to Reading 2 (5.1ml 
(SD=19.6ml) vs 3.7ml (SD=15.7ml)). The estimated ICC between individual IPH volume 
readings for each patient is 0.64 (95% CI 0.49 – 0.75), indicating moderate reliability. The ICC 
between mean readings for each patient is 0.78 (95% CI 0.66 – 0.86), indicating good 
reliability. There is evidence to reject the null hypothesis that neither ICC is zero: F(81, 82) = 
4.57, p<0.0001.  
The mean of the total SDH volume was lower for Reading 1 compared to Reading 2 (12.9ml 
(SD=26.0ml) vs 25.4ml (SD=27.5ml)). The estimated ICC between individual SDH volume 
readings for each patient is 0.59 (95% CI 0.43 – 0.72), indicating moderate reliability. The ICC 
between mean readings for each patient is 0.74 (95% CI 0.60 – 0.83), indicating moderate 









Marshall Classification  
The Marshall Classification rating was missing for 1/83 patients whose pre-randomisation scans 
were read during Reading 1. Of the remaining 82 patients, the Marshall Classification was 
scored as Diffuse Injury I in 3 patients (4%), Diffuse Injury II in 53 patients (65%), Diffuse 
Injury III in 2 patients (2%), Diffuse Injury IV in 3 patients (4%), Evacuated mass lesion in 0 
patients (0%), and Non-evacuated mass lesion in 21 patients (26%). During reading 2, the 
Marshall Classification was rated as Diffuse Injury I in 1 patient (1%), Diffuse Injury II in 48 
patients (59%), Diffuse Injury III in 2 patients (2%), Diffuse Injury IV in 1 patient (1%), 
Evacuated mass lesion in 0 patients (0%) and Non-evacuated mass lesion in 30 patients (37%). 
My pre-randomisation Marshall Classification ratings agreed in 79% of patients (kappa = 0.61, 
substantial) and the hypothesis that these ratings were randomly assigned can be rejected 
(p<0.0001).  
A third of patients whose scans were assessed during Reading 1 were not scanned post-
randomisation (n=28/83). In patients scanned post-randomisation, not all scans were retrievable 
during Reading 1 (largely due to technical difficulties and archiving) but were during Reading 
2. This left 39 patients whose post-randomisation scans were rated using the Marshall 
Classification during both Readings 1 and 2. No patients’ scans were rated as Diffuse Injury I or 
III during either reading. In both readings, Diffuse Injury II was rated in 21 patients (54%), 
Diffuse Injury IV in 1 patient (3%), and Non-evacuated mass lesion in 8 patients (21%). A total 
of 8 patients (21%) were recorded as having an Evacuated mass lesion during Reading 1 and 9 
patients (23%) during Reading 2. My post-randomisation Marshall Classification ratings agreed 
in 95% of patients (kappa = 0.92, perfect) and the hypothesis that these ratings were randomly 
















Research Paper 4 
 
Sections 3.3 to Section 3.6 of this chapter are from Research Paper 4. This paper was submitted 
for publication consideration in October 2019, and is currently undergoing revision. I have 
acquired permission to reproduce this manuscript in this thesis (see Appendix 7) and the full 
submitted manuscript is included in Appendix 8.  
 
Title: TXA in traumatic brain injury: an explanatory study nested within the CRASH-3 trial.   
Journal: European Journal of Trauma and Emergency Surgery  
Authors: Mahmood A, Needham K, Shakur-Still H, Davies D, Belli A, Jamaluddin S F, […], 








































3.4 Intracranial haemorrhage seen pre-randomisation, by GCS score and pupil reaction  
 
Figure 13 shows the type and frequency of intracranial haemorrhage on pre-randomisation CT 
scans according to pre-randomisation GCS. A total of 61% of patients with a pre-randomisation 
CT scan presented with more than one type of haemorrhage. With the exception of EDH, which 
was more prevalent in patients with mild to moderate GCS, all other haemorrhage types were 
more common in patients with a severe GCS. SDH had a larger median volume of 46ml (IQR 
27ml to 71ml) compared to EDH with 6ml (IQR 2ml to 20ml), IPH with 1ml (IQR 0·2ml to 
3ml), and IVH with a median volume of 0·4ml (IQR 0·1ml to 2ml).  
 
 
Figure 13. Pre-randomisation prevalence and type of intracranial bleeding by Glasgow Coma 












Figure 14 shows the volume distribution of intracranial haemorrhage on pre-randomisation CT 
scans by pupil reactions and GCS. The median volumes of 64ml (IQR 26ml to 108ml) in 
patients with no reactive pupils and 48ml (IQR 3ml to 93ml) in patients with one reactive pupil 
were larger than 26ml (IQR 1ml to 55ml) in patients with two reactive pupils. The median 
volumes of 37ml (IQR 3ml to 75ml) in patients with a severe GCS were greater than 28ml (IQR 
1ml to 53ml) for moderate GCS and 18ml (IQR 0·2ml to 41ml) in mild GCS. But there is 
substantial overlap in haemorrhage volumes between pupil reaction groups and GCS groups. 
 
 



















Data on the time of injury (from the CRASH-3 trial entry form) and time of CT scan (from the 
CRASH-3 IBMS) were used to estimate the time-adjusted volume of intracranial haemorrhage. 
Table 11 shows the time-adjusted volume of haemorrhage by pupil reaction, GCS score, and 
type of haemorrhage. The time-adjusted volume of haemorrhage was largest in those with un-
reactive pupils and in those with severe GCS. SDH was more rapid than EDH, IPH, and IVH.  
Table 11. Baseline intracranial bleeding volume (adjusted for time from injury to baseline scan). 
  Median (lower quartile, upper quartile) millilitres / hour 




None react (n=141) 32 (14, 55) 
One react (n=94) 21 (2, 47) 
Both react (n=867) 13 (0·5, 31) 
  
Glasgow coma scale (GCS) score * 
 
Severe (n=388) 20 (2, 41) 
Moderate (n=331) 13 (0·3, 29) 
Mild (n=91) 8 (0·1, 20) 
  
Bilateral un-reactive pupils or GCS 3 * (n=131) 28 (10, 54) 
  
Type of intracranial bleeding  
Subdural (n=732) 25 (13, 42) 
Epidural (n=215) 4 (1, 10) 
Intra-parenchymal (n=709) 0·4 (0·1, 2) 
Intra-ventricular (n=184) 0·3 (0·1, 1) 
 






















But the bleeding rate may not be constant. A non-linear association was found between time and 
bleeding volume (see Figure 15). The majority of expansion occurred in the first 1 to 1·5 hours 
after injury. Patients with a severe GCS seemed to bleed more and faster than patients with 









































3.5 Signs of intracranial pressure on pre-randomisation CT 
 
Compared to patients with mild to moderate GCS, the prevalence of sulcal effacement was 
greater in those with severe GCS (44% vs 59%; n=190/433 vs n=417/702), as was ventricular 
effacement (30% vs 47%; n=128/433 vs 328/702), and midline shift (39% vs 48%; n=169/433 
vs. 337/702). Patients with a severe GCS and midline shift had a median shift of 7·4mm (IQR 
4·1mm to 14·1mm) whilst those with moderate to mild GCS had a median shift of 4·3mm (IQR 
2·8mm to 7·1mm).  
 
3.6 Intracranial haemorrhage seen post-randomisation but not pre-randomisation  
 
Seventy one percent (n=812) of patients with a pre-randomisation CT scan had a second or third 
clinically indicated CT scan. Over a third of these patients (n=318) had a bleed on a subsequent 
scan that was not seen on the first scan. Patients who had their first CT scan soon after injury 
were more likely to have a new bleed on a subsequent scan. The prevalence of new bleeds 
among those scanned ≤1·5 hours, >1·5 to 3 hours, >3 to 8 hours after injury was 46%, 38%, 
31%, respectively. For every 1 hour increase from injury to the baseline scan, the risk of new 
bleeding on a further scan decreased by 12% (RR=0·88 [95% CI 0·80 – 0·96], p=0·0047) 
(adjusted for baseline GCS score, pupil reaction, and time from injury to follow-up scan). The 
sooner the first scan was done after injury, the greater the opportunity for a new bleed to 
manifest on a further scan.  
 
3.7 Pre-randomisation intracranial haemorrhage and pressure, un-reactive pupils, and 
head injury death 
 
An increase in the volume of intracranial bleeding (ml) was associated with an increase in the 
amount (mm) of midline shift (beta coefficient 0·10 [95% CI 0·09-0·10], p<0·0001) (see Figure 
16). An increase in midline shift (mm) was associated with an increase in the risk of having one 
or more un-reactive pupils (RR 1·08 [95% CI 1·07-1·10], p<0·0001) (see Figure 17). Of those 
with pre-randomisation scans available for rating, 247 patients subsequently died from head 
injury. The median time-adjusted volume of intracranial bleeding among patients who died from 
head injury is 37ml/h (IQR 18ml/h to 58ml/h) and in those who did not die of head injury v is 
11ml/h (IQR 0·3ml/h to 28ml/h). Patients who died of head injury within 24 hours of injury had 
a higher median time-adjusted bleeding volume of 51ml/h (IQR 28ml/h to 73ml/h), than those 
who died within 48-72 hours of injury with 39ml/h (IQR 19ml/h to 56ml/h), and beyond 72 
hours of injury with 28ml/h (IQR 14ml/h to 52ml/h).  
                                                     

























































3.8 Effect of TXA on intracranial haemorrhage 
 
As indicated in the statistical analysis plan in the methods chapter, all patients can be included 
in the analyses on the effect of TXA on intracranial haemorrhage volume, even if they were not 
scanned pre-randomisation and post-randomisation.  
 
Appendix 14 shows that haemorrhage volumes were positively skewed (left-skew), and that 
these skewed data can be transformed into a more normal distribution using log transformation. 
This transformation may make any patterns in the data more interpretable. A linear mixed 
model was used to examine the effect of TXA (versus placebo) on log-transformed 
haemorrhage volumes. This analysis included the duration between injury to the pre-
randomisation scan, age, GCS score, systolic blood pressure, and participating hospital site. 
Because haemorrhage volumes were log-transformed, the anti-log of the treatment effect 
estimate and its corresponding 95% confidence intervals (CIs) are presented in Table 12 to aid 
interpretation. See Table 12 for the proportional effect of TXA on intracranial haemorrhage. 
The values provide an estimate of the relative increase or decrease in haemorrhage volume with 
TXA (i.e. the treatment effect). 
 
 Primary analysis: effect of TXA on IPH  
 
There is no evidence for a reduction in IPH with TXA compared to placebo: 1.06, 95% CI (0.84 
– 1.35), p=0.620. The confidence intervals are wide and so the treatment effect estimate is 
compatible with a decrease or increase in IPH with TXA. There is no evidence for a reduction in 
IPH with TXA in patients randomised within 3 hours of injury (1.09, 95% CI (0.81 – 1.45), 
p=0.570) or after 3 hours of injury (0.95, 95% CI (0.63 – 1.43), p=0.789).  
 
Sensitivity analysis: Because a change in haemorrhage volume between pre-randomisation and 
post-randomisation scans could be due to the effect of TXA or neurosurgical haemorrhage 
evacuation, patients who underwent neurosurgical haemorrhage evacuation by the first post-
randomisation scan were removed from the primary analysis. There was no evidence for a 
reduction in IPH with TXA compared to placebo: 1.11, 95% CI (0.73 – 1.67), p=0.629. 
 
 Secondary analysis: effect of TXA on SDH, EDH and IVH 
 
There is no evidence for a reduction in SDH (0.96, 95% CI (0.88 – 1.05), p=0.405) or EDH 
(0.84, 95% CI (0.52 – 1.37), p=0.483) with TXA compared to placebo. There is no evidence for 





There is no clear evidence for a reduction or increase in IVH (1.46, 95% CI (0.98 – 2.19), 
p=0.063) with TXA compared to placebo. There is no evidence for a reduction or increase in 
IVH with TXA in those randomised within three hours of injury (1.24, 95% CI (0.75 – 2.05), 
p=0.399) and no clear evidence for a reduction or increase in IVH in those randomised after 
three hours of injury (2.10, 95% CI (0.94 – 4.66), p=0.069). In most cases, the point estimates 
are imprecise.  
 
Sensitivity analysis: In sensitivity analyses, patients who underwent neurosurgical haemorrhage 
evacuation by the first post-randomisation scan were excluded. There is no evidence for a 
reduction in SDH (1.02, 95% CI (0.93 – 1.12), p=0.630) or EDH (0.95, 95% CI (0.62 – 1.44), 
p=0.803) with TXA. There is no evidence for a reduction in SDH with TXA in those 
randomised within 3 hours of injury (1.03, 95% CI (0.91 – 1.15), p=0.679) or after 3 hours of 
injury (1.00, 95% CI (0.85 – 1.17), p=0.961). There is no evidence for a reduction in EDH with 
TXA in those randomised within 3 hours of injury (1.27, 95% CI (0.63 – 2.52), p=0.504) or 
after 3 hours of injury (0.67, 95% CI (0.38 – 1.18), p=0.167).  
 
 Secondary analysis: effect of TXA on post-neurosurgical haemorrhage 
 
A total of 21% of patients underwent neurosurgical haemorrhage evacuation (n=363/1767). Of 
these, 31% (n=111) had a craniotomy (portion of skull replaced immediately after evacuation) 
and 69% (n=252) had a craniectomy (portion of skull not immediately replaced after 
evacuation).  
 
In patients scanned pre-randomisation and post-randomisation, 24% of patients underwent 
neurosurgical haemorrhage evacuation between pre-randomisation and post-randomisation 
scans (n=192/812). A further 7% of patients who were scanned pre-randomisation showed 
evidence of neurosurgical haemorrhage evacuation on a further post-randomisation scan 
(n=54/812). In patients not scanned pre-randomisation but who had their first scan post-
randomisation, 19% showed evidence of neurosurgical haemorrhage evacuation (n=117/614).  
 
There was no evidence for a reduction in any intracranial haemorrhage with TXA in patients 
who underwent neurosurgical haemorrhage evacuation (0.79, 95% CI (0.57 – 1.11), p=0.182). 
There was no evidence for a reduction in IPH with TXA in patients who underwent 







 Secondary analysis: effect of TXA on SAH 
 
The effect of TXA on SAH was examined using relative risks (RRs) and 95% CIs. A total of 
64% of patients presented with SAH in the TXA group (n=458/715) and 61% in the placebo 
group (n=440/716). Among all patients, there was no evidence for a reduction in SAH with 
TXA: RR=1.02, 95% CI (0.99 – 1.05), p=0.309. There was no evidence for a reduction in SAH 
in patients randomised within 3 hours (65% vs 60%; RR=1.03, 95% CI (0.99 – 1.06), p=0.148) 
or after 3 hours of injury (62% vs 66%; RR=0.98, 95% CI (0.92 – 1.05), p=0.558).  
 
The effect of TXA on the size (large vs small) and spread (diffuse vs focal) of SAH was 
examined. In patients with SAH, there were less patients with large SAH in the TXA group 
compared to placebo group (7% vs 10%). But there was no clear evidence for a reduction in the 
size of SAH with TXA: RR=0.67, 95% CI (0.43 – 1.05), p=0.079. In patients with SAH, there 
were more patients with diffuse SAH in the TXA group compared to placebo group (18% vs 
16%). But there was no evidence for an reduction in the spread of SAH with TXA: RR=1.11, 







           Table 12. Effect of TXA on intracranial bleeding. 
 Proportional effect of TXA (95% CI) 
 ≤3h since injury 
p value 
(two-tailed) 






All patients  
Intra-parenchymal 1.09 (0.81 – 1.45) 0.570 0.95 (0.63 – 1.43) 0.789 1.06 (0.84 – 1.35) 0.620 
   Excl. neurosurgery patients  0.99 (0.71 – 1.37) 0.936 0.96 (0.62 – 1.48) 0.863 1.03 (0.79 – 1.35) 0.804 
Intra-ventricular  1.24 (0.75 – 2.05) 0.399 2.10 (0.94 – 4.66) 0.069 1.46 (0.98 – 2.19) 0.063 
Subdural  0.96 (0.87 – 1.07) 0.475 0.95 (0.82 – 1.10) 0.498 0.96 (0.88 – 1.05) 0.405 
Epidural  1.07 (0.55 – 2.11) 0.834 0.57 (0.29 – 1.12) 0.102 0.84 (0.52 – 1.37) 0.483 
Neurosurgery patients only 
Intra-parenchymal  1.58 (1.00 – 2.48) 0.049 0.50 (0.19 – 1.30) 0.153 1.11 (0.73 – 1.67) 0.629 





3.9 Secondary analysis: effect of TXA on cerebral infarction  
 
The occurrence of cerebral infarction is defined as any patient who presents with acute infarction on 
any post-randomisation brain imaging scan done within 28 days of randomisation. This excludes 
patients who presented with the same infarction on a pre-randomisation scan. A total of 11% of 
patients (n=159/1431) presented with acute infarction post-randomisation, and this was not known 
to be present pre-randomisation.  
 
Relative risk of cerebral infarction 
 
A total of 12% of patients presented with infarction in the TXA group (n=89/715) and 10% in the 
placebo group (n=70/716). There is no clear evidence that TXA increases the risk of cerebral 
infarction: RR=1.27, 95% CI (0.95-1.71), p=0.109.  
 
In those randomised within 3 hours of injury, 12% presented with infarction in the TXA group 
(n=70/561) and 10% in the placebo group (n=59/565). There is no evidence that TXA increases the 
risk of infarction in patients randomised within 3 hours of injury: RR=1.19, 95% CI (0.86 – 1.66), 
p=0.285. In those randomised after 3 hours of injury, 12% of patients presented with infarction in 
the TXA group (n=19/154) and 7% in the placebo group (n=11/151). There is no clear evidence that 
TXA increases the risk of infarction in those randomised after 3 hours of injury: RR=1.69, 95% CI 
(0.83 – 3.44), p=0.145.  
 
The prevalence of infarction was greater amongst those randomised within three hours of injury 
(n=159/1126; 14%) compared to more than three hours of injury (n=30/305; 10%). Because patients 
were not randomised into the CRASH-3 trial on the basis of the duration between their injury and 
randomisation, subgroups of time since injury may be confounded, in this case by baseline severity. 
Therefore, the same analyses reported above were adjusted using factors indicative of severity and 
measured pre-randomisation. After adjusting for GCS score, pupil reaction, systolic blood pressure, 
age, and participating hospital site, there is no evidence that TXA increases the risk of infarction: 
RR=1.26, 95% CI (0.94 – 1.68), p=0.126. In those randomised within 3 hours of injury, there is no 
evidence that TXA increases the risk of infarction: RR=1.16, 95% CI (0.84 – 1.61), p=0.372. There 
is no clear evidence that TXA increases the risk of infarction in those randomised after 3 hours of 
injury: RR=1.91, 95% CI (0.99 – 3.68), p=0.052. Because this group is even smaller than the group 
of patients randomised within 3 hours of injury (n=305 vs. n=1126), the confidence intervals are 




Hazard of infarction 
 
Because TXA may increase the occurrence of cerebral infarction after a certain period after 
randomisation, a Cox proportional hazards model (which provides a rate) may be more appropriate 
(than a RR) for the analysis of TXA on infarction. The RR is the ratio of the risk of the outcome in 
the treated group divided by the risk of the same outcome in the comparison group, at a defined 
endpoint (e.g. end of study follow-up period). The HR is the ratio of the hazard of the outcome in 
the treated group divided by the hazard of same outcome in the comparison group. The hazard is the 
probability that if the outcome has not already occurred, it will occur in the next time interval, 
divided by the length of that interval 190.  
 
The hazard of cerebral infarction in the TXA group is 1.14 and the hazard in the placebo group is 
0.88: HR=1.31, 95% CI (0.95 – 1.80), p=0.100. Among all patients, at any particular time after 
randomisation, there is no evidence for an increase in the hazard of infarction between treatment 
groups. Among those randomised within 3 hours of injury, the hazard of cerebral infarction in the 
TXA group is 1.12 and the hazard in the placebo group is 0.89: HR=1.26, 95% CI (0.88 – 1.79), 
p=0.203. Among those randomised after 3 hours of injury, the hazard of cerebral infarction in the 
TXA group is 1.25 and the hazard in the placebo group is 0.79: HR=1.58, 95% CI (0.74 – 3.34), 
p=0.235. In patients randomised within 3 hours of injury, or after 3 hours of injury, there is no 
evidence for an increase in the hazard of cerebral infarction at any particular time after 
randomisation. 
 
The above analyses on the hazard of infarction in TXA and placebo groups were repeated after 
adjusting for baseline GCS score, pupil reaction, systolic blood pressure, age, and participating 
hospital site. There is no evidence that TXA increases the hazard of infarction in those randomised 
within 3 hours of injury: adjusted HR=1.21, 95% CI (0.85 – 1.73), p=0.297. There is no evidence 
that TXA increases the hazard of infarction in those randomised after 3 hours of injury: adjusted 
HR=1.68, 95% CI (0.78 – 3.59), p=0.185. Among all patients, at any particular time after 
randomisation, there is no evidence that TXA increases the hazard of cerebral infarction: adjusted 
HR=1.28, 95% CI (0.93 – 1.76), p=0.133. 
 
These analyses were not adjusted using the time from injury to the pre-randomisation scan because 
not all patients scanned post-randomisation were scanned pre-randomisation. Adjusting for baseline 
covariates would reduce the sample size to the number of patients who have outcomes for all 




the pre-randomisation scan as a covariate in these analyses would have reduced the sample size by 
43%. Any power gained from adjustment would be less than the large loss in power from dropping 
patients without a pre-randomisation scan 175.  
 
Survival analysis  
 
Because it is not known when exactly a patient will have suffered infarction, it is not possible to 
examine any difference between treatment groups in the time duration between randomisation and 
occurrence of infarction. However, it is possible to use survival analysis to examine any difference 
between treatment groups in the time duration between randomisation and the time of the scan on 
which infarction was first seen (see Figure 18).  
  
 
Figure 18. Time to cerebral infarct detection in tranexamic acid or placebo treated patients.  
 
Figure 18 presents the cumulative proportion of patients who show evidence of infarction by time 
since randomisation 191. The numbers at risk along the x-axis show the number of patients at risk of 
infarction and still in follow-up in each treatment group at the specified time-points. If a patient 
shows evidence of infarction, dies or is discharged within 28 days of randomisation, they exit the 





The median time to the scan showing infarction is 47 hours (IQR 23–113) after randomisation in the 
TXA group and 41 hours (IQR 20–113) after randomisation in the placebo group. Because the data 
to the right of the survival graph is where there is least information and greatest uncertainty, the 
survival plot has not been extended to the end of the follow-up period (but all events are retained in 
analyses) 191. More than 75% of patients who presented with infarction did so within 120 hours of 
randomisation, and so the x-axis of Figure 18 was cut here.  
 
The log-rank test for equality of survival curves tests the null hypothesis that there is no difference 
between treatment groups in the probability of the outcome at any time point after randomisation 
192. The log-rank test suggests that there is no evidence for a difference in the occurrence of 
infarction between TXA and placebo groups: Log-rank = 2.73, p=0.099. The Cox proportional 
hazards model provides an estimate of the size of the difference between treatment groups. There is 
no evidence for a difference between treatment groups in the time duration between randomisation 
and the scan on which infarction was seen: HR=1.31, 95% CI (0.95 – 1.80), p=0.10. There is no 
evidence for a difference between treatment groups in patients treated within 3 hours of injury 
(HR=1.26, (95% CI 0.88 – 1.79), p=0.20) or after 3 hours of injury (HR=1.58, 95% CI 0.74 – 3.34), 
p=0.24).  
 
Because infarction may result as a complication of neurosurgical intervention and not the effect of 
TXA, patients who underwent neurosurgery were excluded in a sensitivity analysis and the survival 
curves re-estimated. In the remaining non-neurosurgery patients, 70 presented with infarction (44 
TXA, 26 placebo). The log-rank test suggests that there is some evidence for a difference in the 
occurrence of infarction between TXA and placebo groups in these non-neurosurgery patients: Log-
rank = 4.55, p=0.033. The Cox proportional hazards model provides an estimate of the size of the 
difference between treatment groups: HR=1.68, 95% CI (1.03 – 2.73), p=0.036. However, this 
sensitivity analysis was based on a post-randomisation exclusion (occurrence of neurosurgery) and 
so should be interpreted carefully, especially in the context of the risk of bias from using post-
randomisation scans done for clinical purposes.   
 
3.10 Secondary analysis: effect of TXA on composite “poor” outcome 
 
The composite “poor” outcome includes patients with progressive haemorrhage, new haemorrhage, 
infarction (not known to be present pre-randomisation), neurosurgery, or head injury death. A total 
of 33% of all patients had at least one of these outcomes (n=586), 13% had two (n=236), 6% had 




composite (n=4). Patients with more than one outcome within the composite were only included in 
the analysis once.  
 
A total of 55% of patients in the TXA group (n=483/884) met the definition for inclusion in the 
composite outcome and 54% in the placebo group (n=478/883). The effect of TXA on the 
composite outcome was evaluated using RRs and 95% CIs. There is no evidence for a reduction in 
the occurrence of the composite outcome with TXA: RR=1.01, 95% CI (0.93 – 1.10), p=0.832. 
There is no evidence for a treatment effect in those randomised within three hours of injury (54% vs 
54%; RR=0.99 (95% CI 0.90-1.10), p=0.920) or after three hours of injury (58% vs 55%; RR=1.05 
(95% CI 0.89 – 1.25), p=0.542).  
 
3.11 Secondary analysis: effect of TXA on oedematous lesions w 
 
In patients scanned post-randomisation, the effect of TXA on oedematous lesions (i.e. haemorrhagic 
lesions surrounded by oedema or residual oedema following haemorrhage resolution) was evaluated 
using RRs and 95% CIs. A total of 41% of patients presented with oedematous lesions in the TXA 
group (n=288/709) and 39% in the placebo group (n=278/712). There is no evidence that TXA 
reduces the risk of oedematous lesions: RR=1.01, 95% CI (0.98 – 1.05), p=0.544. There is no 
evidence that TXA reduces the risk of oedematous lesions in those randomised within 3 hours of 
injury (38% vs 36%): RR=1.01, 95% CI (0.97 – 1.05), p=0.583. There is no evidence that TXA 
reduces the risk of oedematous lesions in those randomised after 3 hours of injury (50% vs 49%): 
RR=1.01, 95% CI (0.94 – 1.09), p=0.818. 
 
3.12 Secondary outcomes in patients scanned pre-randomisation and post-randomisation 
 
In the 46% of patients who were scanned pre-randomisation and post-randomisation (n=812/1767), 
the pre-randomisation scan was done within a median of 2 hours after injury (IQR 1h to 2h) and the 
post-randomisation scan was done within a median of 35 hours after injury (IQR 19h to 77h) and 
29h after randomisation (IQR 15h to 70h). Baseline demographic and clinical characteristics for this 
group of patients are similar to the overall IBMS population (see Table 13). But the proportion of 
patients with bilateral unreactive pupils is greater in the overall IBMS population than in those with 
both pre-randomisation and post-randomisation scans (13% vs. 8%), and the proportion of patients 
                                                     
w Estimating the amount of peri-lesional oedema using the simple manual tools available in the CRASH-3 
IBMS would have resulted in a large amount of measurement error and so this outcome was dichotomized. 
Alternative automated imaging methods and/or cerebral micro-dialysis would provide a more accurate 




with severe GCS is greater in the overall population compared to those with both pre-randomisation 
and post-randomisation scans (65% vs. 62%). 
 






TXA group  
(n=399) 
Placebo group  
(n=413) 
Sex  
   Male 663 (82%) 319 (80%) 344 (83%) 
   Female 149 (18%) 80 (20%) 69 (17%) 
Age  
   Median (IQR) age in years 44 (29 - 62) 45 (29 - 62) 43 (28 - 61) 
Glasgow coma score (GCS)  
   Mild (13-15) 64 (8%) 32 (8%) 32 (8%) 
   Moderate (9-12) 242 (30%) 115 (29%) 127 (31%) 
   Severe (3-8) 506 (62%) 252 (63%) 254 (62%) 
Median (IQR) GCS 7 (3 - 10) 7 (3 - 10) 7 (3 - 11) 
Pupil reaction  
Both react 652 (80%) 318 (80%) 334 (81%) 
One reacts 68 (8%) 35 (9%) 33 (8%) 
None react 66 (8%) 32 (8%) 34 (8%) 
Unable to assess 25 (3%) 13 (3%) 12 (3%) 
Unknown 1 (<1%) 1 (<1%) - 
Systolic blood pressure   
    < 90 7 (1%) 2 (1%) 5 (1%) 
    90 – 119 185 (23%) 94 (24%) 91 (22%) 
    ≥ 120 618 (76%) 302 (76%) 316 (77%) 
    Unknown 2 (<1%) 1 (<1%) 1 (<1%) 
Median (IQR) systolic blood pressure 133 (120 - 153) 133 (120 - 153) 134 (120 - 152) 
Hours since injury  
   ≤1  15 (2%) 6 (2%) 9 (2%) 
   >1 to ≤3 530 (65%) 255 (64%) 275 (67%) 
   >3 267 (33%) 138 (35%) 129 (31%) 
Pre-randomisation CT Scan  
   Yes 812 (100%) 399 (100%) 413 (100%) 
Median (IQR) hours from injury to scan 1.8 (1.5 – 2.3) 1.8 (1.5 – 2.4) 1.8 (1.4 – 2.3) 













3.13 Secondary analysis: effect of TXA on new haemorrhage 
 
A total of 39% of patients (n=318/812) presented with a new haemorrhage (seen post- but not pre-
randomisation): IPH was the most common type of new haemorrhage (n=58%), followed by IVH 
(n=28%), SDH (17%), EDH (6%) and SAH (6%). A total of 15% of patients with new haemorrhage 
presented with more than one type of new haemorrhage. In those with a new IPH, more patients had 
a severe GCS (3-8) at baseline compared to moderate to mild GCS (66% vs 34%). The same pattern 
was seen in those with a new IVH (69% vs 31%), new SDH (62% vs 38%), new EDH (75% vs 
25%) and new SAH (55% vs 45%).  
 
In those with a severe GCS (3-8) at baseline (n=506/812), 24% went on to have a new IPH (n=122), 
12% had a new IVH, 7% had a new SDH (n=33), 3% had a new EDH (n=15) and 2% had a new 
SAH (n=11). In those with bilateral unreactive pupils at baseline (n=66/811), 30% had a new IPH 
(n=20), 14% had a new IVH (n=9), 8% had a new SDH (n=5), 2% had a new EDH (n=1) and 2% 
had a new SAH (n=1). In those with unilateral unreactive pupils at baseline (n=68/811), 24% had a 
new IPH (n=16), 13% had a new IVH (n=9), 9% had a new SDH (n=6), 3% had a new EDH (n=2) 
and 12% had a new SAH (n=8). 
 
The effect of TXA on new haemorrhage was examined using RRs and 95% CIs. A total of 36% of 
patients in the TXA group (n=144/319) had evidence of new haemorrhage post-randomisation and 
42% in the placebo group (n=174/413). There is no clear evidence for a reduction in new 
haemorrhage with TXA: RR=0.86, 95% CI (0.72 – 1.02), p=0.079. But when patients with bilateral 
unreactive pupils at baseline are excluded, there is some evidence for a reduction in new 
haemorrhage with TXA (35% vs 42%): RR=0.83, 95% CI (0.69 – 1.00), p=0.048. When patients 
with unilateral or bilateral unreactive pupils at baseline are excluded, there is some evidence for a 
20% reduction in new haemorrhage with TXA (33% vs 40%): RR=0.80, 95% CI (0.66 – 0.98), 
p=0.033. 
 
There is no clear evidence for a reduction in new haemorrhage with TXA in those treated within 3 
hours of injury (41% vs 45%; RR=0.91, 95% CI (0.75 – 1.10), p=0.343) or after 3 hours of injury 
(26% vs 35%; RR=0.75 (0.52 – 1.08), p=0.121). After the analyses are adjusted for GCS score, 
pupil reaction, systolic blood pressure, site, age, and time from injury to the pre-randomisation scan, 
there is no evidence for a treatment effect in those randomised within 3 hours of injury (41% vs 
45%; RR=0.89, 95% CI (0.73 – 1.08), p=0.224). There is some evidence for a treatment effect in 




Adjustment does not provide clear evidence for a treatment effect in all patients (36% vs 42%; 
RR=0.85 (0.72 – 1.01), p=0.069) but some evidence when excluding those with unilateral or 
bilateral unreactive pupils at baseline (33% vs 40%; RR=0.80, 95% (0.66 – 0.98), p=0.030).  
 
All point estimates are less than 1 and so in the direction of a reduction in new haemorrhage with 
TXA, but imprecise (see Table 14). 
 
3.14 Secondary analysis: effect of TXA on progressive haemorrhage 
 
The effect of TXA on progressive haemorrhage was examined using RRs and 95% CIs. A total of 
29% of patients had evidence of progressive haemorrhage in the TXA group (n=115/399) and 31% 
in the placebo group (n=130/413). There is no clear evidence for a reduction in progressive 
haemorrhage with TXA: RR=0.92, 95% CI (0.74 – 1.13), p=0.411. There is no clear evidence for a 
treatment effect in those randomised within 3 hours of injury (29% vs 31%; RR=0.94, 95% CI (0.73 
– 1.22), p=0.636) or after 3 hours of injury (28% vs 33%; RR=0.87, 95% CI (0.60 – 1.25), 
p=0.447). There is no clear evidence for a reduction in progressive haemorrhage with TXA after 
excluding patients with bilateral unreactive pupils at baseline (29% vs 32%; RR=0.88, 95% CI 
(0.71 – 1.10), p=0.256), and unilateral or bilateral unreactive pupils at baseline (28% vs 32%; 
RR=0.86, 95% CI (0.69 – 1.09), p=0.216). Adjustment for GCS score, pupil reaction, systolic blood 
pressure, site, age, and time from injury to the pre-randomisation scan, does not affect the treatment 
effect estimates when excluding patients with bilateral unreactive pupils: RR=0.89, 95% CI (0.71 – 
1.10), p=0.283); or when excluding patients with unilateral or bilateral unreactive pupils: RR=0.87, 
95% CI (0.69 – 1.10), p=0.242).  
 
3.15 Secondary analysis: effect of TXA on new and progressive haemorrhage in non-
neurosurgery patients  
 
The appearance of new intra-cranial haemorrhage on post-randomisation CT may reflect a 
complication of neurosurgery and not the effect of TXA. Therefore, the effect of TXA on new and 
progressive haemorrhage was re-examined after excluding patients who underwent neurosurgical 
haemorrhage evacuation. These sensitivity analyses provided no evidence that TXA reduces the 
occurrence of new and progressive haemorrhage in patients who did not undergo neurosurgical 
haemorrhage evacuation (see Table 14). However, the decision for neurosurgery can happen after 
randomisation and so could be affected by the receipt of TXA. If TXA reduces bleeding and the 
need for neurosurgery, then by excluding neurosurgery patients, these analyses may include a larger 












TXA group Placebo group RR (95% CI) 
p value 
(two-tailed) 
New bleeds  (unadjusted)     
≤3 hours since injury 108 / 261 (41%) 129 / 284 (45%) 0.91 (0.75 – 1.10) 0.343 
>3 hours since injury 36 / 138 (26%) 45 / 129 (35%) 0.75 (0.52 – 1.08) 0.121 
All patients 144 / 399 (36%) 174 / 413 (42%) 0.86 (0.72 – 1.02) 0.079 
Exclude unreactive pupils (both) 127 / 367 (35%) 158 / 379 (42%) 0.83 (0.69 – 1.00) 0.048 
Exclude unreactive pupils 
(one/both) 
108 / 332 (33%) 140 / 346 (40%) 0.80 (0.66 – 0.98) 0.033 
Exclude neurosurgery patients 81 / 276 (29%) 101 / 290 (35%) 0.84 (0.66 – 1.07) 0.165 
New bleeds (adjusted for GCS, pupil reaction, systolic blood pressure, site, age, and time from injury to pre-randomisation scan) 
≤3 hours since injury 108 / 261 (41%) 129 / 284 (45%) 0.89 (0.73 – 1.08) 0.224 
>3 hours since injury 36 / 128 (26%) 45 / 129 (35%) 0.69 (0.48 – 0.99) 0.044 
All patients 144 / 399 (36%) 174 / 413 (42%) 0.85 (0.72 – 1.01) 0.069 
Exclude unreactive pupils (both) 127 / 367 (35%) 158 / 379 (42%) 0.83 (0.70 – 1.00) 0.052 
Exclude unreactive pupils 
(one/both) 
108 / 332 (33%) 140 / 346 (40%) 0.80 (0.66 – 0.98) 0.030 
Exclude neurosurgery patients 81 / 276 (29%) 101 / 290 (35%) 0.80 (0.63 – 1.02) 0.069 
Progressive bleeds (unadjusted)      
≤3 hours since injury 76 / 261 (29%) 88 / 284 (31%) 0.94 (0.73 – 1.22) 0.636 
>3 hours since injury 39 / 138 (28%) 42 / 129 (33%) 0.87 (0.60 – 1.25) 0.447 
All patients 115 / 399 (29%) 130 / 413 (31%) 0.92 (0.74 – 1.13) 0.411 
Exclude unreactive pupils (both) 105 / 367 (29%) 123 / 379 (32%) 0.88 (0.71 – 1.10) 0.256 
Exclude unreactive pupils 
(one/both) 
92 / 332 (28%) 111 / 346 (32%) 0.86 (0.69 – 1.09) 0.216 
Exclude neurosurgery patients 91 / 276 (33%) 98 / 290 (34%) 0.98 (0.77 – 1.23) 0.836 
Progressive bleeds (adjusted for GCS, pupil reaction, systolic blood pressure, site, age, and time from injury to pre-randomisation scan) 
≤3 hours since injury 76 / 261 (29%) 88 / 284 (31%) 0.92 (0.72 – 1.19) 0.533 
>3 hours since injury 39 / 138 (28%) 42 / 129 (33%) 0.86 (0.58 – 1.28) 0.457 
All patients 115 / 399 (29%) 130 / 413 (31%) 0.91 (0.74 – 1.13) 0.409 
Exclude unreactive pupils (both) 105 / 367 (29%) 123 / 379 (32%) 0.89 (0.71 – 1.10) 0.283 
Exclude unreactive pupils 
(one/both) 
92 / 332 (28%) 111 / 346 (32%) 0.87 (0.69 – 1.10) 0.242 




4 MISSING PRE-RANDOMISATION OR POST-RANDOMISATION SCANS 
 
This section will explore the occurrence of missing scans, which are scans not done pre-randomisation 
or post-randomisation. If scans were done pre-randomisation and post-randomisation in all patients, 
this would mean that baseline adjustment were possible in all patients and outcomes could be 
examined in all patients (improving statistical power and reducing bias). However, because all data 
in the IBMS are from routinely collected brain imaging, not all patients require or have the 
opportunity to have scans done pre-randomisation and post-randomisation into the CRASH-3 trial. If 
scans were mandated in the study protocol, this would reduce the occurrence of missing scans in less 
severely injured patients who would otherwise not require a clinical scan, but there would still be 
missing scans in those who die before the opportunity for a post-randomisation scan. In this chapter, 
I consider whether the occurrence of missing scans is related to the CRASH-3 trial treatment, and if 
so, the extent to which this may bias the treatment effect estimates.   
 
4.1 Examination of pre-randomisation scan missingness by injury severity 
 
Part of the eligibility criteria for randomisation into the CRASH-3 trial was that patients must have 
a GCS score of ≤ 12 or evidence of intracranial bleeding on a pre-randomisation CT scan. Because 
the eligibility criteria for the IBMS was amended to only include patients with a GCS ≤ 12 (to 
reduce missing scans from mildly injured patients), many patients in the IBMS did not have a pre-
randomisation CT scan done. Specifically, 35% of patients in the IBMS did not have a pre-
randomisation scan done (n=615/1767).  
 
In those with missing pre-randomisation scans, 71% had a severe GCS (n=434/615) and 29% had a 
moderate GCS (n=181/615). There were no missing pre-randomisation scans in those with a mild 
GCS (n=0/92). In addition, in those with missing pre-randomisation scans, 15% had bilateral 
unreactive pupils (n=91/615), 17% had unilateral unreactive pupils (n=105/615), and 67% have 
bilateral reactive pupils (n=409/615). Pupil reaction could not be assessed in 2% of patients with 
missing pre-randomisation scans (n=10/615). Most patients without pre-randomisation scans were 
randomised within 3 hours of injury (n=580; 94%) compared to more than 3 hours of injury (n=35; 
6%).  
 
Table 15 presents the baseline clinical presentations and occurrence of head injury death in patients 





Table 15. Baseline clinical presentation and head injury death in patients with a pre-randomisation scan 
compared to patients without a pre-randomisation scan. 
 






    Glasgow Coma Score (GCS)   
        Mild (13-15) 92 (8%) 0 
        Moderate (GCS 9-12) 348 (30%) 181 (29%) 
        Severe (GCS 3-8)  707 (62%) 434 (71%) 
          GCS 3 397 (35%) 181 (29%) 
    Pupil reaction   
        Both react 877 (76%) 409 (67%) 
        One reacts 95 (8%) 105 (17%) 
        None react 141 (12%) 91 (15%) 
        Unable to assess  33 (3%) 10 (2%) 
    Time from injury to randomisation   
         <=3 hours 768 (67%) 580 (94%) 
         >3 hours 379 (33%) 35 (6%) 
      Head injury death 250 (22%) 156 (25%) 
 
Compared to patients with a pre-randomisation scan, a larger proportion of patients without a pre-
randomisation scan have a GCS score of 3-8 (62% vs 71%), unilateral unreactive pupils (8% vs 
17%) and bilateral unreactive pupils (12% vs 15%). Pupil reaction could not be assessed in a similar 
proportion of patients with or without a pre-randomisation scan (3% vs 2%). A larger proportion of 
patients who did not have a pre-randomisation scan were randomised within 3 hours of injury (67% 
vs 94%). Furthermore, a larger proportion of patients without a pre-randomisation scan 
subsequently died from head injury (22% vs 25%).  
 
Missing data from scans not done before randomisation reduces the precision of treatment effect 
estimates because it is not possible to adjust for between patient variability at baseline, in terms of 
intracranial bleeding and other neuropathologies seen on CT. This reduces statistical power to 
observe a treatment effect if it exists, but it does not introduce bias as these scans are done before 
randomisation and therefore cannot be affected by TXA. The occurrence of missing pre-
randomisation scans is approximately balanced between treatment groups (36% TXA group, 34% 
placebo group) and there is no evidence that TXA increases the risk of not having a pre-
randomisation scan done: RR=1.04, 95% CI (0.91 – 1.18), p=0.583. Table 16 describes the 











TXA group  Placebo group RR (95% CI) 
p value 
(two-tailed) 
No pre-randomisation scan 313 / 881 (36%) 302 / 881 (34%) 1.04 (0.91 – 1.18) 0.583 
    Glasgow Coma Score (GCS)     
        Mild (13-15) 0 / 47 (51%) 0 / 45 (49%) - - 
        Moderate (GCS 9-12) 93 / 261 (36%) 88 / 268 (33%) 1.09 (0.86 – 1.37) 0.499 
        Severe (GCS 3-8)  220 / 573 (38%) 214 / 568 (38%) 1.02 (0.88 – 1.18) 0.803 
    Pupil reaction     
        Both react 209 / 635 (33%) 200 / 651 (31%) 1.07 (0.91 – 1.26) 0.399 
        One reacts 47 / 96 (49%) 58 / 104 (56%) 0.88 (0.67 – 1.15) 0.339 
        None react 50 / 124 (40%) 41 / 108 (38%) 1.06 (0.77 – 1.47) 0.715 
        Unable to assess  7 / 25 (28%) 3 / 18 (17%) 1.68 (0.49 – 5.71) 0.406 
 
In those with severe GCS, 38% did not have a pre-randomisation scan in the TXA group and 38% 
in the placebo group. There is no evidence that TXA increases the risk of not having a pre-
randomisation scan done in those with severe GCS: RR=1.02, 95% CI (0.88 – 1.18), p=0.803. In 
those with bilateral unreactive pupils, 40% did not have a pre-randomisation scan done in the TXA 
group and 38% in the placebo group. There is no evidence that TXA increases the risk of not having 
a pre-randomisation scan done in those with bilateral unreactive pupils: RR=1.06, 95% CI (0.77 – 
1.47), p=0.715. The occurrence of missing pre-randomisation scans appears to be balanced between 
treatment groups. 
 
4.2 Examination of post-randomisation scan missingness by injury severity 
 
A total of 19% of patients were not scanned post-randomisation (n=335/1767). If patients who are 
lost from a study are a random sample of all patients in the study (i.e. missing completely at 
random), missing post-randomisation data from patients who are lost will reduce the precision of an 
analysis but not increase the risk of bias 181. In Table 17, I compared the baseline characteristics and 
outcomes of patients with post-randomisation scans against those without post-randomisation scans 










Table 17. Baseline injury severity and head injury death in patients scanned post-randomisation compared 








    Glasgow Coma Score (GCS)   
        Mild (GCS 13-15) 64 (4%) 28 (8%) 
        Moderate (GCS 9-12) 425 (30%) 106 (32%) 
        Severe (GCS 3-8)  942 (66%) 201 (60%) 
          GCS 3 459 (32%) 120 (36%) 
    Pupil reaction   
        Both react 1,064 (74%) 224 (67%) 
        One reacts 174 (12%) 28 (8%) 
        None react 157 (11%) 75 (22%) 
        Unable to assess 35 (2%) 8 (2%) 
    Time from injury to randomisation   
         <=3 hours 1,126 (79%) 223 (67%) 
         >3 hours 305 (21%) 112 (33%) 
      Head injury death 278 (19%) 128 (38%) 
 
Compared to those with a post-randomisation scan, those without a post-randomisation scan appear 
less severely injured according to their GCS group (see Table 17). But the proportion of patients 
who had a GCS score of 3 was greater in those without a post-randomisation scan (32% vs 36%). 
The proportion of patients with bilateral unreactive pupils at baseline is greater in those without a 
post-randomisation scan (11% vs 22%). Furthermore, a larger proportion of patients without a post-
randomisation scan subsequently died from their head injury compared to those who were scanned 
post-randomisation and then died from head injury (38% vs 19%). Compared to those without a 
post-randomisation scan, a larger proportion of patients with a post-randomisation scan were 
randomised within 3 hours of injury (67% vs 79%). 
 
Injury severity may partly explain why some post-randomisation scans were not done, in that those 
not scanned post-randomisation seem to be more severely injured at baseline compared to those 
scanned post-randomisation. The CRASH-3 trial found that the effect of TXA on head injury death 
depended partly on baseline injury severity (as indicated by GCS score and pupil reaction). It is 
possible that the post-randomisation scan information, which was not available in more severely 
injured patients who often died, and not collected in mildly injured patients, may impact treatment 
effect estimates in the IBMS, and therefore affect the extent to which the IBMS can help explain the 
results of the CRASH-3 trial. 
 
If TXA reduces intracranial haemorrhage expansion and the risk of death, patients who receive 
TXA may be more likely to be scanned post-randomisation compared to those who receive placebo. 




randomisation scanning may not be clinically indicated in these patients. A total of 19% of patients 
in the TXA group were not scanned post-randomisation (n=169/884) and 19% in the placebo group 
(n=166/882). There is no evidence that TXA increases the risk of having a missing post-
randomisation scan: RR=1.02, 95% CI (0.84 – 1.23), p=0.874. Table 18 describes the occurrence of 
missing post-randomisation scans by baseline injury severity and split by treatment group.  
 




TXA group  Placebo group RR (95% CI) 
p value 
(two-tailed) 
No post-randomisation scan 169 / 884 (19%) 166 / 882 (19%) 1.02 (0.84 – 1.23) 0.874 
    Glasgow Coma Score (GCS)     
        Mild (GCS 13-15) 15 / 47 (32%) 13 / 45 (29%) 1.10 (0.59 – 2.06) 0.754 
        Moderate (GCS 9-12) 53 / 264 (20%) 53 / 267 (20%) 1.01 (0.72 – 1.42) 0.948 
        Severe (GCS 3-8)  101 / 573 (18%) 100 / 570 (18%) 1.00 (0.78 – 1.29) 0.971 
    Pupil reaction     
        Both react 108 / 637 (17%) 116 / 651 (18%) 0.95 (0.75 – 1.21) 0.683 
        One reacts 14 / 97 (14%) 14 / 105 (13%) 1.08 (0.54 – 2.16) 0.822 
        None react 42 / 124 (34%) 33 / 108 (31%) 1.11 (0.76 – 1.62) 0.592 
        Unable to assess 5 / 25 (20%) 3 / 18 (17%) 1.20 (0.32 – 4.46) 0.785 
 
There is no evidence that TXA increases the risk of having a missing post-randomisation scan in 
those with mild GCS (32% vs 29%), moderate GCS (20% vs 20%), severe GCS (18% vs 18%), 
bilateral reactive pupils (17% vs 18%), unilateral reactive pupils (14% vs 13%) or bilateral 
unreactive pupils (34% vs 31%) – see Table 18. There does not appear to be imbalance in the 

















4.3 Impact of missingness on treatment effect estimates 
 
To explore the impact, if any, of missing outcomes on treatment effect estimates, best-worst and 
worst-best sensitivity analyses were done to further explore the effect of TXA on new haemorrhage, 
progressive haemorrhage, and cerebral infarction. For dichotomous outcomes, the best-worst 
scenario assumes that all patients who were not scanned post-randomisation in the TXA group did 
not have the bad outcome of interest and all patients not scanned post-randomisation in the placebo 
group had this outcome. The worst-best scenario assumes that all patients not scanned post-
randomisation in the TXA group had the bad outcome and all patients not scanned post-




In the best-worst scenario, it was assumed that all patients without a post-randomisation scan in the 
TXA group did not have infarction, whereas all patients without a post-randomisation scan in the 
placebo group did have infarction. In this hypothetical scenario, 10% of patients in the TXA group 
(n=89/884) and 27% of patients in the placebo group (n=236/883) had infarction. If this scenario 
were true, there would be evidence that TXA reduces the risk of infarction: RR=0.38, 95% CI (0.30 
– 0.47), p<0.0001.  
 
In the worst-best scenario, it was assumed that all patients without a post-randomisation scan in the 
TXA group did have infarction, whereas all patients without a post-randomisation scan in the 
placebo group did not have infarction. In this hypothetical scenario, 29% of patients in the TXA 
group (n=258/884) and 8% in the placebo group (n=70/883) had infarction. If this scenario were 
true, there would be evidence that TXA increases the risk of infarction: RR=3.68, 95% CI (2.88 – 




In the best-worst scenario, it is assumed that all patients without a post-randomisation scan in the 
TXA group did not have new bleeding, whereas all patients without a post-randomisation scan in 
the placebo group did have new bleeding. In this hypothetical scenario, 17% of patients in the TXA 
group (n=154/884) and 39% of patients in the placebo group (n=341/883) had new bleeding. If this 
scenario were true, there would be evidence that TXA reduces the risk of new bleeding: RR=0.45, 





In the worst-best scenario, it is assumed that all patients without a post-randomisation scan in the 
TXA group did have new bleeding, whereas all patients without a post-randomisation scan in the 
placebo group did not have new bleeding. In this hypothetical scenario, 37% of patients in the TXA 
group (n=323/884) and 20% in the placebo group (n=175/883) had new bleeding: RR=1.84, 95% CI 




In the best-worst scenario, it is assumed that all patients without a post-randomisation scan in the 
TXA group did not have progressive bleeding, whereas all patients without a post-randomisation 
scan in the placebo group did have progressive bleeding. In this hypothetical scenario, 20% of 
patients in the TXA group (n=115/568) and 51% of patients in the placebo group (n=296/579) had 
progressive bleeding. If this scenario were true, there would be evidence that TXA reduces the risk 
of progressive bleeding: RR=0.40, 95% CI (0.33 – 0.47), p<0.0001.  
 
In the worst-best scenario, it is assumed that all patients without a post-randomisation scan in the 
TXA group did have progressive bleeding, whereas all patients without a post-randomisation scan 
in the placebo group did not have progressive bleeding. In this hypothetical scenario, 50% of 
patients in the TXA group (n=284/568) and 22% in the placebo group (n=130/579) had progressive 
bleeding. If this scenario were true, there would be evidence that TXA increases the risk of 
progressive bleeding: RR=2.22, 95% CI (1.87 – 2.65), p<0.0001.  
 
If best-worst and worst-best scenarios did not give contradicting results for progressive bleeding, 
new bleeding, and cerebral infarction outcomes, the impact of missing scans on the effect of TXA 
on each of these outcomes may have been negligible 183. But because these scenarios give 
qualitatively different results in that the widest possible range of uncertainty spans benefit and 
harm, it is difficult to conclude what effect TXA has on any of these outcomes. This method may be 
useful in a study with a small amount of missing data where best-worst and worst-best scenarios 
would provide a narrower and more meaningful range of uncertainty. But a large proportion of 
patients were not scanned post-randomisation in the CRASH-3 IBMS, and so best-worst and worst-
best scenarios may merely indicate the best case scenario (benefit with trial treatment) and worst 
case scenario (harm with trial treatment) by definition of how the missing values are imputed. For 
these outcomes, the results of the complete case analyses may be more useful, in the context of a 




5 CRITIQUE AND RECOMMENDATIONS 
 
In this final chapter, I consider why the CRASH-3 IBMS was done and why the chosen methods may 
not provide valid and precise estimates of the effects of TXA. I reflect on the limits of this trial in the 
context of previous trials. I finish by considering the implications for research and practice.  
 
5.1 Mechanism of action of TXA in traumatic brain injury 
 
The CRASH-3 trial and IBMS were motivated by the premise that intracranial haemorrhage 
contributes to head injury death in patients with TBI. By inhibiting fibrinolysis, TXA may slow the 
rate of intracranial haemorrhage. The CRASH-3 trial hypothesised that TXA may prevent or reduce 
intracranial haemorrhage, which could in turn reduce the risk of death and disability 109, 193. The 
CRASH-3 trial was done in 12,737 TBI patients 121. When patients with a GCS score of 3 or 
bilateral unreactive pupils at baseline are excluded, there is evidence that TXA reduces the risk of 
head injury death (RR 0·89 [95% CI 0·80–1·00]). TXA reduces the risk of head injury death by 
22% in patients with mild to moderate GCS (RR=0·78, 95% CI 0·64-0·95). Early treatment is more 
effective than late treatment in this group (p=0.005). But there is no apparent reduction in head 
injury death in patients with severe GCS (RR=0·99, 95% CI 0·91-1·07), regardless of the time from 
injury to randomisation (p=0.73). Because the aim of the CRASH-3 trial was to assess the effect of 
TXA on head injury death, to simplify the trial procedures, the investigators did not collect CT scan 
data on the amount of intracranial haemorrhage in all patients. The occurrence of thromboembolic 
events, including stroke, were appropriately assessed using clinical outcomes. In the CRASH-3 
IBMS, I examined routinely collected brain imaging (mainly CT scans) from 14% of CRASH-3 
trial patients to see if TXA reduces intracranial bleeding and/or increases cerebral infarction 123.  
 
5.2 Criteria for valid and precise treatment effect estimates 
 
To provide valid and precise estimates of the effect of TXA on intracranial bleeding and infarction, 
the CRASH-3 IBMS must satisfy key criteria. We should randomly allocate a very large number of 
patients (with good allocation concealment) to receive TXA or placebo, and then obtain precise 
measures of the extent of intracranial bleeding and infarction in all randomised patients, with no 
loss to follow-up.   
The treatment allocation sequence should be randomly generated and concealed to prevent bias 194. 
Random allocation should ensure that the two groups are similar at baseline 115. This can be 
examined using a table of baseline characteristics of all randomised patients split by treatment 




similar apart from the treatment allocation. Problems in the randomisation process may be indicated 
by differences in the expected size of treatment groups, imbalance in key prognostic factors, or 
excessive similarity in baseline characteristics between treatment groups 195. Adjusting for factors 
that are imbalanced between treatment groups does not mitigate failures of randomisation. 
However, if the randomisation process is not at risk of bias, and baseline differences between 
treatment groups arise by chance (e.g. if the sample is small) , adjusting for baseline values of the 
relevant factors can improve the precision of the effect estimates. Furthermore, at baseline some 
patients may have very large bleeds whilst others have small bleeds in each treatment group. 
Adjusting for between patient variability in the analysis may lead to an increase in statistical power 
to detect a treatment effect if it exists 175.  
If there are missing outcomes, this must be minimal so that they could not make an important 
difference to the estimated effect of TXA 195. A large proportion of missing outcomes would reduce 
power, and could bias the treatment effect estimates, especially if the trial treatment affected 
whether the outcomes were observed 181. Examples of large randomised trials at low risk of bias are 
CRASH, CRASH-2, CRASH-3 and WOMAN trials 35, 91, 121, 196. These trials have minimal loss to 
follow-up and so provide valid estimates of the effect of TXA on outcomes like death that can be 
accurately measured.  
 
5.3 Why might the CRASH-3 IBMS not provide valid and precise treatment effect 
estimates? 
 
Small sample size 
The sample size calculation is based on a specific difference in intracranial haemorrhage volume 
between treatment groups. If receiving TXA results in a smaller reduction in haemorrhage volume 
than assumed, this trial may be too small to detect it. Furthermore, the sample size calculation does 
not account for the impact of non-differential misclassification and baseline unsurvivability, which 
bias any treatment effect estimate towards the null. Therefore, even though this trial is larger than 
previous trials in this area, the sample size may still be too small to detect a clinically meaningful 
difference in haemorrhage volume between treatment groups.  
It is logistically difficult to conduct a large randomised trial using imaging outcomes because CT 
scanning, neuro-radiological expertise and data collection are expensive. Estimates vary but the 
average cost of a non-contrast CT head scan is around £100 in the NHS 197 and £550 privately in the 
UK 198. Therefore, it would cost between £200,000 and £1.1 million to scan 1,000 patients before 
and after randomisation. It would take around 4-6 months of full-time work for an experienced 




the average yearly salary of an experienced neuro-radiologist, this would cost around £50,000 in the 
NHS  or £100,000 privately in the UK 199. If estimated costs are based on each individual scan 
report, the cost is likely to be substantially higher. This is partly why routinely collected CT scans 
were used in the CRASH-3 IBMS. But the examination of routinely collected data is also time 
consuming and intensive. I examined routinely collected data from 1,767 trial patients over a period 
of 3 years. I visited 14 different hospitals using a research passport and rated scans on hospital 
software in various offices I did not have priority to be in. I spent extended and often isolating 
placements in different locations in the UK and Malaysia.  
Null bias 
One third of patients included in the IBMS had a GCS score of 3 at baseline. The median baseline 
GCS score of all patients is 7 (IQR 3 to 10). A total of 24% of patients had unilateral or bilateral 
unreactive pupils at baseline. Therefore, a large proportion of patients included in the IBMS had 
severe (and possibly unsurvivable) head injuries before they were randomised into the CRASH-3 
trial. The baseline CT data suggest that patients with severe GCS and/or unreactive pupils have 
more extensive intracranial bleeding (and other intracranial pathologies) compared to those with 
moderate to mild GCS and/or reactive pupils. TXA may have had less potential to prevent 
intracranial haemorrhage progression in severely injured patients, and their inclusion may have 
diluted any treatment effect towards the null.  
Because sites could randomise patients before a CT scan was done if the patient had a GCS score of 
12 or less, many patients had their admission scan done very soon after randomisation. If patients 
had another scan done closer to 24 hours after randomisation, the later scan would be chosen as the 
post-randomisation scan. However, if the early scan was the only scan the patient had done after 
randomisation, it would be rated as the post-randomisation scan. A total of 17% of patients who had 
a post-randomisation scan had their scan done within 1 hour of randomisation (n=248). A total of 
98% of these patients did not have a pre-randomisation scan. Figure 19 shows the distribution of the 
time from randomisation to the post-randomisation scan in patients who had their scan done within 





Figure 19. Time from randomisation to scan in patients scanned within 48 hours of randomisation. 
 
Any effect of TXA may not have had sufficient opportunity to manifest on a CT scan done within 
minutes to a few hours after randomisation. Furthermore, patients who had their post-randomisation 
scan done this soon after randomisation were more severely injured than those who survived to the 
point of a later post-randomisation scan. A larger proportion of patients who had their post-
randomisation scan done within an hour of randomisation (compared to >1h post-randomisation) 
had a GCS score of 3 (40% vs 30%), unilateral or bilateral unreactive pupils (33% vs 21%) and 
subsequently died from head injury (30% vs 17%). The inclusion of these patients may have diluted 
any treatment effect towards the null.  
 
TXA might make bleeds more visible on CT 
CT imaging may not be a valid method to examine whether TXA reduces intracranial haemorrhage. 
The appearance of intracranial haemorrhage on CT is determined by blood clot density changes 
over time 31, 200. These physical density changes reflect clot formation, clot retraction, clot lysis and 
tissue loss 200. In the hyper-acute stage of injury, blood leaves the vascular system (extravastation). 
Post-traumatic hyper-acute intracranial bleeding has not yet clotted and so it has the same density as 
blood flowing through cerebral vessels on non-contrast enhanced CT 31. Therefore, hyper-acute 
bleeding does not have a distinct appearance on CT 31. Some hyper-acute bleeds have a mixed 
density appearance, as the complex mass of red blood cells, white blood cells and platelets is 
forming 200. Patients with mixed density bleeds may be actively bleeding whilst being scanned 201, 
202. In the first few hours of injury, when the hospital admission CT scan is often done, the fibrin 




blood is more dense than brain tissue and so has a marked white appearance on CT (i.e. the bleed 
appears hyper-dense) 31, 200. Intracranial blood clots can break down gradually over days to weeks, 
and in this sub-acute to chronic phase may appear as a similar density to the adjacent brain tissue 
(i.e. the bleed appears iso-dense) 31. Hyper-acute and sub-acute bleeding can therefore be difficult to 
identify and measure on CT. Figure 20 illustrates the density of intracranial bleeding according to 
the age of the bleed 31.  
 
 
Figure 20. Density of intracranial bleeding (as indicated by Hounsfield Units, HU) by age of intracranial 
bleeding, on CT imaging. A higher HU value indicates more clotting. x 
 
TXA inhibits the enzymatic breakdown of fibrin blood clots 78. By inhibiting fibrinolysis and 
stabilizing the blood clot, TXA may make the appearance of intracranial haemorrhage on CT more 
apparent. If unclotted blood does not appear on CT in the hyper-acute phase of injury but bleeding 
clotted with TXA appears, the potential benefit of TXA in reducing early haemorrhage expansion 
may be indicated by the early appearance of intracranial haemorrhage on CT. But all studies in this 
area (including the CRASH-3 IBMS) hypothesised that a reduction in the appearance of intracranial 
haemorrhage with TXA would be considered evidence that TXA reduced intracranial haemorrhage 
106, 107, 123, 203, 204. In retrospect, imaging methods that use clot density to make bleeds visible may not 
be appropriate for the examination of the effects of TXA. This could help explain why no trial using 
CT data has clearly indicated that TXA reduces intracranial haemorrhage expansion.  
                                                     
x Grey matter refers to neural cell bodies and unmyelinated axons, and white matter mainly refers to myelinated 
axons (that transmit signals to grey matter). Figure reproduced from Gaillard F et al. Intracranial haemorrhage. 




If TXA reduces the need for neurosurgery, bleeding may appear to increase in TXA treated 
patients 
A total of 21% of patients had neurosurgical haemorrhage evacuation before their post-
randomisation scan. In these patients, it is not possible to separate the effect of TXA on intracranial 
haemorrhage from the effect of neurosurgery on intracranial haemorrhage. The haemorrhage seen 
on a post-randomisation and post-neurosurgery scan may reflect the combined effect of TXA and 
neurosurgical haemorrhage evacuation 205.  
The decision for neurosurgery made after randomisation could be affected by the receipt of TXA. If 
TXA reduces intracranial haemorrhage, it may reduce the need for that haemorrhage to be 
surgically evacuated. Patients who receive placebo and go on to have their bleed evacuated may 
have less blood on their post-randomisation scan than those who receive TXA and then do not 
undergo neurosurgical haemorrhage evacuation. Therefore, TXA treated patients could present with 
more intracranial haemorrhage post-randomisation compared to placebo treated patients. But TXA 
is expected to reduce intracranial haemorrhage, and so such a finding would be difficult to interpret.  
Outcomes were not accurately measured  
The manual ABC/2 method of measuring haemorrhage volume was not validated in all types of 
intracranial haemorrhage that it was used for in the CRASH-3 IBMS (i.e. IVH) y. The accuracy of 
this method is reduced if bleeds are irregularly shaped or large 146. The measurement of SDH was 
based on a novel approach developed by colleagues at the Queen Elizabeth Hospital in 
Birmingham. The rationale for this is that the ABC/2 method assumes bleeds are almost spherical 
but SDH is typically crescent shaped. Whilst this may be true, the reliability of their method for 
estimating SDH volume is to be confirmed. Finally, unclotted bleeding, micro-bleeding and 
infarction are not visible on CT done soon after injury 165, 200, 206-209. Obviously, bleeds or infarcts 
that are not visible cannot be measured.  
A progressive haemorrhage outcome may have limited clinical value 
The clinical value of a progressive haemorrhage outcome is limited. This is often defined as any 
increase, or a 25% or 33% increase from pre- to post-randomisation. An apparent increase in 
haemorrhage between two scans may not be generalizable because this increase may have different 
clinical implications depending on the type of haemorrhage that expands. Even though SDH/EDH 
are typically larger than IPH/IVH, a 25% increase in SDH/EDH could be managed surgically in the 
                                                     
y I believed that the ABC/2 method had been validated for the measurement of IVH, but I learnt whilst 
conducting the trial that I made an error when interpreting the results of one paper 146. This paper reported the 
accuracy of ABC/2 compared to automated methods in IPH across several trials, one of which is called 
CLEAR-IVH. This trial included patients with both IPH and IVH, and ABC/2 was used for IPH but not IVH. 
Because I had already started using ABC/2 for the measurement of IVH when I learned this, I continued to 




first few hours of injury with good prognostic outcome 61, 62. In contrast, a 25% increase in IPH or 
IVH may have worse prognostic outcome 71, 72.   
Large proportion of missing outcomes 
Outcome data could not be collected in all randomised patients, largely because not all patients 
required a post-randomisation scan or had the opportunity to have one because they had died. A 
total of 19% of randomised patients were not scanned post-randomisation. These missing outcomes 
could relate to whether a patient received TXA. We now know that TXA reduces the risk of head 
injury death , so TXA treated patients might not have needed a clinically indicated post-
randomisation scan. Or they might have had one because they were alive and so available to be 
scanned. Absence of bias is not confirmed by the similar proportion of patients with missing post-
randomisation scans in TXA and placebo groups 195.  
5.4 How have previous trials approached and reported these problems?  
 
Please see Table 19 for the inclusion and exclusion criteria, and decisions to exclude patients after 
randomisation, in double-blind randomised trials in this area. Please see Table 20 for an assessment 
of their risk of bias across five domains: randomisation process, deviation from intended 






Table 19. Inclusion/exclusion criteria & post-randomisation exclusions in randomised trials on effect of TXA on intracranial haemorrhage in 
TBI.  
Perel et al,  
2011 
Effect of TXA in traumatic brain injury: a nested randomised, placebo controlled trial  
(CRASH-2 Intracranial Bleeding Study) 
Inclusion criteria  Adult trauma patients with significant haemorrhage (systolic blood pressure <90 mm Hg or heart rate >110 beats per min, or 
both) or who were considered to be at risk of significant haemorrhage, and who were within 8 hours of injury - but they also 
had TBI (GCS ≤14 and a brain CT compatible with TBI) 
Exclusion criteria  - 
Post-randomisation 
exclusions 
Pregnant women and patients for whom a second brain scan was not possible were excluded. 
Yutthakasemsunt et al,  
2013 
TXA for patients with traumatic brain injury: a randomized, double-blinded, placebo-controlled trial 
Inclusion criteria All patients, older than 16 years, with moderate to severe TBI (post-resuscitation Glasgow Coma Scale (GCS) 4 to 12) who 
had a computerized tomography (CT) brain scan performed within eight hours of injury, and whom there was no immediate 
indication for surgery, were eligible for inclusion. 
Exclusion criteria  
 
Patients were excluded if they were pregnant, had evidences of coagulopathy, known to be receiving a medication which 
affects haemostasis, or had a serum creatinine over than 2 mg/decilitre. Coagulopathy was considered present if any of the 
following hematological parameters were observed: (1) platelet count less than 100,000 cells/mm3; (2) Prothrombin time (PT) 
or international normalized ratio (INR) prolonged more than 1.5 times normal value; (3) activated partial thromboplastin time 




Fakharian et al,  
2019 
Effect of TXA on Prevention of Hemorrhagic Mass Growth in Patients with Traumatic Brain Injury 
Inclusion criteria Patients with isolated TBI or multiple trauma patients, with TBI as the main problem, who arrived at the hospital within 8 
hours of trauma, aged 15 and older, with nonpenetrating injury and any kind of traumatic intracranial bleedings (subdural 
haemorrhage [SDH], subarachnoid hemorrhage, contusion, intraventricular hemorrhage, and epidural hematoma) in admission 
CT scans, no need for brain surgery during the first 8 hours, no coagulation disorder, serum creatinine <2 mg, and 
nonpregnancy were enrolled to the study.  
Exclusion criteria - 
Post-randomisation 
exclusions 
Major organ damage requiring surgical intervention within the first 8 hours, receiving any medication that disturbs 
homeostasis, those who do not have a secondary CT scan, and those who missed follow-up were excluded 
May et al,  
2019 
Prehospital TXA Use for Traumatic Brain Injury 
Inclusion criteria Subjects for whom study drug administration was started and for whom two or more analyzable head CT scans were obtained 
prior to a hematoma evacuation.  
Exclusion criteria -  
Post-randomisation 
exclusions 
Excluded subjects primarily include those who died or withdrew before an initial or second CT scan was taken, who had a 




Mahmood et al,  
2019 
A nested randomised trial of the effect of TXA on intracranial haemorrhage and infarction in TBI (CRASH-3 trial 
intracranial bleeding mechanistic study). 
Inclusion criteria  Patients eligible for the CRASH-3 trial, with a GCS of 12 or less or intracranial bleeding on a pre-randomisation CT scan. 
Exclusion criteria  - 
Post-randomisation 
exclusions 
New and progressive haemorrhage outcomes exclude patients without both pre-randomisation and post-randomisation scans. 
 
Table 20. Epidemiological risk of bias assessment in randomised trials: effect of TXA on intracranial haemorrhage in TBI. 
Risk of bias domain 
Risk of bias assessment (low risk, some concerns, high risk) in each trial 
Perel et al (2011) 
n=270: 
TXA 133, Placebo 
137 
Yuttha… et al (2013) 
n=240: 
TXA 120, Placebo 
120 
Fakha… et al 
(2019) 
n=156: 
TXA 78, Placebo 
78 
May et al (2019) 
n=1,063: 
TXA 718, Placebo 
345 
Mahm… et al 
(2019) 
n=1,767: 




Low Low High No information Low 
Deviation from 
intended intervention aa 
Low Low Some No information Low 
Missing outcome data 
bb 
Some (8%) Some (4%) Low (1%) High (55%) High (19%) 
Measurement of 
outcome cc 
High High High High High 
Selection of the 
reported result dd 
Low Some Low Low Low 
Overall judgement High High High High High 
 
  
                                                     
z Random sequence generation, adequate allocation concealment, treatment groups similar at baseline, exclusions reported  
aa Double-blind, deviations unlikely to affect outcome, appropriate analysis 
bb Outcome data for all (or nearly all) randomised patients, no evidence that the result could be biased by missing outcome data 
cc Method of measuring outcome sensitive to plausible intervention effects, measurement instrument has demonstrated validity, measurement of outcome 
does not differ between treatment groups 
dd There are not multiple outcome measurements and multiple analyses of the data, all reported results correspond to pre-specified plan 
135 
 
Although I previously judged the two trials done before the CRASH-3 IBMS started to be at 
low risk of bias 210, I now judge all trials in this area to be at least some risk of bias. This is 
because the effect of TXA may not manifest on CT in the way people expect (discussed above), 
all trials excluded randomised patients who did not have a post-randomisation scan, and some 
trials excluded randomised patients who had neurosurgery post-randomisation. The potential 
implications of these issues are discussed below.  
The CRASH-2 Intracranial Bleeding Study (IBS) reported that 8% of randomised patients had 
missing post-randomisation scans and these patients were excluded from the analysis 106. The 
trial reports that 24% of the missing scans (n=5/21) were due to death. The trial done in 
Thailand reports that 4% of patients had missing scans, most of whom died (n=7/9). The smaller 
trial done in Iran also excluded patients with missing post-randomisation scans, but reports a 
small proportion of missing scans (1%) and does not confirm if these patients died 203. This trial 
appears to be at risk of bias across several domains. For example, there is insufficient 
information to assess how the allocation sequence was generated and concealed, and it is not 
clear whether the study contributor who was responsible for assigning codes for TXA and 
placebo syringes was a trial investigator or independent of the trial. Furthermore, the trial done 
in Washington reports that patients who died before the opportunity for scanning were not 
included in the outcome on progressive haemorrhage 204. In all these trials, the availability of 
post-randomisation scans could depend on whether a patient was treated with TXA. Because 
exclusions were made on the basis of information known post-randomisation, the treatment 
effect estimates in these studies are at risk of bias.  
Some trials tried to deal with the occurrence of neurosurgical haemorrhage evacuation after 
randomisation by excluding these patients from the study 203, 204. In the CRASH-3 IBMS, I 
learnt that some patients do not show evidence of neurosurgery until a second post-
randomisation scan, or later. Therefore, the decision for neurosurgery can happen after 
randomisation and so could be affected by the receipt of TXA. If TXA reduces intracranial 
haemorrhage, it could reduce the need for neurosurgery. Or TXA treated patients might survive 
to the point of a post-neurosurgery scan because TXA reduced the risk of head injury death 121. 
In these trials, randomised patients were excluded on the basis of a post-randomisation event, 
and this could bias the treatment effect estimates.  
The CRASH-2 IBS and trials from Thailand and Iran reported a small proportion of missing 
post-randomisation scans (8%, 4%, 1%) compared to the Washington trial and CRASH-3 IBMS 
(55%, 19%). The CRASH-2 IBS, Thai and Iranian trials mandated that scans should be done 
after randomisation. This is a limitation of the CRASH-3 IBMS and Washington trial. In the 
CRASH-3 IBMS, we did not have post-randomisation data from patients with milder injuries 
who the CRASH-3 trial results suggest probably benefited from TXA. It is expensive to 




very small trials. Ideally, we would have a very accurate outcome measure in all patients 
randomised into a large trial. But we must often decide between a small study with a very 
accurate method or a larger study with a less accurate method. In the CRASH-3 IBMS we chose 
the latter because we prioritized a reduction in random error over measurement error. But this 
came at the expense of the methodological problems associated with routine imaging. 
Mandating post-randomisation scans can avoid some of the bias that comes with using routine 
imaging. But it is almost impossible to avoid the substantial risk of bias that results from 
missing outcome scans as a result of death and neurosurgery.   
 
5.5 How can we learn from the CRASH-3 IBMS? 
 
Based on my experience of conducting the CRASH-3 IBMS, I would not recommend that trials 
in this area use radiological outcomes, especially not those measured on routine imaging. This is 
because the effect of TXA may not manifest on brain imaging in the way people expect, and the 
availability of post-randomisation imaging probably depends on the trial treatment. The 
National Institutes of Health recently proposed guidelines on how “the link between prevention 
of haemorrhage growth [with haemostatic therapy] and clinical outcome” can be studied using 
radiological outcomes 211. I am sceptical about the use of using such outcomes for this purpose. 
Efforts should be focused on large randomised trials that do not measure intracranial 
haemorrhage but a clinically relevant proxy that can be accurately measured in all randomised 
patients (e.g. TBI death within 24 hours of injury).  
 
If despite these recommendations, such radiological outcomes are used, there should be marked 
effort to reduce bias and random error for valid inference. A large high-quality randomised trial 
must be done where all randomised patients are scanned after randomisation. Inclusion should 
not be based on information known post-randomisation or restricted in terms of injury severity. 
A trial in a smaller proportion of severely injured patients overall would reduce the need for 
neurosurgery before the post-randomisation scan is done. It would also reduce missing post-
randomisation scans as a result of death, thereby reducing bias from unobserved outcomes. The 
problem of missing post-randomisation scans in patients who do not require a clinical scan 
should be addressed by mandating that a post-randomisation scan is done at a set time point 
post-randomisation. Patients who will not be scanned after randomisation because they die 
could be scanned soon after death. Imaging has historically been used as part of the post-
mortem procedure to determine who needs an autopsy 212. The neuropathology of deceased 
patients could provide an insight into whether a reduction in death due to head injury with TXA 
is due to a reduction in intracranial haemorrhage. If patients have neurosurgery, the time this 
decision is made must be recorded so investigators can explore the extent to which this biases 




micro-bleeding 208 and infarction 165, 209. Investigators should clearly report the number of 
randomised patients, the proportion of randomised patients with post-randomisation scans, and 
the proportion of randomised patients who have missing post-randomisation scans by treatment 
group. There should be a clear effort to explore and report why there are missing scans. There 
should be a thorough consideration of the implications of missing outcomes on the validity of 
treatment effect estimates, before any conclusions are drawn and recommendations are made.  
 
5.6 Additional contribution to knowledge 
 
The baseline CT data improves understanding of the neuropathological presentation of TBI 
patients. The existing knowledge on intracranial haemorrhage, and other features of TBI, is 
based on smaller studies with different and restrictive inclusion criteria. The larger sample and 
less restrictive inclusion criteria of the CRASH-3 IBMS allowed this study to explore the 
natural occurrence of intracranial pathologies at baseline. These data suggest that compared to 
patients with mild to moderate GCS and/or reactive pupils, patients with severe GCS and/or 
unreactive pupils often present with extensive intracranial bleeding and a number of other 
intracranial pathologies. Patients with a mild to moderate GCS may be more likely to benefit 
from TXA because they have less intracranial bleeding at baseline. However, because 
intracranial bleeding occurs soon after injury, treatment delay reduces the benefit. On the other 
hand, patients with a severe GCS have less to gain from treatment because they already have 
extensive intracranial bleeding at baseline and/or other intracranial pathologies that TXA cannot 
plausibly affect. This supports the decision to exclude very severely injured patients from the 
CRASH-3 trial primary analysis, and exploration of the treatment effect by baseline injury 
severity. This could help explain why the CRASH-3 trial found that TXA appears to be more 
effective in patients who were less severely injured at baseline, and ineffective (or less 
effective) in patients with more severe injuries. In some patients, the immediate neurologic 
damage from the trauma may have been too severe to be alterable. TXA may have had little 
potential to reduce intracranial haemorrhage progression and the risk of head injury death in 
these patients. 
This has implications for practice. The CRASH-3 trial treatment was given after arrival in 
hospital. Less than 20% of patients were treated within an hour of injury 121. If severely injured 
patients had already bled extensively by the point of hospital admission, and this is why there is 
no apparent reduction in head injury death in patients with severe GCS, a proportion of severely 
injured patients might have benefited if treated pre-hospital. In many high-income countries, 
TXA is routinely administered by paramedics at the scene of the injury to treat acute severe 
bleeding 213. In low-income and middle-income settings, this is not always possible due to 
resource constraints and a lack of health workers who can administer intravenous drugs in the 




injection would be easier, require less training, and may reduce time to treatment 215. However, 
patients with severe injuries in settings with insufficient in-hospital resources may die despite an 
early reduction in intracranial bleeding. Evidence suggests that patients with severe TBI in low- 
and middle-income settings may be more likely to die compared to those in high-income 
settings 216. More rapid administration of TXA in settings with adequate medical care for 
patients with major trauma could increase the proportion of TBI patients who have the potential 
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Abstract 
Purpose: The CRASH-3 trial is a randomised trial of TXA (TXA) on death and disability in 
patients with traumatic brain injury (TBI). It is based on the hypothesis that early TXA treatment 
can prevent deaths from post-traumatic intracranial bleeding. The results showed that timely TXA 
treatment reduces head injury deaths in patients with reactive pupils and those with a mild to 
moderate GCS at baseline. We examined routinely collected CT scans in a sample of 1767 
CRASH-3 trial patients to explore if, why, and how patients are affected by TXA. 
Methods: The CRASH-3 IBMS is an explanatory study nested within the CRASH-3 trial. We 
measured the volume of intracranial bleeding on CT scans using established methods (e.g. 
ABC/2).  
Results: Patients with any un-reactive pupil had a median intracranial bleeding volume of 60ml 
(IQR 18ml to 101ml) and patients with reactive pupils had a median volume of 26ml (IQR 1ml 
to 55ml). Patients with severe GCS had median intracranial bleeding volume of 37ml (IQR 3ml 
to 75ml) and patients with moderate to mild GCS had a median volume of 26ml (IQR 0·4ml to 
50ml). For every hour increase from injury to the baseline scan, the risk of new bleeding on a 
further scan decreased by 12% (adjusted RR=0·88 [95% CI 0·80–0·96], p=0·0047). 
Conclusion: Patients with reactive pupils and/or mild to moderate GCS may have benefited from 
TXA in the CRASH-3 trial because they had less intracranial bleeding at baseline. However, 
because bleeding occurs soon after injury, treatment delay reduces the benefit of TXA.  
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The CRASH-3 trial is a multi-centre, randomised, placebo-controlled trial of the effects of TXA 
on death and disability in patients with traumatic brain injury (TBI) [1]. Adults with TBI who 
were within 3 hours of their injury and had a Glasgow coma scale score (GCS) ≤12 or any 
intracranial bleeding on CT scan were included in the primary analysis. We hypothesised that 
early administration of TXA might prevent deaths from post-traumatic intracranial bleeding. We 
found that rapid TXA treatment reduces head injury deaths in patients with mild to moderate head 
injury (RR=0·78 95% CI 0·64-0·95) but there was no apparent reduction in severe head injury 
(RR=0·99, 95% CI 0·91-1·07), regardless of time to treatment. Because our main aim was to 
assess the effect of TXA on head injury death, to simplify the trial procedures, we did not plan to 
collect data on the amount of intracranial bleeding in all patients. However, while the trial was 
underway, the data monitoring committee asked us to consider collecting these data on a sample 
of trial patients “to explore if, why, and how patients are affected by TXA.” In response, routinely 
collected brain imaging data (mainly CT scans) were assessed in 1,767 CRASH-3 trial patients. 
Because early TXA treatment is expected to be more effective than late treatment [2], to reduce 
time to randomisation, many patients were randomised into the CRASH-3 trial without a baseline 
CT scan.  A total of 1,147 patients in the IBMS had a baseline (prior to randomisation) CT scan, 
of whom 812 patients had another clinically indicated brain scan. We measured the volume of 
intracranial bleeding on scans using established methods (e.g. ABC/2) [3] and collected data on 
other CT features of TBI. Here we consider the CRASH-3 trial results in light of the CT scan 
data.   
 
Methods 
The protocols for the CRASH-3 trial and Intracranial Bleeding Mechanistic Study (IBMS) are 
published separately [4-5]. The CRASH-3 IBMS is an explanatory study nested within the 
CRASH-3 trial. Patients who fulfilled the eligibility criteria for the CRASH-3 trial, with a GCS 
of 12 or less or intracranial bleeding on a CT scan done before randomisation, were eligible for 
inclusion in the IBMS. Routinely collected CT scans were examined between February 2016 and 
January 2019 across 14 hospitals in the UK and Malaysia. Most patients in the IBMS were 
randomised into the CRASH-3 trial within 3 hours of injury (76%, n=1350); the rest were 
randomised between 3 and 8 hours of injury. Patients had a median age of 45 years, median 
systolic blood pressure of 136 mmHg, and median GCS of 7 (80% male, 20% female). In the 
CRASH-3 IBMS, a total of 65% of patients (n=1147) had a baseline CT scan done within a 
median of 2 hours after injury (IQR 1h to 2h), of whom 71% had another clinically indicated brain 





Simple validated scales were used to estimate intracranial haemorrhage volume on CT scans. The 
ABC/2 method is a quick and easy technique used to estimate intracranial haemorrhage volume. 
This method selects a representative slice near the centre of the haematoma on which the bleed is 
most visible. On this slice, two measurements are taken: (A) the maximal diameter; (B) width 
perpendicular to A. For the measurement of depth, the maximal number of slices on which the 
haematoma is visible is multiplied by slice thickness (C). These three measurements are 
multiplied and the sum divided by two (ABC/2) to provide the volume measurement in cm3 (ml). 
One cubic centimetre is equivalent to one millilitre. Clinical outcomes (e.g. GCS score, pupil 




Intracranial bleeding on baseline CT scan  
Figure 1 shows the type and frequency of intracranial bleeding on baseline CT scans according 
to baseline GCS. A total of 61% of patients with a baseline scan presented with more than one 
type of bleed. With the exception of epidural bleeding, which was more prevalent in patients with 
mild to moderate GCS, all other bleed types were more common in patients with a severe GCS. 
Subdural bleeds had a larger median volume of 46ml (IQR 27ml to 71ml) compared to epidural 
bleeds with 6ml (IQR 2ml to 20ml), intra-parenchymal bleeds with 1ml (IQR 0·2ml to 3ml), and 
intra-ventricular bleeds with a median volume of 0·4ml (IQR 0·1ml to 2ml).  
Figure 2 shows the volume distribution of intracranial bleeding on baseline CT scans by pupil 
reactions and GCS. The median volumes of 64ml (IQR 26ml to 108ml) in patients with no reactive 
pupils and 48ml (IQR 3ml to 93ml) in patients with one reactive pupil were larger than 26ml (IQR 
1ml to 55ml) in patients with two reactive pupils. The median volumes of 37ml (IQR 3ml to 75ml) 
in patients with a severe GCS were greater than 28ml (IQR 1ml to 53ml) for moderate GCS and 
18ml (IQR 0·2ml to 41ml) in mild GCS. But there is substantial overlap in bleeding volumes 
between pupil reaction groups and GCS groups. 
We used data on the time of injury and time of CT scan to estimate the time-adjusted volume of 
intracranial bleeding. Table 1 shows the time-adjusted volume of bleeding by pupil reaction, GCS 
score, and type of bleed. The time-adjusted volume of bleeding was largest in those with un-
reactive pupils and in those with severe GCS. Subdural bleeding was more rapid than epidural, 







Table 1 Baseline intracranial bleeding volume (adjusted for time from injury to baseline scan) 
  Median (lower quartile, upper quartile) millilitres / hour 




None react (n=141) 32 (14, 55) 
One react (n=94) 21 (2, 47) 
Both react (n=867) 13 (0·5, 31) 
  
Glasgow coma scale (GCS) score * 
 
Severe (n=388) 20 (2, 41) 
Moderate (n=331) 13 (0·3, 29) 
Mild (n=91) 8 (0·1, 20) 
  
Bilateral un-reactive pupils or GCS 3 * (n=131) 28 (10, 54) 
  
Type of intracranial bleeding  
Subdural (n=732) 25 (13, 42) 
Epidural (n=215) 4 (1, 10) 
Intra-parenchymal (n=709) 0·4 (0·1, 2) 
Intra-ventricular (n=184) 0·3 (0·1, 1) 
*Glasgow Coma Scale (GCS) score assessed before intubation / sedation (n=814 / 1,135) (72%) 
 
 
But the bleeding rate may not be constant. We found a non-linear association between time and bleeding 
volume (see Figure 3). The majority of expansion occurred in the first 1 to 1·5 hours after injury. Patients 
with a severe GCS seemed to bleed more and faster than patients with moderate to mild GCS. 
  
Other intracranial pathologies on baseline CT scans 
TBI patients often present with intracranial pathologies in addition to intracranial bleeding. Compared to 
patients with mild to moderate GCS, the prevalence of sulcal effacement was greater in those with severe 
GCS (44% vs 59%; n=190/433 vs n=417/702), as was ventricular effacement (30% vs 47%; n=128/433 vs 
328/702), and midline shift (39% vs 48%; n=169/433 vs. 337/702). Patients with a severe GCS and midline 
shift had a median shift of 7·4mm (IQR 4·1mm to 14·1mm) whilst those with moderate to mild GCS had 
a median shift of 4·3mm (IQR 2·8mm to 7·1mm).  
 
Intracranial bleeding on follow-up CT scans 
Seventy one percent (n=812) of patients with a baseline CT scan had a second or third clinically indicated 
CT scan. Over a third of these patients (n=318) had a bleed on a subsequent scan that was not seen on the 
first scan. Patients who had their first CT scan soon after injury were more likely to have a new bleed on a 
subsequent scan. The prevalence of new bleeds among those scanned ≤1·5 hours, >1·5 to 3 hours, >3 to 8 
hours after injury was 46%, 38%, 31%, respectively. For every 1 hour increase from injury to the baseline 
scan, the risk of new bleeding on a further scan decreased by 12% (RR=0·88 [95% CI 0·80 – 0·96], 
p=0·0047) (adjusted for baseline GCS score, pupil reaction, and time from injury to follow-up scan). The 
sooner the first scan was done after injury, the greater the opportunity for a new bleed to manifest on a 







Baseline intracranial bleeding, raised intracranial pressure, un-reactive pupils, and head injury 
death 
An increase in the volume of intracranial bleeding (ml) was associated with an increase in the amount (mm) 
of midline shift (beta coefficient 0·10 [95% CI 0·09-0·10], p<0·0001) (see Figure 4). An increase in midline 
shift (mm) was associated with an increase in the risk of having one or more un-reactive pupils (RR 1·08 
[95% CI 1·07-1·10], p<0·0001) (see Figure 5). Of those with baseline scans available for rating, 247 
patients subsequently died from head injury. The median time-adjusted volume of intracranial bleeding 
among patients who died from head injury is 37ml/h (IQR 18ml/h to 58ml/h) and in those who survived 
head injury death is 11ml/h (IQR 0·3ml/h to 28ml/h). Patients who died of head injury within 24 hours of 
injury had a higher median time-adjusted bleeding volume of 51ml/h (IQR 28ml/h to 73ml/h), than those 
who died within 48-72 hours of injury with 39ml/h (IQR 19ml/h to 56ml/h), and beyond 72 hours of injury 





The CRASH-3 trial results suggest that the effect of TXA on head injury death depends on the time interval 
between injury and the start of treatment and on the severity of TBI [1]. Early treatment of patients with a 
mild to moderate GCS reduces head injury death, but there is no evidence for benefit in patients with a 
severe GCS, regardless of time to treatment. The CT scan data are consistent with the hypothesis that TXA 
reduces head injury deaths by reducing intracranial bleeding. Patients with a mild to moderate GCS may 
be more likely to benefit from TXA because they have less intracranial bleeding at baseline. However, 
because bleeding occurs soon after injury, treatment delay reduces the benefit. On the other hand, patients 
with a severe GCS have less to gain from treatment because they already have extensive intracranial 
bleeding at baseline and/or other intracranial pathologies that are not affected by TXA. Our explanatory 
hypothesis is illustrated in Figure 6.  
The CRASH-3 investigators anticipated in their statistical analysis plan [6] that TBI patients with GCS 3 
or bilateral un-reactive pupils at baseline would have little potential to benefit from TXA and their inclusion 
in the analysis would dilute any treatment effect towards the null. They therefore pre-specified a sensitivity 
analysis that excluded these patients. Our CT data supports this decision, showing that these patients have 
extensive intracranial bleeding, and other intracranial pathologies, prior to treatment. However, whilst 
patients with bilateral un-reactive pupils were excluded, those with unilateral un-reactive pupils were not, 
despite having high volumes of intracranial bleeding at baseline. Patients with unilateral un-reactive pupils 
might also have brain herniation and their inclusion might have diluted the treatment effect. Indeed, when 
patients with GCS 3 and any un-reactive pupils at baseline are excluded, the effect of TXA on head injury 








Research in context. 
 
Evidence before this study 
Prior to this study, in 2015 we conducted a systematic search of all randomised trials of antifibrinolytic 
agents and identified two completed trials of TXA in TBI. These trials used CT scans to examine the extent 
of intracranial bleeding before and after randomisation. The following databases were searched: the 
Cochrane Injuries Group's Specialised Register, The Cochrane Library, Ovid MEDLINE(R), Ovid 
MEDLINE(R) In-Process & Other Non-Indexed Citations, Ovid MEDLINE(R) Daily and Ovid 
OLDMEDLINE(R), Embase Classic+Embase (OvidSP), PubMed and clinical trials registries. Both trials 
were judged to be at low risk of bias across several domains (sequence generation, allocation concealment, 
blinding, incomplete outcome data and selective reporting). When the two trials are combined in a meta-
analysis, there is a statistically significant reduction in intracranial haemorrhage with TXA (RR 0.75; 95% 
CI 0.58 to 0.98, p = 0.03). However, the confidence intervals are wide and the trials are small (n=249, 
n=229). Furthermore, although both trials measured intracranial haemorrhage on baseline scans, they did 
not examine whether the effect of TXA in TBI varies by baseline severity. 
 
Added value of this study 
The findings from the current study may help explain the results of the largest randomised trial in TBI to 
date; the recently published CRASH-3 trial. If at baseline TBI patients present with intracranial bleeding 
and a number of other neuropathological changes that TXA cannot plausibly affect, their potential to 
benefit from TXA may reduce. Although clinical signs such as GCS score and pupil reaction were 
assessed at baseline, the CRASH-3 trial procedure did not involve examining the intracranial pathologies 
that may lead to these clinical signs. In severely injured patients, the immediate neurologic damage from 
the trauma may have been too severe to be alterable and TXA may have little potential to reduce 
intracranial bleeding progression and the risk of head injury death. In this study, we considered the 
occurrence of secondary neuropathological changes that occur after the primary TBI and before 
randomisation into the CRASH-3 trial. Knowledge of these changes can inform understanding of the 
potential for TXA to improve patient outcome, and may help explain any variations in treatment effect by 
baseline injury severity in the CRASH-3 trial. 
 
Implications of all the available evidence 
The CRASH-3 trial treatment was given after arrival at hospital. Less than 20% of patients were treated 
within an hour of injury. Although there was no apparent benefit in patients with a low GCS on hospital 
arrival, if our explanatory hypothesis is correct, some of these patients might have benefited had they been 
treated in the pre-hospital setting. In many high-income countries, TXA is routinely administered by 
paramedics at the scene of the injury to treat acute severe bleeding. In low- and middle-income settings, 
this is not always possible due to resource constraints and a lack of health workers who can  administer 
intravenous drugs in the pre-hospital setting. Alternatives to intravenous administration of TXA such as 
intramuscular injection would be easier, require less training, and may reduce time to treatment. However, 




reduction in intracranial bleeding. Evidence suggests that patients with severe TBI in low- and middle-
income settings may be more likely to die compared to those in high-income settings. More rapid 
administration of TXA in settings with adequate medical care for patients with major trauma could increase 
the proportion of TBI patients who have the potential to benefit.  
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Haemorrhage; CT: computed tomography; IQR: interquartile range; RR: relative risk; TBI: traumatic brain 
injury. 
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Data sharing 
Following publication of the analyses detailed in the CRASH-3 IBMS statistical analysis plan, individual 
de-identified patient data, including a data dictionary, will be made available via our data-sharing portal, 
The Free Bank of Injury and Emergency Research Data (freeBIRD) website (http://freebird.Lshtm.ac.uk) 
indefinitely. This will allow for maximum utilisation of the data to improve patient care and advance 
medical knowledge. The study protocol, statistical analysis plan and publications will be freely available at 
http://www.txacentral.org/. If additional analyses are proposed, we would request a protocol and expect 
that a data access agreement is in place. 
Informed consent 
In the CRASH-3 trial, patients were unable to provide consent and so consent was sought from the 
patient’s relative, legal representative, or the responsible clinician. If and when the patient regained 
capacity to provide informed consent, they were informed about the trial and written consent sought to 
continue participation in the trial. If a patient or patient representative declined consent, they were 
withdrawn from the trial. For patients who were included in the trial but did not regain capacity, written 
informed consent was sought from a relative or legal representative. The requirements of relevant local 





The CRASH-3 trial included consent to extract data from patient medical records. Collecting CT scan 
data for the explanatory study was consistent with the consent procedure used in the CRASH-3 trial. It 
would be impractical to re-consent patients or relatives/legal representatives to access CT scans, 
particularly for patients who had deceased or were disabled as a result of their injuries where re-consent 
would have been distressing and unwelcome. The London School of Hygiene and Tropical Medicine and 
national Ethics Committees extended their approvals to extract CT data from the CRASH-3 trial without 




The Medical Research and Ethics Committee and Health Research Authority reviewed the protocol and 
supporting documents for the CRASH-3 explanatory study and provided a favourable ethical opinion on 8 
June 2016 (Research Ethics Committee Reference 12/EE/0274). All participating hospitals provided local 
approvals and letters of access for the CRASH-3 explanatory study to be conducted at their respective sites. 
Favourable ethical opinion was received from the Observational/Interventions Research Ethics Committee 
at the London School of Hygiene and Tropical Medicine on 24 May 2016 (Reference 11535).  
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Fig. 6 Hypothesis: association between bleeding rate and treatment effect 
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Appendix 9. Working procedures: (01) data collection; (02) data management plan. 
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PURPOSE 
To define the CRASH-3 Trial Intracranial Bleeding Mechanistic Sub-Study (CRASH-3 IBMS) data 
collection process to ensure scan data and all other related data are collected and recorded 
across all relevant sites in a uniform way and according to the protocol, International Conference 
on Harmonisation (ICH) Good Clinical Practice (GCP) standards and applicable regulatory 
requirements.  
 
INSTITUTIONAL SOP POLICY 
All Working Practice Documents (WPDs) for the CRASH-3 IBMS are produced in conjunction with 
the London School of Hygiene & Tropical Medicine (LSHTM) policies and procedures and the 
WPDs of the Clinical Trials Unit (CTU) and the CRASH-3 trial. 
 
OTHER POLICIES 
The CRASH-3 IBMS will be carried out in accordance with the sub-study protocol, ICH GCP 
standards, national regulatory authorities’ requirements, and the CRASH-3 IBMS WPDs. 
 
RESPONSIBLE PERSONNEL  
CRASH-3 IBMS lead (PhD Candidate) 
LSHTM CTU | Email: crash@lshtm.ac.uk  
Abda Mahmood (CRASH-3 IBMS Lead, PhD Candidate) is responsible for ensuring that all data 
for the CRASH-3 IBMS is collected and recorded completely and accurately. Abda Mahmood 
holds letters of access (and Research and Development (R&D) approvals where relevant) for 




CRASH-3 IBMS, letters of access and R&D approvals, where relevant, will be obtained prior to 
data collection at each site.  
 
BACKGROUND 
Before data collection can take place at a site, the CTU Co-Directors will work with the CRASH-3 
IBMS lead to make contact with the Principal Investigators (PIs) at each selected site to facilitate 
the data collection process. If the relevant PI approves for the CRASH-3 IBMS to be conducted 
at their site, the CRASH-3 IBMS lead will send all relevant documents to apply for a Letter of 
Access and any relevant R&D approvals. Relevant documents include the CRASH-3 IBMS 
protocol, ethics and regulatory submissions and approvals, a recent Good Clinical Practice 
training certificate and an updated CV for the CRASH-3 IBMS lead, and other requested 
documents. The CRASH-3 Trial Manager, and Senior Trial Manager, will support the CRASH-3 
IBMS lead to ensure that all relevant regulatory and site-specific approvals are in place for the 
CRASH-3 IBMS prior to beginning data collection at each site. The CRASH-3 Trial Manager will 
work with the CRASH-3 IBMS lead to ensure that any substantial amendments to the protocol 
are documented in accord with regulatory guidelines. The CRASH-3 Trial Manager and Senior 
Trial Manager will support the CRASH-3 IBMS lead to ensure that the Trial Master File for the 
CRASH-3 IBMS meets all relevant regulatory requirements.  
 
PROCEDURE   
 
• The CRASH-3 trial Entry Form data (see CRASH-3 trial protocol) in the CRASH-3 trial 
database will be used to prepare a list of all trial patients at the sub-study site with a 
Glasgow Coma Scale score of 12 or less. The list will include randomisation (box and pack) 
numbers, date and time of randomisation, number of hours and minutes between injury 
and randomisation (i.e. time since injury) and whether or not a CT scan was done before 
randomisation. The CRASH-3 trial Entry Data for patients who have withdrawn from the 
CRASH-3 trial will not be included in the above list. 
 
• Once at the participating CRASH-3 IBMS site, the CRASH-3 IBMS lead will provide the 
hospital research staff with a list of randomisation numbers for patients included in the sub-
study. The hospital research staff will access their clinical and research records (including 
the Randomisation Log) to identify the patients and provide the CRASH-3 IBMS lead with a 
list of corresponding hospital numbers. Although the CRASH-3 Entry Form records the 




several hospital numbers (e.g. older patients, patients transferred from other hospitals, 
patients enrolled using trauma numbers). The on-site Randomisation Log will have a log of 
each patient’s hospital numbers and other information including the patient name and date 
of birth; which can all be used to identify patients on site. 
 
• Case report form (CRF) data will be directly recorded in a web based sub-study database 
designed, developed and validated in consultation with appropriate regulatory authorities, 
including ICH GCP guidelines (see WPD 02 Data & Database Management Plan). The web 
database will be accessed at each participating site to enter the CRF data directly into the 
database. 
 
• In rare cases when the data cannot be recorded directly into the database, for example, if 
the database cannot be accessed at the site because of a poor internet connection or 
inadequate facilities, data will be recorded using paper CRFs (see Appendix 1 of CRASH-3 
IBMS Protocol). These paper CRFs will be transcribed into the database as soon as possible, 
within 1 week of data collection completion at each site and quality controlled at the end 
of the trial (see WPD 02 Data & Database Management Plan).  
 
• Two online data forms will be completed for each patient (pre-randomisation scan form 
and post-randomisation scan form – see Appendix 1 of CRASH-3 IBMS Protocol). A second 
post-randomisation scan form may be completed if the patient has had neurosurgery after 
the first post-randomisation scan and re-scanned following neurosurgery.  
 
• If there are multiple post-randomisation scans, the post-randomisation scan CRF will be 
completed using the first post-randomisation scan. The first scan is sometimes done very 
soon after randomisation (from a few minutes to a few hours) because sites are encouraged 
to randomise patients into the CRASH-3 trial on the basis of total GCS score rather than 
bleeding on CT. If this is the only post-randomisation scan available, it will be rated as the 
post-randomisation scan. If there is a later scan done closer to 24 hours post-randomisation 
(and without evidence of neurosurgical haemorrhage evacuation), this scan will be rated as 
the post-randomisation scan. All scans done within 28 days after randomisation will be 
examined for evidence of cerebral infarcts.  
 
• If the patient does not have a post-randomisation scan, only the pre-randomisation scan 




randomisation scan form will still be completed and it will be recorded on the database that 
there is no post-randomisation scan for this patient.  
 
• If the patient does not have a pre-randomisation scan, only the post-randomisation scan 
form will be completed. It will be recorded on the database that there is no pre-
randomisation scan for this patient.  
 
• All data will be collected as per the data collection CRFs (Appendix 1 of CRASH-3 IBMS 
Protocol). Using methods detailed in the protocol (Section 3.8 Outcome Measurement, 
Page 7), scans will be evaluated alongside the accompanying radiology report for evidence 
of intracranial haemorrhage, ischaemic infarcts, haemorrhagic oedema, mass effect 
(ventricular effacement, sulcal effacement and midline shift), neurosurgery and other 
endpoints defined on the CRFs.  
 
• Additional data, including the date and time of each patient’s pre-randomisation scan and 
post-randomisation scans, and the date and time of neurosurgery (if relevant), will be 
recorded in an excel spreadsheet held on a protected network drive with restricted access 
(see WPD 02 Data & Database Management Plan). The excel spreadsheet will be used to 
calculate: (1) time of injury (time of randomisation minus hours since injury); (2) number of 
hours and minutes between randomisation and post-randomisation scan; (3) number of 
hours between randomisation and neurosurgery. These time intervals will be calculated 
and recorded in the CRFs so the CRFs do not contain patient identifiable data (such as the 
dates and times of scans). 
 
• If the sub-study data suggests that patients have been scanned very soon after injury (i.e. 
from a few minutes to an hour), the Emergency Sheets on the relevant hospital clinical 
portal system and/or medical records will be checked where possible to confirm that the 
recorded Time Since Injury on the CRASH-3 Trial database is plausible given the mechanism 
of injury and patient/relative correspondence with the emergency services. If this check 
reveals that the data recorded on the CRASH-3 Trial Entry Form is inaccurate, the 
discrepancy is logged on a CRASH-3 Source Data Verification form, signed by the relevant 
Principal Investigator/Research Nurse, and amended on the CRASH-3 trial database by the 
Data Manager/Delegate.  
 
• All CRASH-3 IBMS data will be reviewed on an ongoing basis (see WPD 02 Data & Database 




the Trial Co-Ordinating Centre, clinical trial staff at relevant hospitals, Project Directors and 
the Chief Investigator of the CRASH-3 trial, and statistical advisors for the CRASH-3 IBMS, 
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DATA & DATABASE MANAGEMENT PLAN 
Abbreviations 
CRASH-3 Clinical Randomisation of an Antifibrinolytic in Significant 
Haemorrhage 
CRASH-3 IBMS CRASH-3 Trial Intracranial Bleeding Mechanistic Sub-study 
CRF Case report form 
CT Computed tomography 
CTU Clinical Trials Unit 
DMP Data Management Plan 
GCP Good Clinical Practice 
ICH International Conference on Harmonisation 
LSHTM London School of Hygiene & Tropical Medicine 
SDV Source Data Verification 
SOP Standard Operating Procedure 
TMF Trial Master File 
UAT User Acceptance Testing 
WP Working Procedures 
Purpose 
The Data Management Plan (DMP) documents procedures that should be followed for the 
processing of data for the CRASH-3 Trial Intracranial Bleeding Mechanistic Sub-Study (CRASH-3 
IBMS). The DMP ensures that the integrity of the data is maintained in accord with the CRASH-
3 IBMS protocol, International Conference on Harmonisation (ICH) Good Clinical Practice (GCP)1 
standards, and applicable regulatory requirements. 
 
PREPARATION 
Protocol Development                       CRF Development                       CRF guidance completed 
                                 Software chosen                    
 
                                                                  Database design               Data Management documentation 
 
                                                          User Acceptance Testing  
  
                                                 Data Management System signed off  
PROCESSING 
  CRF completed    Data entry 
 
                                                     Data cleaning and validation                     Queries raised/resolved 
ANALYSIS AND REPORTING 
               Database locked 
 
                                                      Quality assurance completed  
 






Institutional Working Procedure Policy 
All Working Procedures (WPs) for the CRASH-3 IBMS are produced in conjunction with the 
London School of Hygiene & Tropical Medicine (LSHTM) policies and procedures and the WPs of 
the Clinical Trials Unit (CTU). 
Other Policies 
The CRASH-3 IBMS will be carried out in accordance with the ICH GCP1 standards, national 
regulatory authorities’ requirements, and the CRASH-3 Trial IBMS WPs. 
Background 
The CRASH-3 IBMS is nested within the CRASH-3 trial and examines the effect of TXA on 
intracranial bleeding and infarction in patients with isolated traumatic brain injury. A potential 
benefit of TXA is that it will reduce intracranial bleeding. The CRASH-3 IBMS aims to quantify any 
difference in bleeding volume between TXA and placebo groups. A potential harm of TXA is that 
it will increase the risk of cerebral thrombosis and infarction. The CRASH-3 IBMS aims to examine 
whether patients treated with TXA are more likely to experience these endpoints compared with 
patients treated with placebo. The CRASH-3 IBMS will be conducted in a selection of 
approximately 1,000 patients enrolled in the CRASH-3 trial.  
Many traumatic brain injury patients undergo a brain scan (e.g. computed tomography (CT) as 
soon as possible after arriving in the emergency department, as part of routine medical care (i.e. 
before they are randomised into the CRASH-3 trial). Many patients will be scanned again for 
clinical diagnostic purposes (i.e. after they are randomised into the CRASH-3 trial). This sub-study 
will examine pre-randomisation and post-randomisation brain scans as per the data collection 
forms (see Appendix 1 of the CRASH-3 IBMS Protocol) and methods detailed in the protocol (see 
CRASH-3 IBMS Protocol). The Data & Database Management Plan for the CRASH-3 IBMS should 
be read in conjunction with the CRASH-3 trial Data Management Plan (CRASH-3 02 Data 
Management Plan). 
Anonymized data will be recorded in a web database, exported in a csv format, and summarised 
and analysed using Stata IC 15 software. In order to ensure the integrity of the data:  
(1) the sub-study protocol details the aims, methods and plans for statistical analyses;  
(2) the protocol and statistical analysis plan will be published in peer reviewed medical 
journals; 
(3) the Working Procedure 01 document details the procedure of data collection; 
(4) all data points in entry and outcome forms are labelled with identifiable headings and 
descriptions; 




Responsible Personnel  
CRASH-3 IBMS lead (PhD Candidate) roles 
LSHTM CTU 
Email: crash@lshtm.ac.uk  
The CRASH-3 IBMS lead (Abda Mahmood) is responsible for: 
- the overall conduct and management of the CRASH-3 IBMS; 
- working with the CRASH-3 trial staff at the trial coordinating centre and research 
staff at the relevant hospitals to gain the LSHTM, regulatory and site-specific ethical 
approvals for the sub-study; 
- working with the CRASH-3 trial manager, the senior trial manager, the project 
director, and the CRASH-3 chief investigator to ensure compliance with ICH GCP1 
standards, national regulatory authorities’ requirements, and the CRASH-3 Trial 
IBMS WPs; 
- working with the IT manager to develop the web database;  
- collecting, managing, cleaning and analysing data for the CRASH-3 IBMS; 
- working with the hospital research staff to extract the patient data using 
anonymised trial information;  
- working with hospital clinical staff (including the site Principal Investigator) to 
resolve queries regarding scan assessment and data monitoring; 
- working with a delegate from the data team to validate any electronic CRFs that are 
transcribed from paper CRFs; 
- working with the project director, chief investigator of the CRASH-3 trial, and 
statistical advisors for the CRASH-3 IBMS to discuss methodological issues that may 
arise during data collection; 
- working with other investigators following data collection and analysis, to write up 
and submit the results for publication in peer reviewed medical journals as per the 
protocol and statistical analysis plan, and disseminate the sub-study findings using 










CTU IT Manager and Database Developer roles 
LSHTM CTU 
Email: crash@lshtm.ac.uk 
The IT Manager (Hakim Miah) is responsible for developing the web database for the purpose 
of the CRASH-3 IBMS in consultation with the sub-study lead and in accord with the data 
collection forms, Specification document and Form Specification Matrix  (see Appendix 1 of the 
CRASH-3 IBMS Protocol, the Specification Document and Form Specification Matrix) and ICH GCP 
standards. The IT manager is responsible for responding to release requests and development 
testing. The IT manager and sub-study lead are responsible for ensuring that all changes made 
to the database are documented using release request forms and user acceptance testing forms. 
CTU Data Assistant/Data Manager/Delegate roles 
LSHTM CTU 
Email: crash.data@lshtm.ac.uk 
A delegate from the Data Team is responsible for working with the sub-study lead to ensure that 
any changes in the CRASH-3 trial entry and outcome data (i.e. following CRASH-3 IBMS data 
collection) are recorded appropriately with the relevant Source Data Verification forms and the 
CRASH-3 trial database is updated accordingly.  
CTU CRASH-3 Trial Manager and Senior Trial Manager 
LSHTM CTU 
Email: crash@lshtm.ac.uk 
The CRASH-3 trial manager (Lauren Frimley), and senior trial manager (Danielle Beaumont), are 
responsible for working with the sub-study lead to ensure all relevant regulatory and local 
ethical approvals are in place for the CRASH-3 IBMS, and all amendments are documented in 
accord with regulatory guidelines. The trial managers are responsible for working with the sub-
study lead to ensure that the trial master file for the CRASH-3 IBMS meets all relevant regulatory 
requirements.  
CTU Project Director and CRASH-3 Chief Investigator (i.e. CTU Co-Directors) roles 
LSHTM CTU 
Email: crash@lshtm.ac.uk 
The CTU Co-Directors are responsible for working with the CRASH-3 IBMS lead to oversee the 







Time plan of Trial Activities 
Data collection starts Feb 2016 
Data collection ends  ~ January 2019 
Database hardlock ~ Feb 2019 
Start of Result Analysis ~ Feb 2019 
Completion of Close out and Publication ~ September 2019 
Study Archive ~  December 2019 
Case Report Form (CRF) Development and Piloting 
The Case Report Forms (baseline and follow-up outcome forms) will be designed according to 
the LSHTM SOP 025 CRF Design and Approval and will be part of the protocol development. The 
Protocol Committee is responsible for final approval of the CRFs as part of the protocol. The 
CRFs (see Appendix 1 of the CRASH-3 IBMS Protocol) will be piloted at the Neurosurgical Trauma 
Unit at the Queen Elizabeth Hospital in Birmingham (Site 1) as per the methods detailed in the 
protocol (see Protocol for CRASH-3 IBMS). The on-site piloting process will take place under the 
supervision of Clinical Research Fellow and Neurosurgical Registrar at the Queen Elizabeth 
Hospital in Birmingham, Mr Dave Davies.  
Data Flow 
Blinding of the trial drug/placebo 
The CRASH-3 IBMS is nested in a cohort of CRASH-3 trial patients. As such, the blinding of the 
trial drug and placebo is the same as that detailed in the CRASH-3 trial Data Management Plan 
(DMP) v.1.1.  
Randomisation 
The randomisation process is the same as that detailed in the CRASH-3 trial DMP v.1.1. 
Inclusion criteria  
Patients who have a Glasgow Coma Scale score of 12 or less or intracranial bleeding on a CT scan 
performed before randomisation into the CRASH-3 trial, and fulfil the inclusion criteria for the 
CRASH-3 trial, are eligible for inclusion in the CRASH-3 IBMS.  
Consent to participate 
The CRASH-3 trial includes consent to extract data from patient medical records. Collecting CT 
scan data for the CRASH-3 IBMS is consistent with the consent procedure used in the CRASH-3 
trial. It would be impractical to re-consent patients or relatives/legal representatives to access 
CT scans, particularly for patients who have deceased or are disabled as a result of their injuries 




Tropical Medicine and national Ethics Committees extended their approvals to extract CT data 
from the CRASH-3 trial without further patient consent. Patients who withdrew from the main 
CRASH-3 trial would not be included in the CRASH-3 IBMS. 
Protocol deviations and violations 
Any unintentional (protocol deviation) or intentional (protocol violation) failures to adhere to 
the CRASH-3 trial protocol will be dealt with as per the procedure detailed in the CRASH-3 trial 
Data Management Plan v.1.1. The sub-study lead will create a list of all patients eligible for the 
CRASH-3 IBMS and will collect the CRASH-3 IBMS data directly from the source data at each 
relevant site. There are no expected protocol deviations or violations for the CRASH-3 IBMS.  
Unblinding during the trial 
The unblinding process for the CRASH-3 trial is detailed in the CRASH-3 trial DMP v.1.1 (see Work 
Procedure: Unblinding). The sub-study involves retrospective analysis of CT scans that were 
done for clinical reasons, therefore, it will not be necessary to unblind a patient after their CT 
scans have been assessed for the CRASH-3 IBMS.  
Adverse Event Reporting 
Any adverse events will be reported in accordance with the procedures followed in the CRASH-
3 trial.  
Pre-randomisation CT data and post-randomisation CT data transmission 
The data will be collected by the sub-study lead in accord with the CRASH-3 IBMS Working 
Procedure 01: Data Collection. The sub-study lead will manually enter the CRASH-3 IBMS pre-
randomisation scan data and post-randomisation scan data into the web database from the 
source data at each participating site. In rare cases where it is not possible to enter the data 
directly into the web database, the paper CRFs will be completed on site and these uploaded to 
the web database as soon as possible, ideally within 1 week of data collection completion at the 
relevant site. Paper CRFs that are transcribed to the web database will be quality controlled as 
detailed in the QA/QC section.  
Queries  
Following data collection at each site, where possible, queries will be resolved on site by 
accessing the site clinical systems and in consultation with the site staff. If it is not possible to 
resolve queries when on site, queries will be collated and emailed to the trial staff on site as 
soon as possible, within 1 month following data collection completion at the relevant site. These 
may include the trial entry form stating that a patient was scanned before randomisation but 




period after randomisation. All queries will be followed up before the end of the trial. Once any 
queries have been confirmed, the database will be updated as soon as possible, within 1 week 
of the query being resolved. Any query resolution correspondence will be documented in the 
Trial Master File. 
A query may concern the CRASH-3 trial data in addition to the CRASH-3 IBMS data, for example, 
querying a short duration between injury and first CT scan may highlight an error in the time 
between injury and randomisation. If there is an error in the CRASH-3 trial entry or outcome 
data, the sub-study lead will complete the relevant Source Data Verification (SDV) form and any 
relevant additional documents, including emails, will be attached to the SDV. If an error is found 
between trial and source data at the participating site and the SDV form is completed at site, 
the site staff will be asked to sign the SDV to confirm the discrepancy. Paper SDVs will be passed 
on to the CRASH-3 trial Data Team who will update the CRASH-3 trial database accordingly. The 
sub-study lead may also send corrections of the CRASH-3 trial entry or outcome data to the 
CRASH-3 Data Team via email. If relevant, the Data Team will advise the relevant on site team 
to amend their on-site records.  
 
All queries will be resolved or reconciled prior to hardlock. If a query cannot be resolved, the 
sub-study lead will discuss the query with the Project Director and CRASH-3 Chief Investigator 
to decide how to proceed.  
Self-evident corrections 
Following data collection at each site, the data will be exported as reports using a download 
report facility in the web database. If the error is self-evident, the relevant CRF will be corrected 
by the sub-study lead without prior permission from the site. Any self-evident corrections 
immediately following detection. For example:  
- If the post-randomisation scan forms indicate that the patient has had neurosurgical 
haemorrhage evacuation (Neurosurgery fields) but the Marshall Classification (which 
also records whether a patient has had a haemorrhage evacuation) does not record 
neurosurgical haemorrhage evacuation, the outcome form will be re-checked and the 
Marshall Classification or Neurosurgery fields amended, as appropriate.  
- If the patient has been recorded as having a very large and improbable haemorrhage 
volume (i.e. several thousand milliliters), the volume will be re-estimated using the 
recorded A (maximum length of haemorrhage), B (maximum width perpendicular to A) 
and C (depth of haemorrhage), to ensure that the total volume recorded is correct. If 
there has been a simple error in multiplication (A  x B x C), the total volume will be 




and this is self-evident, this will be corrected (e.g. all fields are recorded to 1 decimal 
place and one value does not contain a decimal place, resulting in a very large number). 
If the error is not self-evident and requires further investigation, this will be confirmed 
using the source data as detailed in the Query section above. 
 
Database Development, Testing and Validation 
• The web database for the CRASH-3 IBMS will be developed in consultation with the 
following: 
o CRASH-3 SOP: Database Development and Validation Plan,  
o CTU SOP: Data Management Systems Development and Validation,  
o CTU IT SOPs: 001 IT Systems; 002 Server Setup & Conventions; 003 Backup, 
Logical & Physical Security of Data; and 004 Software Development,  
o appropriate regulatory authorities, including ICH GCP guidelines (1).  
• A Risk Analysis will be performed to identify and minimize risks and hazards of using a 
custom developed web database. The Risk Analysis will be saved here: 
J:\TCC\CRASH3\CT scan substudy\6. Data management\Database\Risk Analysis.  
• The database will be developed in accord with the approved CRFs, the Specification 
Document and the Form Specification Matrix. The database will include required fields; 
certain questions must be answered otherwise a form cannot be submitted and saved. 
More details about these rules is provided in the Computerized Validation Checks 
section below. The Specification Document and Form Specification Matrix will be saved 
here: J:\TCC\CRASH3\CT scan substudy\6. Data management\Database\Specification. 
• Prior to release, the electronic CRFs will be tested in a test database against the Form 
Specification Matrix. The sub-study lead will check that data can be entered in the 
correct format in all fields. The pre-submission data will be compared to the submitted 
data, and the data in the csv reports, to ensure that it has not been transformed. Once 
all UAT has passed, a live version of the database will then be released. All relevant 
database testing documents will be saved here: J:\TCC\CRASH3\CT scan substudy\6. 
Data management\Database\Testing.  
• Any change made to the live version of the database will be requested by the sub-
study lead in the form of a Release Request form and approved by the IT Manager. All 
testing forms and release requests will be saved here: J:\TCC\CRASH3\CT scan 
substudy\8. Web Database\4_Release Requests and User Acceptance Testing.  




• Anonymised data (identifiable using box-pack numbers only) will be directly entered into 
the web database from the source data at each participating site. The data will be 
automatically uploaded into a central server on form submission. 
• All submitted forms will be editable and any revisions to a form following submission will 
be saved automatically in a database log with details of who edited the data and when edits 
were made. Any changes made from the initial form submission will be highlighted in each 
amended version of a form.  
• The sub-study lead will enter all data into the database and will not be able to delete a form 
following submission and upload. If it is later found that the form was entered in error, the 
sub-study lead must formally request for the relevant form to be deleted, by the IT 
manager, with an explanation for why the form must be deleted. Then, the IT Manager 
must access the relevant form from the back end of the server and delete the erroneous 
data.  
• After data collection is complete at each site, using a download report facility, the data will 
be exported in a csv format and checked in STATA IC 15 for any missing or irregular data. If 
necessary and appropriate, the data will be amended (i.e. if the error is self-evident, the 
error will be corrected using a self-evident correction as detailed in the self-evident 
corrections section above). If the sub-study data is not consistent with the CRASH-3 trial 
entry or outcome data, the sub-study lead will query with the research/clinical staff on site 
and assess whether the queries can be confirmed when on site or if required will re-attend 
the relevant site to examine queries. For example, if the trial entry data says that a patient 
was scanned before randomisation but the time of the first CT scan is a substantial period 
after randomisation, this will be investigated further using the paper case report forms, 
ambulance sheets and the relevant onsite clinical portal. More details of how Queries will 
be dealt with is provided in the Queries section below.  
• As the CRASH-3 trial and CRASH-3 IBMS are ongoing, the CRASH-3 IBMS lead will analyse 
the blinded data to explore the frequency and distribution of the outcomes. 
• When the CRASH-3 trial has completed recruitment, the CRASH-3 IBMS lead will analyse 
the unblinded data as per the protocol and statistical analysis plan, and in consultation with 
the CTU Project Director, CRASH-3 Chief Investigator, and statistical advisors for the CRASH-









The data collection will be done in line with the CRASH-3 IBMS Working Procedure 01: Data 
Collection. Data review will be done on an ongoing basis by the sub-study lead to ensure the 
integrity and accuracy of the data. Both manual and electronic validation checks will be carried 
out on the data from the CRASH-3 IBMS.  
Manual checks 
The web CRFs will be manually checked once submitted onto the database to ensure that the 
data has not been changed from entry to submission. This manual check should also identify any 
outliers and irregularities. The following checks will be performed for the following questions.  
 
Has this patient been scanned before randomisation?  
*This question is in the pre-randomisation scan form only.* 
- The sub-study lead will check that this box has been selected if the patient has been 
scanned before randomisation. She will also check that if this box is selected, the pre-
randomisation form must be complete, or an explanation given in the Notes section at 
the end of the form for why the form has not been completed (e.g. the scan was done 
but not available to review because the patient was scanned at another site before 
being randomised into the trial).  
Box-pack 
- The sub-study lead will check that the box and pack fields are the correct length (i.e. 
four numbers for Box, two numbers for Pack).  
Is there any intracranial bleeding on the scan? 
- The sub-study lead will check that if the answer to this question is Yes, that the type 
and, if relevant, volume of haemorrhage has been recorded. If the answer to this 
question is No, then there shouldn’t be any information in the following haemorrhage 
fields. If this has been selected No, but there is information regarding type and/or 
volume of haemorrhage in the proceeding fields, it is likely that this question should 
have been answered Yes. The sub-study lead will review the relevant scan on site and 
amend the answer accordingly.  
Is this a new bleed? * This question is on the post-randomisation scan forms only*.  
- This should be answered Yes if there is a new bleed seen after randomisation that was 
not seen before randomisation. If there is a new bleed, the sub-study lead will 
highlight which of the recorded bleeds are new in the Note section associated with this 




Marshall classification  
- If there is no bleeding on the scan, the ‘is there any intracranial bleeding on the scan’ 
question should be answered as No, and the Marshall Classification should be ‘Diffuse 
injury I – no visible pathology’. The sub-study lead will check for consistency across 
these fields.  
- If Diffuse Injury II or III is selected and there is evidence of midline shift, the midline 
shift degree field should be less than 5mm, and the volume of intracranial bleeding 
should also be less than 25ml. These fields will be checked for consistency.  
- If Diffuse Injury IV is selected, the degree of midline shift degree field should be more 
than 5mm, and the volume of intracranial bleeding less than 25ml. These fields will be 
checked for consistency. 
- If Evacuated Mass Lesion is selected, the Neurosurgery fields should be complete.  
- If Non-evacuated Mass Lesion is selected, the volume of intracranial bleeding should 
be more than 25ml.  
Is there any evidence of acute focal ischaemic lesion? 
- The sub-study lead will check that this field has been answered (Yes/No). 
Is there any evidence of an oedematous lesion? 
- The sub-study lead will check that this field has been answered (Yes/No). 
Is there any sign of ventricular effacement? 
- The sub-study lead will check that this field has been answered (Yes/No). 
Is there any sign of sulcal effacement? 
- The sub-study lead will check that this field has been answered (Yes/No). 
Is there any sign of midline shift? 
- The sub-study lead will check that this field has been answered (Yes/No). If there is 
evidence of midline shift, the sub-study lead will check that the degree of mass effect 
has been entered. The sub-study lead will check that the number is plausible (usually 
between 3mm and 30mm), and that it is consistent with the rating of the Marshall 
Classification (see above).  
Has the patient has neurosurgery (Yes/No)? 
- The sub-study lead will check that if the answer is Yes, that the type of neurosurgery 
has been specified. If the type of neurosurgery has been entered but whether the 
patient has had surgery is selected as No, the sub-study lead will re-assess the scan 
and amend the answers accordingly.  
- If the patient has had a neurosurgical haemorrhage evacuation, the Marshall 
Classification should be answered ‘Evacuated Mass Lesion’. The sub-study lead will 




Date of scan reading 
- The sub-study lead will check that the correct date has been entered.  
Was the patient scanned after randomisation? * This question is in the pre-randomisation scan 
form only. * 
- The sub-study lead will check that if this has been entered as Yes, the post-
randomisation scan form is complete, and if the scan was done and not available to rate, 
there should be a comment in the notes section to this effect.  
Computerised validation checks (CVCs) 
Computerised validation checks (CVCs) will be built into the CRASH-3 IBMS web database 
according to the Database Development, Testing and Validation section above. Rules will be 
built into the form builder so that certain entries will be flagged upon submission, and to ensure 
that certain fields are complete before the form is submitted.  
o For example, if the same randomisation number is entered for more than one patient, 
an error box will appear when submission is attempted. The person entering the data 
will be able to edit the form with the correct randomisation number and save the 
amended version of the form with the correct randomisation number.  
o If in a time field (i.e., HH:MM), a semi-colon (;) is used rather than a comma (:), an error 
will appear when submission is attempted and the form will not save until the data is in 
the HH:MM format.  
o All details regarding the CVCs will be detailed in the CRASH-3 IBMS Form Specification 
Matrix.  
o On each CRF there will be an option to ‘ignore validation rules’ in order to allow the user 
to switch off the CVCs, if necessary. The ‘ignore validation rules’ field at the end of the 
pre-randomisation scan form will be selected in case the patient has not been scanned 
before randomisation. Selection of this field will mean that all rules built into the form 
builder will be ignored for that particular form. Selection of this field will allow 
submission of an empty pre-randomisation scan form so that the post-randomisation 
scan form data can be entered if the patient was scanned after randomisation and not 
before. 
Data review  
The sub-study lead will extract all data using a download report facility within the database and 
review the data for logical inconsistencies. If possible, this review will be done on site when data 
collection is complete at each site so that any necessary amendments can be made in 
consultation with the site source data. If it is not possible to do this review on site, it will be done 




consulting the site staff via email. This review will include checks to ensure that the data can be 
exported into the relevant reports, that any outliers (e.g. very large haemorrhage volume) are 
flagged, and any queries are raised as per the process detailed in the Queries and Self-Evident 
Corrections sections. The review will also include checks to confirm that the data is able to 
capture expected relationships and is not completely random. For example, statistical software 
Stata IC 15 will be used to check whether patients with larger bleeds on the pre-randomisation 
scan are more likely to undergo neurosurgery before the post-randomisation scan. The data 
review for all CRASH-3 IBMS data should be done within 1 month of data collection completion 
at each site. Any data that the sub-study lead first enters manually on paper CRFs on site and 
then transcribes into the web database at the CTU will be cross-checked by a delegate as 
detailed in the Quality Control and Quality Assurance section.  
Inter-rater reliability 
The CRASH-3 trial Entry Form collects data on the location of intracranial haemorrhage on a CT 
scan done before randomisation (see CRASH-3 Trial Protocol: Entry Form Questions 13 and 14). 
This information is often from a CT radiology report written by a trainee radiologist and 
confirmed by a consultant radiologist. The relevant CRASH-3 trial Entry Form data will be cross-
checked against the pre-randomisation scan data collected as part of CRASH-3 IBMS to check for 
inter-rater reliability.  
Quality Control and Quality Assurance 
Quality control procedures will be built into each of the data management activities:  
• CRF Design 
• Clinical trial database user acceptance testing 
Quality control of CRF Design 
Case report forms will be designed according to CTU SOP 003 Case Report Form Design and 
Approval. 
Clinical trial database design and development  
The sub-study database will be designed and developed by the sub-study lead and IT Managers 
at the CTU.  
- The sub-study lead will create the database specification as per the approved protocol 
CRFs.  
- The IT Manager will review the database specification and make necessary suggestions.  
- The sub-study lead and IT Managers will build the web CRFs as per the final specification 




- The sub-study lead will conduct UAT on the test version of the database. This test will 
include entering data into all the fields to check that: 1) data can be entered in all fields 
and in the required format; 2) data does not change from entry to submission; 3) the 
required rules have been built into the form; 4) data can be exported into the report 
using the download report facility.  
- Once the database has been tested by the sub-study lead in the test version of the 
database, any feedback will be relayed to the IT Manager who will make any relevant 
amendments.  
- Once all UAT has been passed, and the sign-off document has been approved, the 
current database version will go live.  
- Any amendments made to the live version of the database will be requested by the sub-
study lead using a Release Request form. For example, if a new site has agreed to 
participate in the sub-study as the sub-study is ongoing, the sub-study lead will ask the 
IT Manager to add this site to the list of site names in the sub-study database, using a 
release request form. The IT manager will advise whether the requested change is 
feasible and update the test database with the proposed revision. The sub-study lead 
will conduct UAT on all revisions in the test database and communicate any feedback to 
the IT manager. The IT Manager is responsible for development testing. The live version 
of the database will be updated with approval from the sub-study lead, IT Manager and 
Project Director.   
Source Data Monitoring  
The CRASH-3 IBMS data will be collected directly from the imaging system and other clinical 
portals at each relevant site (i.e. the source data) and manually entered into the web database. 
Therefore, source data monitoring is not relevant for the CRASH-3 IBMS.   
Data Monitoring Committee 
The rules and responsibilities of the Data Monitoring Committee are laid down in the DMC 
Charter and CRASH-3 trial Protocol. The CRASH-3 IBMS is nested within the CRASH-3 trial and 
does not have its own Data Monitoring Committee. 
Quality Assurance (QA)/Quality Control (QC) of CRF data 
- CRASH-3 IBMS data that is manually entered from the source data into the web 
database will have less transcription error than data entered manually onto paper CRFs 
from the source data and then transcribed to the web database. Therefore, direct 
database entry will be prioritised at all participating sites to minimize transcription error. 




- In cases where the web database is temporarily inaccessible at a site (in cases of poor 
internet connection or inadequate facilities) and the data is first recorded using paper 
CRFs and then transcribed into the web database, the data in the paper forms will be 
cross-checked against the corresponding data in the web database at a later date. A 
delegate will check all the paper CRFs for inconsistencies in data between paper and 
web versions. The sub-study database will be updated accordingly if there are any errors 
in transcription.   
- The delegate may be an independent person (not related to the trial) and will be used 
for CRF quality control / assurance activities (e.g. before any medical review meeting or 
database locks).  
- After database lock, QA will be carried out (see below Database Lock and Unlock).  
QC/QA of Data Queries 
All open data queries will be checked by the sub-study lead on an on-going basis. The sub-study 
lead will correct any inconsistencies found and will update the trial database as necessary as per 
query responses.  
QA of the IMP blinding procedure 
The quality assurance of the blinding procedure is detailed in the CRASH-3 trial DMP.  
 
Database Lock and Unlock 
Soft Lock  
The CRASH-3 trial will conduct regular interim analyses of the data and soft lock will take place 
three months prior to a scheduled Data Monitoring Committee Meeting (see CRASH-3 DMP). 
There are no interim analyses planned for the CRASH-3 IBMS, therefore soft lock is not relevant 
for the CRASH-3 IBMS.  
Hard Lock and Read Only Access 
Hard lock of the CRASH-3 trial database will take place at the end of the trial; within 3 months 
of the end of CRF data collection and once data has been cleaned. Hard lock will adhere to the 
principles in CTU SOP Database Lock, Release and Unlock (see Work Procedure: Database lock 
and unlock and Work Procedure: Extracting data).  
The CRASH-3 IBMS database will be locked by restricting access to Read Only; within 3 months 
of the end of CRF data collection and once data has been cleaned. The IT Manager is 
responsible for restricting access. Prior to data extraction, the sub-study lead will ensure that 




will be resolved or reconciled prior to data extraction. The sub-study lead, in discussion with 
the Project Director and CRASH-3 Trial Chief Investigator, will prepare guidance on the 
database handling of unresolved queries and will produce a report on database status at time 
of lock (see Appendix 2). When lock has taken place, the sub-study lead will sign the 
Certification of Lock (see Appendix 3). The treatment allocation code file will be sent to the 
sub-study lead after database hard lock (CRASH-3 trial) and access has been changed to Read 
Only (CRASH-3 IBMS database). The unblinded codes will be stored in a secure folder.  
 
Data Extraction  
All data stored on the database will be extracted using the download report facility within the 
database. The csv output will be stored in the CRASH-3 IBMS folder (J:\TCC\CRASH3\CT scan 
substudy) and automatically password protected and zipped. Prior to beginning the analysis, a 
check will be done to see if the csv file is accurate and the data has not been transformed from 
the individual CRF data.  
Final Analysis  
As soon as possible following database hard lock, the CRASH-3 IBMS lead will unblind the data 
and run the analysis as per the protocol and statistical analysis plan, using Stata IC 15. The 
statistical analysis will also be done by the statistical advisors for the CRASH-3 IBMS to check for 
consistency in results.  
Unlock 
In the event that the database has to be unlocked, permission to unlock must be given by the 
Project Director. Access must be restricted to a member of the team who has remained blinded 
to the results (treatment allocation).  The data will be extracted prior to re-lock as detailed under 
hard lock. The database should then be relocked and certified as such.  The CRASH-3 IBMS lead 
will check the system log to confirm that the actions detailed were carried out and no other 
changes were made, and sign off the report (see Appendix 3). 
 
Security 
• All CRASH-3 IBMS data will be held on a web database and in a protected network drive.  
• LSHTM IT Support will be responsible for all security, backups and recovery issues. 






The data will be held securely with restricted access that is logged. 
a) Data will be stored on a dedicated server by Rackspace who are ISO27001 accredited. Copies 
of the data forms (image files) sent as email attachments or uploaded onto the CTU secure 
server will also be held on a protected network drive.   
b) Access to the server is only possible for authorised individuals, who have login accounts and 
passwords. Only individuals employed by the CTU will have access and the network folders are 
visible only to them. External access to the LSHTM network from the internet is protected by a 
firewall which operates a deny-all policy so that only identified traffic to certain allowed hosts is 
permitted.  
c) All staff have confidentiality clauses in their contracts.   
Environment 
All data will be held in a secure environment (electronic).   
a) The LSHTM buildings are protected by an electronic entry system and by a security guard on-
site to ensure 24-hour protection.   
b) Servers are held in secure data centres within the LSHTM buildings. 
c) Servers are also held by Rackspace in their secure London data centre. Rackspace manage the 
servers patching and updating the software. 
 
Backup 
To prevent accidental loss of data there is a network-wide backup system.  
a) The LSHTM backup system involves nightly, weekly and monthly backups of the network to 
tape and disk. Backups are kept in a secure area with access via electronic keypad. Tapes are 
stored in secure fireproof safes.   
b) Backup of the entire network is made on two sites separated geographically, and in the event 
of a major systems failure the mirror site will retain a full backup.  
c) Rackspace have daily back ups going back the last two weeks. There is an encrypted daily back 
up of the databases sent to the LSHTM secure network drive.  
Archive and destruction 
Any paper data will be kept in a secure archive for a period of five years as per the CRASH-3 
protocol section 2.14 monitoring. The data shall then be shredded and all storage media shall 
be destroyed. A Certificate of Destruction will be issued by the company who carries out the 
destruction under contract to the LSHTM. The CTU and the archivist will retain copies of the 




FreeBIRD (freebird.lshtm.ac.uk). Any information which might lead to identification as to where 
the data originated from will not be made publicly available. 
Confidentiality 
The CRASH-3 IBMS will only collect data relevant to the trial. No patient names or patient 
identifiable information will be collected. Only unique randomisation numbers will be recorded 
on data forms. The randomisation number and hospital ID number will only be used to establish 
the identity and existence of patients at the participating sites and to cross check the CRFs and 
CT scans associated with a patient. 
 
Two methods of data collection will be designed/managed to ensure confidentiality: 
1) The CRASH-3 IBMS lead will directly enter data into the online CRFs (identifiable using 
box-pack numbers only) held on the web database and accessed at the participating 
site. The CRASH-3 IBMS lead will be issued with a unique username, password and PIN 
to access the database. The CRASH-3 IBMS web database is accessible to a restricted 
number of users (CRASH-3 IBMS lead, IT Manager, CTU Co-Directors) who have a unique 
username, pin and password to access the database. Only designated CTU staff (IT 
managers, data assistants and managers) have access to the server. Uploads are 
automatically logged with the source IP address, date and time.  
2) This method should only be used if it is not possible to use the web database when on 
site. Paper CRF entry at site and web entry at the CTU. Paper CRFs will be stored in the 
sub-study Trial Master File (TMF) (more details in Data Storage below).  
Database Authorisation 
Only authorised personnel will have access to the CRASH-3 IBMS database. Access to the trial 
database will be gained through a password system which includes a username, password and 
pin.   
• The IT Manager will grant/remove access as well as managing granularity of access to the 
database. 
• A log file of login successes/failures/attempts will be available.  
File Transfer security 
All file transfers will be done through secure protocols and files held on secure servers. 
 
Data Storage  
• A hard copy of the TMF is held in a locked filing cabinet at the CTU – keys are held 




LSHTM Shared Network (J:\TCC\CRASH3\CT scan substudy). All relevant folders are 
saved in the order they are referred to in the TMF Index.  
• The database is stored on secure servers (ISO27001 accredited data centre in London, by 
Rackspace) and protected by privileged password protected access. Supplementary data 
is stored on the LSHTM Secure Network Drive (J Drive).  
• Each patient’s anonymised CT scan data is saved in the secure online database under the 
unique patient randomisation number. When the data is exported, it will be organized 
by pre-defined variable names as per the Database Specification.  
• An excel datasheet with pre-loaded anonymised data (from the CRASH-3 Trial Entry 
Form) and the time of scans has been labelled with column headings and structured so 
data is entered chronologically (i.e. date and time of injury, date and time of pre-
randomisation scan, date and time of post-randomisation scan, data and time of 
neurosurgery). This datasheet is used to collate the randomisation numbers, date and 
time of randomisation, and time since injury, for patients eligible for the sub-study. It is 
also used to record the dates and times of scans, and calculate the intervals between 
injury and scan (pre-randomisation scan form), scan and randomisation (post-
randomisation scan form), and randomisation and neurosurgery (post-randomisation 
scan form). This spreadsheet does not contain any outcome data and is only used to 
supplement the CRFs. This spreadsheet is held on a LSHTM Secure Network Drive (J 
Drive).   
 
Downloadable Reports  
Data from each form will be collated in reports, which are available for download from the 
CRASH-3 IBMS web database. There will be one report with the pre-randomisation data from all 
patients (pre-randomisation data form). There will be three forms for the post-randomisation 
scan data (first post-randomisation scan form, second post-randomisation scan form, third post-
randomisation scan form). The second and third forms tend to be relevant if the patient has had 
neurosurgery following randomisation and therefore has been scanned several times. All reports 
will have unique and identifiable column headings.  
 
Archiving of Data Collection Documents 





Paper archiving will follow the paper archiving format as the CRASH-3 trial DMP (see WPD 007 
Managing Paper Data and Self Evident Corrections). 
Electronic archive 
Electronic archiving of files will follow the same electronic file structure as the CRASH-3 trial 
DMP (see CRASH-3 Trial DMP Appendix 9).  
 
Dissemination  
• In order to fulfil ethical obligations to participants and the research community and 
reduce publication bias, the sub-study is registered on www.clinicaltrials.gov and 
ISRCTN. The protocol and statistical analysis plan will be published in a peer reviewed 
medical journals prior to unblinding the trial results.  
• The results will be reported to trial collaborators and published in peer reviewed 
medical journals. Dissemination of results to patients will take place via the media, trial 
website (www.crash3@lshtm.ac.uk) and relevant patient organisations. Credit in key 























DATA MANAGEMENT PLAN: REFERENCES 
 
ICH-GCP Guidelines 
Located at:  
http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6/E6_R2_
_Step_4_2016_1109.pdf 
• ICH Harmonised Tripartite Guideline for Good Clinical Practice (2016)  
 
Protocols 
Located at J:\TCC\CRASH3\Protocol (generic)\Generic 
• CRASH-3 Trial Protocol 
Located at J:\TCC\CRASH3\CT scan substudy\1. Protocol and outcome forms\Protocol 
• CRASH-3 Trial IBMS Protocol 
 
SOPs/WPs 
Located at: J:\TCC\CRASH3\Standard Operating Procedures 
• CRASH-3 Trial Database Development and Validation Plan 
• CRASH-3 Trial Data Management Plan v1.1 
• CRASH-3 WP: Unblinding 
• CRASH-3 WP: Database lock and unlock 
• CRASH-3 WP: Extracting data 
• CRASH-3 WPD 007 Managing Paper Data and Self Evident Corrections 
 
Located at J:\TCC\CRASH3\CT scan substudy\6. Working Procedures 
• CRASH-3 IBMS WP 01 Data Collection 
Located at J:\TCC\GENERAL_TCC\01 SOPs, Policies and  GUIDANCE DOCS\03CTU SOPs 
• CTU SOP: Database Lock, Release & Unlock 
 
Associated Documents 
Located at J:\TCC\GENERAL_TCC\01 SOPs, Policies and GUIDANCE DOCS\03CTU SOPs 
• CTU SOP: 031-02 Data Management Systems Development and Validation 
• CTU IT SOP: 001 IT Systems 
• CTU IT SOP: 002 Server Setup & Conventions 
• CTU IT SOP: 003 Backup, Logical & Physical Security of Data 




Located at J:\TCC\CRASH3\CT scan substudy\8. Web Database 
• CRASH-3 CT Sub-study Risk Analysis 
• CRASH-3 CT Sub-study Specification 
• CRASH-3 CT Sub-study Testing 
• CRASH-3 CT Sub-study post-release changes 
 
Located at J:\TCC\GENERAL_TCC\01. SOPs, Policies and GUIDANCE DOCS\02LSHTM SOPs 
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In accordance with Working Practice Document: Database Lock and Unlock authorisation 
to unlock was given by: 






























Appendix 10. Formula to estimate subdural haemorhage volume. 
 
      [4/3 π (6.85)3 - 4/3 π (6.85-r)3] 
           ______________________________________ 
                        8 
We used the longitudinal diameter (temporal-temporal): 137mm or 13.7cm (6.85cm radius) 172. 
r is the maximum diameter of the subdural haemorrhage.  
 
For example, for a subdural haemorrhage with a diameter of 7.7mm (i.e. 0.77cm): 
 
4/3π(6.85)3 = 1346.35728 
4/3π(6.85 – 0.77)3 = 4/3π(6.08)3 = 941.45452 
1346.35728 - 941.45452 = 404.90276 
404.90276 / 8 = 51cm3 (i.e. 51ml) 
 
For example, for a subdural haemorrhage with a diameter of 3.5mm (i.e. 0.35cm): 
4/3π(6.85 – 0.35)3 = 4/3π(6.5)3 = 1150 
1346 – 1150 = 196 
196 / 8 = 25ml 
For example, for a subdural haemorrhage with a diameter of 6mm (i.e. 0.6cm): 
4/3π(6.85 – 0.6)3 = 4/3π(6.25)3 = 1023 
1346 - 1023 = 323 




J. Talairach and P. Tournoux, "Co-planar Stereotaxic Atlas of the Human Brain: 3-Dimensional 
Proportional System - an Approach to Cerebral Imaging", Thieme Medical Publishers, New 
















Appendix 12. Pre-randomisation and post-randomisation CT scan forms (paper version adapted 








































































Appendix 14. Histograms of original baseline intracranial haemorrhage volume and log-transformed intracranial haemorrhage volume.  
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